

肿瘤放射治疗原则

Principle of Cancer Radiotherapy

1

- [1] Delaney G, Jacob S, Featherstone C, et al. The role of radiotherapy in cancer treatment: estimating optimal utilisation from a review of evidence-based clinical guidelines. *Cancer*. 2005; 104: 1129–37.
- [2] Eccles CL, Dawson LA, Moseley JL, Brock KK. Interfraction liver shape variability and impact on GTV position during liver stereotactic radiotherapy using abdominal compression. *Int J Radiat Oncol Biol Phys*. 2011; 80(3): 938–46.
- [3] Shimohigashi Y, Toya R, Saito T, et al. Tumor motion changes in stereotactic body radiotherapy for liver tumors: an evaluation based on four-dimensional cone-beam computed tomography and fiducial markers. *Radiat Oncol*. 2017; 12(1): 61.
- [4] RTOG-1112 Randomized phase III study of sorafenib versus stereotactic body radiation therapy followed by sorafenib in hepatocellular carcinoma. *NRG Oncol*. <https://www.nrgoncology.org/Clinical-Trials/Protocol/rtog-1112?filter=rtog-1112>
- [5] Hanna GG, Murray L, Patel R, et al. UK consensus on normal tissue dose constraints for stereotactic radiotherapy. *Clin Oncol (R Coll Radiol)*. 2018; 30(1): 5–14.
- [6] Pollom EL, Chin AL, Diehn M, Loo BW, Chang DT. Normal tissue constraints for abdominal and thoracic stereotactic body radiotherapy. *Semin Radiat Oncol*. 2017; 27: 197–208.
- [7] Thomas TO, Hasan S, Small W Jr, et al. The tolerance of gastrointestinal organs to stereotactic body radiation therapy: what do we know so far? *J Gastrointest Oncol*. 2014; 5: 236–46.
- [8] Milano MT, Katz AW, Schell MC, Phillip A, Okunieff P. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. *Int J Radiat Oncol Biol Phys*. 2008; 72: 1516–22.
- [9] von Siebenthal M, Székely G, Lomax AJ, Cattin PC. Systematic errors in respiratory gating due to interfraction deformations of the liver. *Med Phys*. 2007; 34(9): 3620–9.
- [10] Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. *Am J Roentgenol Radium Therapy Nucl Med*. 1965; 93: 200–8.
- [11] Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. *Int J Radiat Oncol Biol Phys*. 2002; 53: 810–21.
- [12] Hou JZ, Zeng ZC, Wang BL, Yang P, Zhang JY, Mo HF. High dose radiotherapy with image-guided hypo-IMRT for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombi is more feasible and efficacious than conventional 3D-CRT. *Jpn J Clin Oncol*. 2016; 46(4): 357–62.
- [13] Wang PM, Hsu WC, Chung NN, et al. Feasibility of stereotactic body radiation therapy with volumetric modulated arc therapy and high intensity photon beams for hepatocellular carcinoma patients. *Radiat Oncol*. 2014; 9: 18.
- [14] Bae SH, Jang WI, Park HC. Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results. *Oncotarget*. 2017; 8(35): 59965–76.
- [15] Kim JW, Kim DY, Han KH, Seong J. Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma. *Dig Liver Dis*. 2019; 51(3): 445–51.
- [16] Scorsetti M, Comito T, Cozzi L, et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). *J Cancer Res Clin Oncol*. 2015; 141(7): 1301–9.
- [17] Jin L, Price RA, Wang L, et al. Dosimetric and delivery efficiency investigation for treating hepatic lesions with a MLC-equipped robotic radiosurgery-radiotherapy combined system. *Med Phys*. 2016; 43(2): 727–33.
- [18] Venkatanarasimha N, Gogna A, Tong KTA, et al. Radioembolisation of hepatocellular carcinoma: a primer. *Clin Radiol*. 2017; 72: 1002–13.
- [19] Riaz A, Kulik L, Lewandowski RJ, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. *Hepatology*. 2009; 49: 1185–93.
- [20] Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. *J Clin Oncol*. 2018; 36(19): 1913–21.
- [21] Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. *Lancet Oncol*. 2017; 18(12): 1624–36.
- [22] Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. *J Clin Oncol*. 2013; 31: 1631–9.
- [23] Chapman TR, Bowen SR, Schaub SK, et al. Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: defining clinically relevant endpoints. *Pract Radiat Oncol*. 2017; 8(3): 157–66.
- [24] Culleton S, Jiang H, Haddad CR, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. *Radiother Oncol*. 2014; 111: 412–7.
- [25] Lasley FD, Mannina EM, Johnson CS, et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. *Pract Radiat Oncol*.

- 2015; 5: e443–9.
- [26] Que J, Kuo HT, Lin LC, et al. Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma. *BMC Cancer*. 2016; 16: 451.
- [27] Sanuki N, Takeda A, Oku Y, et al. Influence of liver toxicities on prognosis after stereotactic body radiation therapy for hepatocellular carcinoma. *Hepatol Res*. 2015; 45: 540–7.
- [28] Sanuki N, Takeda A, Oku Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. *Acta Oncol*. 2014; 53: 399–404.
- [29] Song JH, Jeong BK, Choi HS, et al. Defining radiation-induced hepatic toxicity in hepatocellular carcinoma patients treated with stereotactic body radiotherapy. *J Cancer*. 2017; 8: 4155–61.
- [30] Velec M, Haddad CR, Craig T, et al. Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2017; 97: 939–46.
- [31] Giovannini G, Bohlen T, Cabal G, et al. Variable RBE in proton therapy: comparison of different model predictions and their influence on clinical-like scenarios. *Radiat Oncol*. 2016; 11: 68.
- [32] Paganetti H. Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer. *Phys Med Biol*. 2014; 59: R419–72.
- [33] Paganetti H, Niemierko A, Ancukiewicz M, et al. Relative biological effectiveness (RBE) values for proton beam therapy. *Int J Radiat Oncol Biol Phys*. 2002; 53: 407–21.
- [34] Habermehl D, Ilicic K, Dehne S, et al. The relative biological effectiveness for carbon and oxygen ion beams using raster-scanning technique in hepatocellular carcinoma cell lines. *PLoS One*. 2014; 9: e113591.
- [35] Habermehl D, Debus J, Ganten T, et al. Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma -feasibility and clinical response. *Radiat Oncol*. 2013; 18: 59.
- [36] El Shafie RA, Habermehl D, Rieken S, et al. In vitro evaluation of photon and raster-scanned carbon ion radiotherapy in combination with gemcitabine in pancreatic cancer cell lines. *J Radiat Res*. 2013; 54(Suppl 1): i113–9.
- [37] Dreher C, Habermehl D, Ecker S, et al. Optimization of carbon ion and proton treatment plans using the raster-scanning technique for patients with unresectable pancreatic cancer. *Radiat Oncol*. 2015; 10: 237.
- [38] Combs SE, Zipp L, Rieken S, et al. In vitro evaluation of photon and carbon ion radiotherapy in combination with chemotherapy in glioblastoma cells. *Radiat Oncol*. 2012; 7: 9.
- [39] Kamada T, Tsujii H, Blakely EA, et al. Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience. *Lancet Oncol*. 2015; 16: e93–e100.
- [40] Dehne S, Fritz C, Rieken S, et al. Combination of photon and carbon ion irradiation with targeted therapy substances temsirolimus and gemcitabine in hepatocellular carcinoma cell lines. *Front Oncol*. 2017; 7: 35.

- [1] Kaplan HS, Bagshaw MA. Radiation hepatitis: possible prevention by combined isotopic and external radiation therapy. *Radiology*. 1968; 91(6): 1214–20.
- [2] Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. *Am J Roentgenol Radium Therapy, Nucl Med*. 1965; 93: 200–8.
- [3] Borgelt BB, Gelber R, Brady LW, Griffin T, Hendrickson FR. The palliation of hepatic metastases: results of the radiation therapy oncology group pilot study. *Int J Radiat Oncol Biol Phys*. 1981; 7(5): 587–91.
- [4] Russell AH, Clyde C, Wasserman TH, Turner SS, Rotman M. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. *Int J Radiat Oncol Biol Phys*. 1993; 27(1): 117–23.
- [5] Stillwagon GB, Order SE, Guse C, Klein JL, Lechner PK, Leibel SA, et al. 194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a radiation therapy oncology group study. *Int J Radiat Oncol Biol Phys*. 1989; 17(6): 1223–9.
- [6] Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. *Int J Radiat Oncol Biol Phys*. 1991; 21(1): 109–22.
- [7] Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. *Int J Radiat Oncol Biol Phys*. 2002; 53(4): 810–21.
- [8] Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. *Int J Radiat Oncol Biol Phys*. 2010; 76(3 Suppl): S94–100.
- [9] Ohri N, Tome WA, Mendez Romero A, Miften M, Ten Haken RK, Dawson LA, et al. Local control after stereotactic body radiation therapy for liver tumors. *Int J Radiat Oncol Biol Phys*. 2018; <https://doi.org/10.1016/j.ijrobp.2017.12.288>.
- [10] Mahadevan A, Blanck O, Lanciano R, Peddada A, Sundaraman S, D'Ambrosio D, et al. Stereotactic body radiotherapy (SBRT) for liver metastasis—clinical outcomes from the international multi-institutional RSSearch® patient registry. *Radiat Oncol*. 2018; 13(1): 26.
- [11] Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. *J Clin Oncol*. 2001; 19(1): 164–70.
- [12] Hoyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellesmann H, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. *Acta Oncol*. 2006; 45(7): 823–30.
- [13] Mendez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study. *Acta Oncol*. 2006; 45(7): 831–7.
- [14] Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. *Int J Radiat Oncol Biol Phys*. 2005; 62(5): 1371–8.
- [15] Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. *J Clin Oncol*. 2009; 27(10): 1572–8.
- [16] Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. *J Clin Oncol*. 2009; 27(10): 1585–91.
- [17] Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. *Int J Radiat Oncol Biol Phys*. 2010; 78(2): 486–93.
- [18] Scorsetti M, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarra P, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. *Int J Radiat Oncol Biol Phys*. 2013; 86(2): 336–42.
- [19] Ambrosino G, Polistina F, Costantin G, Francescon P, Guglielmi R, Zanco P, et al. Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. *Anticancer Res*. 2009; 29(8): 3381–4.
- [20] Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. *Science*. 2003; 300(5622): 1155–9.
- [21] Lee Y, Auh SL, Wang Y, Burnette B, Meng Y, Beckett M, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. *Blood*. 2009; 114(3): 589–95.
- [22] Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. *Clin Cancer Res*. 2015; 21(16): 3727–39.
- [23] Kawashita Y, Deb NJ, Garg M, Kabarriti R, Alfieri A, Takahashi M, et al. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. I. Flt3 ligand gene transfer increases antitumor effects of a radio-inducible suicide gene therapy in an ectopic tumor model. *Radiat Res*. 2014; 182(2): 191–200.
- [24] Kawashita Y, Deb NJ, Garg MK, Kabarriti R, Fan Z, Alfieri AA, et al. An autologous in situ tumor vaccination approach for

- hepatocellular carcinoma. 2. Tumorspecific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model. *Radiat Res.* 2014; 182(2): 201–10.
- [25] Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. *Int J Radiat Oncol Biol Phys.* 1995; 31(5): 1237–48.
- [26] Ogata K, Hizawa K, Yoshida M, Kitamuro T, Akagi G, Kagawa K, et al. Hepatic injury following irradiation: a morphologic study. *Tokushima J Exp Med.* 1963; 43: 240–51.
- [27] Reed GB Jr, Cox AJ Jr. The human liver after radiation injury. A form of veno-occlusive disease. *Am J Pathol.* 1966; 48(4): 597–611.
- [28] DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). *Semin Liver Dis.* 2002; 22(1): 27–42.
- [29] Sempoux C, Horsmans Y, Geubel A, Fraikin J, Van Beers BE, Gigot JF, et al. Severe radiation-induced liver disease following localized radiation therapy for biliopancreatic carcinoma: activation of hepatic stellate cells as an early event. *Hepatology.* 1997; 26(1): 128–34.
- [30] Anscher MS, Crocker IR, Jirtle RL. Transforming growth factor-beta 1 expression in irradiated liver. *Radiat Res.* 1990; 122(1): 77–85.
- [31] Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. *N Engl J Med.* 1993; 328(22): 1592–8.
- [32] Guha C, Kavanagh BD. Hepatic radiation toxicity: avoidance and amelioration. *Semin Radiat Oncol.* 2011; 21(4): 256–63.
- [33] Cheng JC, Wu JK, Lee PC, Liu HS, Jian JJ, Lin YM, et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. *Int J Radiat Oncol Biol Phys.* 2004; 60(5): 1502–9.
- [34] Guha C, Sharma A, Gupta S, Alfieri A, Gorla GR, Gagandeep S, et al. Amelioration of radiation-induced liver damage in partially hepatectomized rats by hepatocyte transplantation. *Cancer Res.* 1999; 59(23): 5871–4.
- [35] Kim JH, Park JW, Kim TH, Koh DW, Lee WJ, Kim CM. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2007; 69(3): 813–9.
- [36] Chou CH, Chen PJ, Lee PH, Cheng AL, Hsu HC, Cheng JC. Radiation-induced hepatitis B virus reactivation in liver mediated by the bystander effect from irradiated endothelial cells. *Clin Cancer Res.* 2007; 13(3): 851–7.
- [37] Miften M, Vinogradskiy Y, Moiseenko V, Grimm J, Yorke E, Jackson A, et al. Radiation dose-volume effects for liver SBRT. *Int J Radiat Oncol Biol Phys.* 2018; <https://doi.org/10.1016/j.ijrobp.2017.12.290>.
- [38] Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. *J Clin Oncol.* 2013; 31(13): 1631–9.
- [39] Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2011; 81(4): e447–53.
- [40] Su TS, Luo R, Liang P, Cheng T, Zhou Y, Huang Y. A prospective cohort study of hepatic toxicity after stereotactic body radiation therapy for hepatocellular carcinoma. *Radiother Oncol.* 2018; 129(1): 136–42.
- [41] Hasan S, Thai N, Uemura T, Kudithipudi V, Renz P, Abel S, et al. Hepatocellular carcinoma with child Pugh-a cirrhosis treated with stereotactic body radiotherapy. *World J Gastrointest Surg.* 2017; 9(12): 256–63.
- [42] Nabavizadeh N, Waller JG, Fain R 3rd, Chen Y, Degnin CR, Elliott DA, et al. Safety and efficacy of accelerated hypofractionation and stereotactic body radiation therapy for hepatocellular carcinoma patients with varying degrees of hepatic impairment. *Int J Radiat Oncol Biol Phys.* 2018; 100(3): 577–85.
- [43] Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. *Hepatology.* 2000; 31(4): 864–71.
- [44] Martin AP, Bartels M, Hauss J, Fangmann J. Overview of the MELD score and the UNOS adult liver allocation system. *Transplant Proc.* 2007; 39(10): 3169–74.
- [45] Trey C, Burns DG, Saunders SJ. Treatment of hepatic coma by exchange blood transfusion. *N Engl J Med.* 1966; 274(9): 473–81.
- [46] Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. *Gastroenterology.* 1996; 111(4): 1018–22.
- [47] Grossmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. *Hepatology.* 2004; 39(2): 280–2.
- [48] Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. *J Clin Oncol.* 2015; 33(6): 550–8.
- [49] Liu PH, Hsu CY, Hsia CY, Lee YH, Chiou YY, Huang YH, et al. ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD era. *J Gastroenterol Hepatol.* 2017; 32(4): 879–86.
- [50] Lee SK, Song MJ, Kim SH, Park M. Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: a nationwide cohort study. *PLoS One.* 2019; 14(5): e0216173.
- [51] Mathew AS, Atenafu EG, Owen D, Maurino C, Brade A, Brierley J, et al. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. *Eur J Cancer.* 2020; 134: 41–51.
- [52] Feng M, Suresh K, Schipper MJ, Bazzi L, Ben-Josef E, Matuszak MM, et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial. *JAMA Oncol.* 2018; 4(1): 40–7.
- [53] Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, et al. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis trial. *Hepatology.* 2012; 55(4): 1019–29.
- [54] Burton JR, Helmke S, Lauriski S, Kittelson J, Everson GT. The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology. *Transl Res.* 2021; <https://doi.org/10.1016/>

- j.trsl.2020.12.010.
- [55] Kurland IJ, Broin P, Golden A, Su G, Meng F, Liu L, et al. Integrative metabolic signatures for hepatic radiation injury. *PLoS One*. 2015; 10(6): e0124795.
- [56] Ng SSW, Jang GH, Kurland IJ, Qiu Y, Guha C, Dawson LA. Plasma metabolomic profiles in liver cancer patients following stereotactic body radiotherapy. *EBioMedicine*. 2020; 59: 102973.
- [57] Cutler C, Kim HT, Ayanian S, Bradwin G, Revta C, Aldridge J, et al. Prediction of veno-occlusive disease using biomarkers of endothelial injury. *Biol Blood Marrow Transplant*. 2010; 16(8): 1180–5.
- [58] Lee JH, Lee KH, Kim S, Seol M, Park CJ, Chi HS, et al. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide. *Br J Haematol*. 2002; 118(4): 1087–94.
- [59] Salat C, Holler E, Kolb HJ, Reinhardt B, Pihusch R, Wilmanns W, et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. *Blood*. 1997; 89(6): 2184–8.
- [60] Yamanouchi K, Zhou H, Roy-Chowdhury N, Macaluso F, Liu L, Yamamoto T, et al. Hepatic irradiation augments engraftment of donor cells following hepatocyte transplantation. *Hepatology*. 2009; 49(1): 258–67.
- [61] Fried MW, Duncan A, Soroka S, Connaghan DG, Farrand A, Peter J, et al. Serum hyaluronic acid in patients with veno-occlusive disease following bone marrow transplantation. *Bone Marrow Transplant*. 2001; 27(6): 635–9.
- [62] Tabbara IA, Ghazal CD, Ghazal HH. Early drop in protein C and antithrombin III is a predictor for the development of venoocclusive disease in patients undergoing hematopoietic stem cell transplantation. *J Hematother*. 1996; 5(1): 79–84.
- [63] Roeker LE, Kim HT, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J, et al. Early clinical predictors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after myeloablative stem cell transplantation. *Biol Blood Marrow Transplant*. 2019; 25(1): 137–44.
- [64] Eltumi M, Trivedi P, Hobbs JR, Portmann B, Cheeseman P, Downie C, et al. Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen. *Lancet*. 1993; 342(8870): 518–21.
- [65] Rio B, Bauduer F, Arrago JP, Zittoun R. N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin. *Bone Marrow Transplant*. 1993; 11(6): 471–2.
- [66] Cao Y, Pan C, Balter JM, Platt JF, Francis IR, Knol JA, et al. Liver function after irradiation based on computed tomographic portal vein perfusion imaging. *Int J Radiat Oncol Biol Phys*. 2008; 70(1): 154–60.
- [67] Cao Y, Wang H, Johnson TD, Pan C, Hussain H, Balter JM, et al. Prediction of liver function by using magnetic resonance-based portal venous perfusion imaging. *Int J Radiat Oncol Biol Phys*. 2013; 85(1): 258–63.
- [68] Yannam GR, Han B, Setoyama K, Yamamoto T, Ito R, Brooks JM, et al. A nonhuman primate model of human radiation-induced venoocclusive liver disease and hepatocyte injury. *Int J Radiat Oncol Biol Phys*. 2014; 88(2): 404–11.
- [69] Kabarriti R, Brodin NP, Yaffe H, Barahman M, Koba WR, Liu L, et al. Non-invasive targeted hepatic irradiation and SPECT/CT functional imaging to study radiation-induced liver damage in small animal models. *Cancers (Basel)*. 2019; 11(11): 1796.
- [70] Ward J, Guthrie JA, Sheridan MB, Boyes S, Smith JT, Wilson D, et al. Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases. *J Clin Oncol*. 2008; 26(26): 4304–10.
- [71] Kwon AH, Ha-Kawa SK, Uetsuji S, Inoue T, Matsui Y, Kamiyama Y. Preoperative determination of the surgical procedure for hepatectomy using technetium-99m-galactosyl human serum albumin (99mTc-GSA) liver scintigraphy. *Hepatology*. 1997; 25(2): 426–9.
- [72] de Graaf W, van Lienden KP, van Gulik TM, Bennink RJ. (99m)Tc-mebrofenin hepatobiliary scintigraphy with SPECT for the assessment of hepatic function and liver functional volume before partial hepatectomy. *J Nucl Med*. 2010; 51(2): 229–36.
- [73] Tsegmed U, Kimura T, Nakashima T, Nakamura Y, Higaki T, Imano N, et al. Functional image-guided stereotactic body radiation therapy planning for patients with hepatocellular carcinoma. *Med Dosim*. 2017; 42(2): 97–103.
- [74] Chan SS, Colecchia A, Duarte RF, Bonifazi F, Ravaioli F, Bourhis JH. Imaging in hepatic veno-occlusive disease/sinusoidal obstruction syndrome. *Biol Blood Marrow Transplant*. 2020; 26(10): 1770–9.
- [75] Reddivalla N, Robinson AL, Reid KJ, Radhi MA, Dalal J, Opfer EK, et al. Using liver elastography to diagnose sinusoidal obstruction syndrome in pediatric patients undergoing hematopoietic stem cell transplant. *Bone Marrow Transplant*. 2020; 55(3): 523–30.
- [76] Trenker C, Sohlbach K, Dietrich CF, Görg C. Clinical diagnosis of veno-occlusive disease using contrast enhanced ultrasound. *Bone Marrow Transplant*. 2018; 53(10): 1369–71.
- [77] Berzigotti A. Non-invasive evaluation of portal hypertension using ultrasound elastography. *J Hepatol*. 2017; 67(2): 399–411.
- [78] Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. *Blood*. 1997; 89(5): 1501–6.
- [79] Koay EJ, Owen D, Das P. Radiation-induced liver disease and modern radiotherapy. *Semin Radiat Oncol*. 2018; 28(4): 321–31.
- [80] Feng M, Smith DE, Normolle DP, Knol JA, Pan CC, Ben-Josef E, et al. A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy. *Int J Radiat Oncol Biol Phys*. 2012; 83(5): 1441–7.
- [81] Seidensticker M, Seidensticker R, Damm R, Mohnike K, Pech M, Sangro B, et al. Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity. *PLoS One*. 2014; 9(11): e112731.
- [82] Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology*. 2018; 67(4): 1560–99.
- [83] Zhou H, Dong X, Kabarriti R, Chen Y, Avsar Y, Wang X, et al. Single liver lobe repopulation with wildtype hepatocytes using regional hepatic irradiation cures jaundice in Gunn rats. *PLoS One*. 2012; 7(10): e46775.

- [84] Kabarriti RZH, Vainshtein JV, Saha S, Hannan R, Thawani N, Alfieri A, Kalnicki S, Guha C. Transplantation of liver sinusoidal endothelial cells repairs HIR induced hepatic endothelial cell damage. *Int J Radiat Oncol Biol Phys.* 2010; 78(3): S41.
- [85] Barahman M, Asp P, Roy-Chowdhury N, Kinkhabwala M, Roy-Chowdhury J, Kabarriti R, et al. Hepatocyte transplantation: Quo Vadis? *Int J Radiat Oncol Biol Phys.* 2019; 103(4): 922–34.
- [86] McGee HM, Daly ME, Azghadi S, Stewart SL, Oesterich L, Schlom J, et al. Stereotactic ablative radiation therapy induces systemic differences in peripheral blood immunophenotype dependent on irradiated site. *Int J Radiat Oncol Biol Phys.* 2018; 101(5): 1259–70.
- [87] Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. *Clin Cancer Res.* 2009; 15(17): 5379–88.
- [88] Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. *Nat Commun.* 2017; 8(1): 1751.
- [89] MacLennan I, Kay H. Analysis of treatment in childhood leukemia. IV. The critical association between dose fractionation and immunosuppression induced by cranial irradiation. *Cancer.* 1978; 41(1): 108–11.
- [90] Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. *J Clin Invest.* 2010; 120(3): 694–705.
- [91] Brown JM. Vasculogenesis: a crucial player in the resistance of solid tumours to radiotherapy. *Br J Radiol.* 2014; 87(1035): 20130686.
- [92] Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. *Cancer Res.* 2010; 70(14): 5679–85.
- [93] Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity.* 2013; 39(1): 1–10.
- [94] Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. *Cell.* 2016; 167(6): 1540–54. e12
- [95] Minn AJ, Wherry EJ. Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling. *Cell.* 2016; 165(2): 272–5.
- [96] Ministro A, de Oliveira P, Nunes RJ, dos Santos RA, Correia A, Carvalho T, et al. Low-dose ionizing radiation induces therapeutic neovascularization in a pre-clinical model of hindlimb ischemia. *Cardiovasc Res.* 2017; 113(7): 783–94.
- [97] Potiron VA, Abderrahmani R, Clément-Colmou K, Marionneau-Lambot S, Oullier T, Paris F, et al. Improved functionality of the vasculature during conventionally fractionated radiation therapy of prostate cancer. *PLoS One.* 2013; 8(12): e84076.

- [1] Chiu RY, Yap WW, Patel R, Liu D, Klass D, Harris AC. Hepatocellular carcinoma post embolotherapy: imaging appearances and pitfalls on computed tomography and magnetic resonance imaging. *Can Assoc Radiol J*. 2016; 67(2): 158–72. <https://doi.org/10.1016/j.carj.2015.09.006>.
- [2] Murakami T, Kim T, Kawata S, Kanematsu M, Federle MP, Hori M, et al. Evaluation of optimal timing of arterial phase imaging for the detection of hypervascular hepatocellular carcinoma by using triple arterial phase imaging with multidetectorrow helical computed tomography. *Invest Radiol*. 2003; 38(8): 497–503. <https://doi.org/10.1097/01.rli.0000074584.12494.e3>.
- [3] Monzawa S, Ichikawa T, Nakajima H, Kitanaka Y, Omata K, Araki T. Dynamic CT for detecting small hepatocellular carcinoma: usefulness of delayed phase imaging. *AJR Am J Roentgenol*. 2007; 188(1): 147–53. <https://doi.org/10.2214/ajr.05.0512>.
- [4] Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, et al. Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. *Radiology*. 2018; 289(3): 816–30. <https://doi.org/10.1148/radiol.2018181494>.
- [5] European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol*. 2018; 69(1): 182–236. <https://doi.org/10.1016/j.jhep.2018.03.019>.
- [6] Hope TA, Fowler KJ, Sirlin CB, Costa EA, Yee J, Yeh BM, et al. Hepatobiliary agents and their role in LI-RADS. *Abdom Imaging*. 2015; 40(3): 613–25. <https://doi.org/10.1007/s00261-014-0227-5>.
- [7] Lukovic J, Henke L, Gani C, Kim TK, Stanescu T, Hosni A, et al. MRI-based upper abdominal organs-at-risk atlas for radiation oncology. *Int J Radiat Oncol Biol Phys*. 2020; 106(4): 743–53. <https://doi.org/10.1016/j.ijrobp.2019.12.003>.
- [8] Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. *J Hepatobiliary Pancreat Surg*. 2005; 12(5): 351–5. <https://doi.org/10.1007/s00534-005-0999-7>.
- [9] Murakami G, Hata F. Human liver caudate lobe and liver segment. *Anat Sci Int*. 2002; 77(4): 211–24. <https://doi.org/10.1046/j.0022-7722.2002.00033.x>.
- [10] Auh YH, Rosen A, Rubenstein WA, Engel IA, Whalen JP, Kazam E. CT of the papillary process of the caudate lobe of the liver. *AJR Am J Roentgenol*. 1984; 142(3): 535–8. <https://doi.org/10.2214/ajr.142.3.535>.
- [11] Majno P, Mentha G, Toso C, Morel P, Peitgen HO, Fasel JH. Anatomy of the liver: an outline with three levels of complexity: a further step towards tailored territorial liver resections. *J Hepatol*. 2014; 60(3): 654–62. <https://doi.org/10.1016/j.jhep.2013.10.026>.
- [12] Ohtani O, Ohtani Y. Lymph circulation in the liver. *Anat Rec (Hoboken)*. 2008; 291(6): 643–52. <https://doi.org/10.1002/ar.20681>.
- [13] Tanaka M, Iwakiri Y. The hepatic lymphatic vascular system: structure, function, markers, and lymphangiogenesis. *Cell Mol Gastroenterol Hepatol*. 2016; 2(6): 733–49. <https://doi.org/10.1016/j.jcmgh.2016.09.002>.
- [14] Lupinacci RM, Paye F, Coelho FF, Kruger JA, Herman P. Lymphatic drainage of the liver and its implications in the management of colorectal cancer liver metastases. *Updat Surg*. 2014; 66(4): 239–45. <https://doi.org/10.1007/s13304-014-0265-0>.
- [15] Ercolani G, Grazi GL, Ravaioli M, Grigioni WF, Cescon M, Gardini A, et al. The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy. *Ann Surg*. 2004; 239(2): 202–9. <https://doi.org/10.1097/01.sla.0000109154.00020.e0>.
- [16] Xiaohong S, Huikai L, Feng W, Ti Z, Yunlong C, Qiang L. Clinical significance of lymph node metastasis in patients undergoing partial hepatectomy for hepatocellular carcinoma. *World J Surg*. 2010; 34(5): 1028–33. <https://doi.org/10.1007/s00268-010-0400-0>.
- [17] Sun HC, Zhuang PY, Qin LX, Ye QH, Wang L, Ren N, et al. Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy. *J Surg Oncol*. 2007; 96(1): 37–45. <https://doi.org/10.1002/jso.20772>.
- [18] Watanabe J, Nakashima O, Kojiro M. Clinicopathologic study on lymph node metastasis of hepatocellular carcinoma: a retrospective study of 660 consecutive autopsy cases. *Jpn J Clin Oncol*. 1994; 24(1): 37–41. <https://doi.org/10.1093/oxfordjournals.jjco.a039672>.
- [19] Xia F, Wu L, Lau WY, Li G, Huan H, Qian C, et al. Positive lymph node metastasis has a marked impact on the long-term survival of patients with hepatocellular carcinoma with extrahepatic metastasis. *PLoS One*. 2014; 9(4): e95889. <https://doi.org/10.1371/journal.pone.0095889>.
- [20] Choi JW, Kim TK, Kim KW, Kim AY, Kim PN, Ha HK, et al. Anatomic variation in intrahepatic bile ducts: an analysis of intraoperative cholangiograms in 300 consecutive donors for living donor liver transplantation. *Korean J Radiol*. 2003; 4(2): 85–90. <https://doi.org/10.3348/kjr.2003.4.2.85>.
- [21] Jabbour SK, Hashem SA, Bosch W, Kim TK, Finkelstein SE, Anderson BM, et al. Upper abdominal normal organ contouring guidelines and atlas: a Radiation Therapy Oncology Group consensus. *Pract Radiat Oncol*. 2014; 4(2): 82–9. <https://doi.org/10.1016/j.prro.2013.12.003>.

- org/10.1016/j.pro.2013.06.004.
- [22] Kamiyoshihara M, Ibe T, Takeyoshi I. Chilaiditi's sign mimicking a traumatic diaphragmatic hernia. *Ann Thorac Surg.* 2009; 87(3): 959–61. <https://doi.org/10.1016/j.athoracsur.2008.07.033>.
- [23] Ahn JH, Yu JS, Hwang SH, Chung JJ, Kim JH, Kim KW. Nontumorous arterioportal shunts in the liver: CT and MRI findings considering mechanisms and fate. *Eur Radiol.* 2010; 20(2): 385–94. <https://doi.org/10.1007/s00330-009-1542-z>.
- [24] Xiao YD, Ma C, Zhang ZS, Liu J. Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular carcinoma and arterioportal shunt: a single-center experience. *Cancer Manag Res.* 2019; 11: 1551–7. <https://doi.org/10.2147/CMAR.S193948>.
- [25] Choi BI, Lee KH, Han JK, Lee JM. Hepatic arterioportal shunts: dynamic CT and MR features. *Korean J Radiol.* 2002; 3(1): 1–15. <https://doi.org/10.3348/kjr.2002.3.1.1>.
- [26] Jang HJ, Khalili K, Yu H, Kim TK. Perfusion and parenchymal changes related to vascular alterations of the liver. *Abdom Imaging.* 2012; 37(3): 404–21. <https://doi.org/10.1007/s00261-011-9767-0>.
- [27] Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. *Radiology.* 2014; 273(1): 30–50. <https://doi.org/10.1148/radiol.14132362>.
- [28] Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Muhi A, et al. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. *Radiology.* 2010; 256(1): 151–8. <https://doi.org/10.1148/radiol.10091885>.
- [29] Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. *Radiology.* 2014; 272(3): 635–54. <https://doi.org/10.1148/radiol.14132361>.
- [30] Edmondson HA, Steiner PE. Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies. *Cancer.* 1954; 7(3): 462–503. [https://doi.org/10.1002/1097-0142\(195405\)7:3<462::AIDCNCR2820070308>3.0.CO;2-E](https://doi.org/10.1002/1097-0142(195405)7:3<462::AIDCNCR2820070308>3.0.CO;2-E).
- [31] Llovet JM, Fuster J, Bruix J, Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. *Liver Transpl.* 2004; 10(2 Suppl 1): S115–20. <https://doi.org/10.1002/lt.20034>.
- [32] Cannella R, Taibbi A, Porrello G, Dioguardi Burgio M, Cabibbo G, Bartolotta TV. Hepatocellular carcinoma with macrovascular invasion: multimodality imaging features for the diagnosis. *Diagn Interv Radiol.* 2020; 26(6): 531–40. <https://doi.org/10.5152/dir.2020.19569>.
- [33] Raab BW. The thread and streak sign. *Radiology.* 2005; 236(1): 284–5. <https://doi.org/10.1148/radiol.2361030114>.
- [34] Tublin ME, Dodd GD 3rd, Baron RL. Benign and malignant portal vein thrombosis: differentiation by CT characteristics. *AJR Am J Roentgenol.* 1997; 168(3): 719–23. <https://doi.org/10.2214/ajr.168.3.9057522>.
- [35] Catalano OA, Choy G, Zhu A, Hahn PF, Sahani DV. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. *Radiology.* 2010; 254(1): 154–62. <https://doi.org/10.1148/radiol.09090304>.
- [36] Sandrasegaran K, Tahir B, Nutakki K, Akisik FM, Bodanapally U, Tann M, et al. Usefulness of conventional MRI sequences and diffusion-weighted imaging in differentiating malignant from benign portal vein thrombus in cirrhotic patients. *AJR Am J Roentgenol.* 2013; 201(6): 1211–9. <https://doi.org/10.2214/ajr.12.10171>.
- [37] Ascenti G, Sofia C, Mazziotti S, Silipigni S, D'Angelo T, Pergolizzi S, et al. Dual-energy CT with iodine quantification in distinguishing between bland and neoplastic portal vein thrombosis in patients with hepatocellular carcinoma. *Clin Radiol.* 2016; 71(9): 938.e1–9. <https://doi.org/10.1016/j.crad.2016.05.002>.
- [38] Kojiro M, Kawabata K, Kawano Y, Shirai F, Takemoto N, Nakashima T. Hepatocellular carcinoma presenting as intrabiliary duct tumor growth: a clinicopathologic study of 24 cases. *Cancer.* 1982; 49(10): 2144–7. [https://doi.org/10.1002/1097-0142\(19820515\)49:10<2144::aid-cnrcr2820491026>3.0.co;2-o](https://doi.org/10.1002/1097-0142(19820515)49:10<2144::aid-cnrcr2820491026>3.0.co;2-o).
- [39] Zeng H, Xu LB, Wen JM, Zhang R, Zhu MS, Shi XD, et al. Hepatocellular carcinoma with bile duct tumor thrombus: a clinicopathological analysis of factors predictive of recurrence and outcome after surgery. *Medicine (Baltimore).* 2015; 94(1): e364. <https://doi.org/10.1097/MD.0000000000000364>.
- [40] Tseng JH, Hung CF, Ng KK, Wan YL, Yeh TS, Chiu CT. Icteric-type hepatoma: magnetic resonance imaging and magnetic resonance cholangiographic features. *Abdom Imaging.* 2001; 26(2): 171–7. <https://doi.org/10.1007/s002610000136>.
- [41] Seo N, Kim DY, Choi JY. Cross-sectional imaging of intrahepatic cholangiocarcinoma: development, growth, spread, and prognosis. *AJR Am J Roentgenol.* 2017; 209(2): W64–75. <https://doi.org/10.2214/ajr.16.16923>.
- [42] Jung AY, Lee JM, Choi SH, Kim SH, Lee JY, Kim SW, et al. Computed tomography features of an intraductal polypoid mass: differentiation between hepatocellular carcinoma with bile duct tumor invasion and intraductal papillary cholangiocarcinoma. *J Comput Assist Tomogr.* 2006; 30(1): 18–24. <https://doi.org/10.1097/01.rct.0000188837.71136.fe>.
- [43] Liu Q, Chen J, Li H, Liang B, Zhang L, Hu T. Hepatocellular carcinoma with bile duct tumor thrombi: correlation of magnetic resonance imaging features to histopathologic manifestations. *Eur J Radiol.* 2010; 76(1): 103–9. <https://doi.org/10.1016/j.ejrad.2009.05.020>.
- [44] Shiomi M, Kamiya J, Nagino M, Uesaka K, Sano T, Hayakawa N, et al. Hepatocellular carcinoma with biliary tumor thrombi: aggressive operative approach after appropriate preoperative management. *Surgery.* 2001; 129(6): 692–8. <https://doi.org/10.1067/msy.2001.113889>.
- [45] Qin LX, Ma ZC, Wu ZQ, Fan J, Zhou XD, Sun HC, et al. Diagnosis and surgical treatments of hepatocellular carcinoma with tumor thrombosis in bile duct: experience of 34 patients. *World J Gastroenterol.* 2004; 10(10): 1397–401. <https://doi.org/10.3748/wjg.v10.i10.1397>.
- [46] Peng BG, Liang LJ, Li SQ, Zhou F, Hua YP, Luo SM. Surgical treatment of hepatocellular carcinoma with bile duct tumor thrombi. *World J Gastroenterol.* 2005; 11(25): 3966–9. <https://doi.org/10.3748/wjg.v11.i25.3966>.
- [47] Gabata T, Terayama N, Kobayashi S, Sanada J, Kadoya M, Matsui O. MR imaging of hepatocellular carcinomas with biliary tumor thrombi. *Abdom Imaging.* 2007; 32(4): 470–4. <https://doi.org/10.1007/s00261-006-9154-4>.
- [48] Kim HD, Lim YS, Han S, An J, Kim GA, Kim SY, et al. Evaluation of early stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions

- and increases overall survival. *Gastroenterology*. 2015; 148(7): 1371–82. <https://doi.org/10.1053/j.gastro.2015.02.051>.
- [49] Yang SL, Luo YY, Chen M, Zhou YP, Lu FR, Deng DF, et al. A systematic review and meta-analysis comparing the prognosis of multicentric occurrence and vs. intrahepatic metastasis in patients with recurrent hepatocellular carcinoma after hepatectomy. *HPB (Oxford)*. 2017; 19(10): 835–42. <https://doi.org/10.1016/j.hpb.2017.06.002>.
- [50] Yu JS, Chung JJ, Kim JH, Cho ES, Kim DJ, Ahn JH, et al. Detection of small intrahepatic metastases of hepatocellular carcinomas using diffusion-weighted imaging: comparison with conventional dynamic MRI. *Magn Reson Imaging*. 2011; 29(7): 985–92. <https://doi.org/10.1016/j.mri.2011.04.010>.
- [51] Holzapfel K, Eiber MJ, Fingerle AA, Bruegel M, Rummeny EJ, Gaa J. Detection, classification, and characterization of focal liver lesions: value of diffusion-weighted MR imaging, gadoxetic acid-enhanced MR imaging and the combination of both methods. *Abdom Imaging*. 2012; 37(1): 74–82. <https://doi.org/10.1007/s00261-011-9758-1>.
- [52] Lowenthal D, Zeile M, Lim WY, Wybranski C, Fischbach F, Wieners G, et al. Detection and characterisation of focal liver lesions in colorectal carcinoma patients: comparison of diffusion-weighted and Gd-EOB-DTPA enhanced MR imaging. *Eur Radiol*. 2011; 21(4): 832–40. <https://doi.org/10.1007/s00330-010-1977-2>.
- [53] Kim YK, Kim YK, Park HJ, Park MJ, Lee WJ, Choi D. Noncontrast MRI with diffusion-weighted imaging as the sole imaging modality for detecting liver malignancy in patients with high risk for hepatocellular carcinoma. *Magn Reson Imaging*. 2014; 32(6): 610–8. <https://doi.org/10.1016/j.mri.2013.12.021>.
- [54] Lee MW, Lim HK. Management of sub-centimeter recurrent hepatocellular carcinoma after curative treatment: current status and future. *World J Gastroenterol*. 2018; 24(46): 5215–22. <https://doi.org/10.3748/wjg.v24.i46.5215>.
- [55] Park CJ, An C, Park S, Choi JY, Kim MJ. Management of subcentimetre arterially enhancing and hepatobiliary hypointense lesions on gadoxetic acid-enhanced MRI in patients at risk for HCC. *Eur Radiol*. 2018; 28(4): 1476–84. <https://doi.org/10.1007/s00330-017-5088-1>.
- [56] Yu MH, Kim JH, Yoon JH, Kim HC, Chung JW, Han JK, et al. Small (≤ 1 -cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging. *Radiology*. 2014; 271(3): 748–60. <https://doi.org/10.1148/radiol.14131996>.
- [57] Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. *Semin Liver Dis*. 2010; 30(1): 52–60. <https://doi.org/10.1055/s-0030-1247132>.
- [58] Dioguardi Burgio M, Sartoris R, Libotean C, Zappa M, Sibert A, Vilgrain V, et al. Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response. *Cancer Imaging*. 2019; 19(1): 75. <https://doi.org/10.1186/s40644-019-0260-2>.
- [59] Hussein RS, Tantawy W, Abbas YA. MRI assessment of hepatocellular carcinoma after locoregional therapy. *Insights Imaging*. 2019; 10(1): 8. <https://doi.org/10.1186/s13244-019-0690-1>.

放射治疗相关的肝脏功能评估

Functional Assessment of Liver for Radiation Oncologist

4

- [1] Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. *Int J Radiat Oncol*. 2010; 76: S94–100.
- [2] Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. *J Clin Oncol*. 2013; 31: 1631–9.
- [3] Choi SH, Seong J. Strategic application of radiotherapy for hepatocellular carcinoma. *Clin Mol Hepatol*. 2018; 24: 114–34.
- [4] Khozouz RF, Huq SZ, Perry MC. Radiation-induced liver disease. *J Clin Oncol*. 2008; 26: 4844–5.
- [5] Kim J, Jung Y. Radiation-induced liver disease: current understanding and future perspective. *Exp Mol Med*. 2017; 49: e359.
- [6] Guha C, Kavanagh BD. Hepatic radiation toxicity: avoidance and amelioration. *Semin Radiat Oncol*. 2011; 21: 256–63.
- [7] Koay EJ, Owen D, Das P. Radiation-induced liver disease and modern radiotherapy. *Semin Radiat Oncol*. 2018; 28: 321–31.
- [8] Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. *Am J Roentgenol Radium Therapy, Nucl Med*. 1965; 93: 200–8.
- [9] Cheng JC, Wu JK, Huang CM, Liu HS, Huang DY, Cheng SH, et al. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. *Int J Radiat Oncol*. 2002; 54: 156–62.
- [10] Jung J, Yoon SM, Kim SY, Cho B, Park JH, Kim SS, et al. Radiation induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters. *Radiat Oncol*. 2013; 8: 249.
- [11] Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. *Int J Radiat Oncol Biol Phys*. 1995; 31: 1237–48.
- [12] Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. *Int J Radiat Oncol Biol Phys*. 2002; 53: 810–21.
- [13] Christiansen H, Saile B, Neubauer-Saile K, Tippelt S, Rave-Frank M, Hermann RM, et al. Irradiation leads to susceptibility of hepatocytes to TNF-alpha mediated apoptosis. *Radiation Oncol*. 2004; 72: 291–6.
- [14] Yamanouchi K, Zhou H, Roy-Chowdhury N, Macaluso F, Liu L, Yamamoto T, et al. Hepatic irradiation augments engraftment of donor cells following hepatocyte transplantation. *Hepatology*. 2009; 49: 258–67.
- [15] Du SS, Qiang M, Zeng ZC, Ke AW, Ji Y, Zhang ZY, et al. Inactivation of Kupffer cells by gadolinium chloride protects murine liver from radiation-induced apoptosis. *Int J Radiat Oncol Biol Phys*. 2010; 76: 1225–34.
- [16] Child CG, Turcotte JG. Surgery and portal hypertension. *Major Probl Clin Surg*. 1964; 1: 1–85.
- [17] Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg*. 1973; 60: 646–9.
- [18] Cheng JC, Wu JK, Lee PC, Liu H, Jian JJ, Lin Y, et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. *Int J Radiat Oncol Biol Phys*. 2004; 60: 1502–9.
- [19] Cardenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. *Clin Transl Oncol*. 2010; 12: 218–25.
- [20] Chino F, Stephens SJ, Choi SS, Marin D, Kim CY, Morse MA, et al. The role of external beam radiotherapy in the treatment of hepatocellular cancer. *Cancer*. 2018; 124: 3476–89.
- [21] Bae SH, Park HC, Yoon WS, Yoon SM, Jung I, Lee IJ, et al. Treatment outcome after fractionated conformal radiotherapy for hepatocellular carcinoma in patients with Child-Pugh classification B in Korea (KROG 16-05). *Cancer Res Treat*. 2019; 51: 1589–99.
- [22] Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. *Hepatology*. 2000; 31: 864–71.
- [23] Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, et al. MELD and PELD: application of survival models to liver allocation. *Liver Transpl*. 2001; 7: 567–80.
- [24] Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. *Gastroenterology*. 2003; 124: 91–6.
- [25] Klein KB, Stafinski TD, Menon D. Predicting survival after liver transplantation based on pre-transplant MELD score: a systematic review of the literature. *PLoS One*. 2013; 8: e80661.
- [26] Teh SH, Christein J, Donohue J, Que F, Kendrick M, Farnell M, et al. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. *J Gastrointest Surg*. 2005; 9: 1207–15.
- [27] Okazaki E, Yamamoto A, Nishida N, Hamuro M, Ogino R, Hosono M, et al. Three-dimensional conformal radiotherapy for locally advanced hepatocellular carcinoma with portal vein tumour thrombosis: evaluating effectiveness of the model for end-stage liver disease (MELD) score compared with the Child-

- Pugh classification. *Br J Radiol.* 2016; 89: 20150945.
- [28] Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. *J Clin Oncol.* 2015; 33: 550–8.
- [29] Hiraoka A, Kumada T, Kudo M, Hirooka M, Tsuji K, Itobayashi E, et al. Albumin-Bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and Child-Pugh classifications. *Liver Cancer.* 2017; 6: 204–15.
- [30] Chan AW, Kumada T, Toyoda H, Tada T, Chong CC, Mo FK, et al. Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. *J Gastroenterol Hepatol.* 2016; 31: 1300–6.
- [31] Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. *J Hepatol.* 2017; 66: 338–46.
- [32] Toyoda H, Lai PB, O'Beirne J, Chong CC, Berhane S, Reeves H, et al. Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. *Br J Cancer.* 2016; 114: 744–50.
- [33] Hickey R, Mouli S, Kulik L, Desai K, Thornburg B, Ganger D, et al. Independent analysis of albumin-bilirubin grade in a 765-patient cohort treated with transarterial locoregional therapy for hepatocellular carcinoma. *J Vasc Interv Radiol.* 2016; 27: 795–802.
- [34] Edeline J, Blanc JF, Johnson P, Campillo-Gimenez B, Ross P, Ma YT, et al. A multicentre comparison between Child Pugh and albumin-bilirubin scores in patients treated with sorafenib for hepatocellular carcinoma. *Liver Int.* 2016; 36: 1821–8.
- [35] Lo CH, Liu MY, Lee MS, Yang JF, Jen YM, Lin CS, et al. Comparison between Child-Turcotte-Pugh and albumin-bilirubin scores in assessing the prognosis of hepatocellular carcinoma after stereotactic ablative radiotherapy. *Int J Radiat Oncol Biol Phys.* 2017; 99: 145–52.
- [36] Mathew AS, Atenafu EG, Owen D, Maurino C, Brade A, Brierley J, et al. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. *Eur J Cancer.* 2020; 134: 41–51.
- [37] Velec M, Haddad CR, Craig T, Wang L, Lindsay P, Brierley J, et al. Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2017; 97: 939–46.
- [38] Murray LJ, Sykes J, Brierley J, Kim JJ, Wong RKS, Ringash J, et al. Baseline albumin-bilirubin (ALBI) score in western patients with hepatocellular carcinoma treated with stereotactic body radiation therapy (SBRT). *Int J Radiat Oncol Biol Phys.* 2018; 101: 900–9.
- [39] Leevy CM, Smith F, Longueville J, Paumgartner G, Howard MM. Indocyanine green clearance as a test for hepatic function. Evaluation by dichromatic ear densitometry. *JAMA.* 1967; 200: 236–40.
- [40] Seyama Y, Kokudo N. Assessment of liver function for safe hepatic resection. *Hepatol Res.* 2009; 39: 107–16.
- [41] Yamamoto Y, Ikoma H, Morimura R, Konishi H, Murayama Y, Komatsu S, et al. Clinical analysis of anatomical resection for the treatment of hepatocellular carcinoma based on the stratification of liver function. *World J Surg.* 2014; 38: 1154–63.
- [42] Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, et al. Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: a multicenter analysis. *Liver Cancer.* 2019; 8: 121–9.
- [43] Suresh K, Owen D, Bazzi L, Jackson W, Ten Haken RK, Cuneo K, et al. Using indocyanine green extraction to predict liver function after stereotactic body radiation therapy for hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2018; 100: 131–7.
- [44] Cheng SH, Lin YM, Chuang VP, Yang PS, Cheng JC, Huang AT, et al. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. *J Gastroenterol Hepatol.* 1999; 14: 1025–33.
- [45] Yoon HI, Koom WS, Lee IJ, Jeong K, Chung Y, Kim JK, et al. The significance of ICG-R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. *Liver Int.* 2012; 32: 1165–71.
- [46] Stenmark MH, Cao Y, Wang H, Jackson A, Ben-Josef E, Ten Haken RK, et al. Estimating functional liver reserve following hepatic irradiation: adaptive normal tissue response models. *Radiother Oncol.* 2014; 111: 418–23.
- [47] Feng M, Suresh K, Schipper MJ, Bazzi L, Ben-Josef E, Matuszak MM, et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial. *JAMA Oncol.* 2018; 4: 40–7.
- [48] Rassam F, Olthof PB, Bennink RJ, van Gulik TM. Current modalities for the assessment of future remnant liver function. *Visc Med.* 2017; 33: 442–8.

肝癌中的抗病毒治疗

Antiviral Therapy in Liver Cancer

5

- [1] Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol.* 2006; 45(4): 529–38. <https://doi.org/10.1016/j.jhep.2006.05.013>.
- [2] Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. *JAMA Oncol.* 2017; 3(12): 1683–91. <https://doi.org/10.1001/jamaoncol.2017.3055>.
- [3] European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. *J Hepatol.* 2017; 67(2): 370–98. <https://doi.org/10.1016/j.jhep.2017.03.021>.
- [4] Korean Association for the Study of the Liver. KASL clinical practice guidelines for management of chronic hepatitis B. *Clin Mol Hepatol.* 2019; 25(2): 93–159. <https://doi.org/10.3350/cmh.2019.1002>.
- [5] Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology.* 2018; 67(4): 1560–99. <https://doi.org/10.1002/hep.29800>.
- [6] Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, et al. Comparison of clinical practice guidelines for the management of chronic hepatitis B: when to start, when to change, and when to stop. *Clin Mol Hepatol.* 2020; <https://doi.org/10.3350/cmh.2020.0049>.
- [7] Agarwal K, Brunetto M, Seto WK, Lim Y-S, Fung S, Marcellin P, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. *J Hepatol.* 2018; 68(4): 672–81. <https://doi.org/10.1016/j.jhep.2017.11.039>.
- [8] Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA.* 2006; 295(1): 65–73. <https://doi.org/10.1001/jama.295.1.65>.
- [9] Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med.* 2004; 351(15): 1521–31. <https://doi.org/10.1056/NEJMoa033364>.
- [10] Singal AK, Salameh H, Kuo YF, Fontana RJ. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. *Aliment Pharmacol Ther.* 2013; 38(2): 98–106. <https://doi.org/10.1111/apt.12344>.
- [11] Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. *Hepatology.* 2013; 58(5): 1537–47. <https://doi.org/10.1002/hep.26301>.
- [12] Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. *Hepatology.* 2013; 58(1): 98–107. <https://doi.org/10.1002/hep.26180>.
- [13] Ahn J, Lim JK, Lee HM, Lok AS, Nguyen M, Pan CQ, et al. Lower observed hepatocellular carcinoma incidence in chronic hepatitis B patients treated with Entecavir: results of the ENUMERATE study. *Am J Gastroenterol.* 2016; 111(9): 1297–304. <https://doi.org/10.1038/ajg.2016.257>.
- [14] Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh PV, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. *Cancer.* 2015; 121(20): 3631–8. <https://doi.org/10.1002/cncr.29537>.
- [15] Lim YS, Han S, Heo NY, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. *Gastroenterology.* 2014; 147(1): 152–61. <https://doi.org/10.1053/j.gastro.2014.02.033>.
- [16] Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, et al. Nucleos(t)ide analogues for reducing hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis. *Gut Liver.* 2020; 14(2): 232–47. <https://doi.org/10.5009/gnl18546>.
- [17] Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim YS. Risk of hepatocellular carcinoma in patients treated with Entecavir vs Tenofovir for chronic hepatitis B: a Korean Nationwide Cohort Study. *JAMA Oncol.* 2019; 5(1): 30–6. <https://doi.org/10.1001/jamaoncol.2018.4070>.
- [18] Kim SU, Seo YS, Lee HA, Kim MN, Lee YR, Lee HW, et al. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in South Korea. *J Hepatol.* 2019; 71(3): 456–64. <https://doi.org/10.1016/j.jhep.2019.03.028>.
- [19] Lee SW, Kwon JH, Lee HL, Yoo SH, Nam HC, Sung PS, et al. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. *Gut.* 2020; 69(7): 1301–8. <https://doi.org/10.1136/gutjnl-2019-318947>.
- [20] Hsu YC, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, et al. Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B. *Am J Gastroenterol.* 2020; 115(2): 271–80. <https://doi.org/10.1093/ajg/115.2.271>.

- org/10.14309/ajg.0000000000000428.
- [21] Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, et al. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. *J Hepatol.* 2020; <https://doi.org/10.1016/j.jhep.2020.06.011>.
- [22] Yip TC, Wong VW, Chan HL, Tse YK, Lui GC, Wong GL. Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China. *Gastroenterology.* 2020; 158(1): 215–25. <https://doi.org/10.1053/j.gastro.2019.09.025>.
- [23] Gu L, Yao Q, Shen Z, He Y, Ng DM, Yang T, et al. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis. *J Gastroenterol Hepatol.* 2020; <https://doi.org/10.1111/jgh.15036>.
- [24] Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, et al. Induction of IFN-lambda3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. *Gut.* 2018; 67(2): 362–71. <https://doi.org/10.1136/gutjnl-2016-312653>.
- [25] Kim SU, Seo YS, Lee HA, Kim MN, Lee EJ, Shin HJ, et al. Hepatocellular carcinoma risk steadily persists over time despite long-term antiviral therapy for hepatitis B: a multicenter study. *Cancer Epidemiol Biomark Prev.* 2020; 29(4): 832–7. <https://doi.org/10.1158/1055-9965.EPI-19-0614>.
- [26] Korean Liver Cancer Association, National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma. *Gut Liver.* 2019; 13(3): 227–99. <https://doi.org/10.5009/gnl19024>.
- [27] Lee EC, Kim SH, Park H, Lee SD, Lee SA, Park SJ. Survival analysis after liver resection for hepatocellular carcinoma: a consecutive cohort of 1002 patients. *J Gastroenterol Hepatol.* 2017; 32(5): 1055–63. <https://doi.org/10.1111/jgh.13632>.
- [28] Yang HJ, Lee JH, Lee DH, Yu SJ, Kim YJ, Yoon JH, et al. Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. *Radiology.* 2014; 271(3): 909–18. <https://doi.org/10.1148/radiol.13131760>.
- [29] Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. *J Hepatol.* 2003; 38(2): 200–7. [https://doi.org/10.1016/s0168-8278\(02\)00360-4](https://doi.org/10.1016/s0168-8278(02)00360-4).
- [30] Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. *J Hepatol.* 2009; 51(5): 890–7. <https://doi.org/10.1016/j.jhep.2009.07.009>.
- [31] Sohn W, Paik YH, Kim JM, Kwon CH, Joh JW, Cho JY, et al. HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma. *Ann Surg Oncol.* 2014; 21(7): 2429–35. <https://doi.org/10.1245/s10434-014-3621-x>.
- [32] Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. *J Clin Oncol.* 2013; 31(29): 3647–55. <https://doi.org/10.1200/JCO.2012.48.5896>.
- [33] Wu C-Y, Chen Y-J, Ho HJ, Hsu Y-C, Kuo KN, Wu M-S, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. *JAMA.* 2012; 308(18): 1906–13. <https://doi.org/10.1001/2012.jama.11975>.
- [34] Huang G, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. *Ann Surg.* 2015; 261(1): 56–66. <https://doi.org/10.1097/SLA.0000000000000858>.
- [35] Sun P, Dong X, Cheng X, Hu Q, Zheng Q. Nucleot(s) ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. *PLoS One.* 2014; 9(7): e102761. <https://doi.org/10.1371/journal.pone.0102761>.
- [36] Cho H, Ahn H, Lee DH, Lee JH, Jung YJ, Chang Y, et al. Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals. *J Viral Hepat.* 2018; 25(6): 707–17. <https://doi.org/10.1111/jvh.12855>.
- [37] Choi J, Jo C, Lim YS. Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. *Hepatology.* 2020; <https://doi.org/10.1002/hep.31289>.
- [38] Kim JH, Park JW, Koh DW, Lee WJ, Kim CM. Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma. *Liver Int.* 2009; 29(2): 203–7. <https://doi.org/10.1111/j.1478-3231.2008.01828.x>.
- [39] Jin YJ, Shim JH, Lee HC, Yoo DJ, Kim KM, Lim YS, et al. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma. *J Gastroenterol Hepatol.* 2011; 26(9): 1380–8. <https://doi.org/10.1111/j.1440-1746.2011.06776.x>.
- [40] Chong CC, Wong GL, Wong VW, Ip PC, Cheung YS, Wong J, et al. Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. *Aliment Pharmacol Ther.* 2015; 41(2): 199–208. <https://doi.org/10.1111/apt.13034>.
- [41] Xu L, Gao H, Huang J, Wang H, Zhou Z, Zhang Y, et al. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. *J Gastroenterol Hepatol.* 2015; 30(6): 1032–9. <https://doi.org/10.1111/jgh.12910>.
- [42] Yang Y, Wen F, Li J, Zhang P, Yan W, Hao P, et al. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. *Liver Int.* 2015; 35(9): 2147–54. <https://doi.org/10.1111/liv.12805>.
- [43] Kim BH, Lim YS, Kim EY, Kong HJ, Won YJ, Han S, et al. Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population. *J Gastroenterol Hepatol.* 2017; <https://doi.org/10.1111/jgh.13848>.
- [44] Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. *Lancet.* 2012; 379(9822): 1245–55. [https://doi.org/10.1016/S0140-6736\(11\)61347-0](https://doi.org/10.1016/S0140-6736(11)61347-0).
- [45] Choi J, Han S, Kim N, Lim YS. Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population. *Hepatology.* 2017; <https://doi.org/10.1002/hep.29321>.
- [46] Kubo S, Nishiguchi S, Hamba H, Hirohashi K, Tanaka H, Shuto

- T, et al. Reactivation of viral replication after liver resection in patients infected with hepatitis B virus. *Ann Surg.* 2001; 233(1): 139–45. <https://doi.org/10.1097/0000658-200101000-00020>.
- [47] Huang L, Li J, Yan J, Sun J, Zhang X, Wu M, et al. Antiviral therapy decreases viral reactivation in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy: a randomized controlled trial. *J Viral Hepat.* 2013; 20(5): 336–42. <https://doi.org/10.1111/jvh.12036>.
- [48] Dan JQ, Zhang YJ, Huang JT, Chen MS, Gao HJ, Peng ZW, et al. Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: a retrospective study. *Eur J Surg Oncol.* 2013; 39(8): 865–72. <https://doi.org/10.1016/j.ejso.2013.03.020>.
- [49] Yoshida H, Yoshida H, Goto E, Sato T, Ohki T, Masuzaki R, et al. Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. *Hepatol Int.* 2008; 2(1): 89–94. <https://doi.org/10.1007/s12072-007-9020-7>.
- [50] Lao XM, Luo G, Ye LT, Luo C, Shi M, Wang D, et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. *Liver Int.* 2013; 33(4): 595–604. <https://doi.org/10.1111/liv.12112>.
- [51] Lao XM, Wang D, Shi M, Liu G, Li S, Guo R, et al. Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma. *Hepatol Res.* 2011; 41(6): 553–63. <https://doi.org/10.1111/j.1872-034X.2011.00796.x>.
- [52] Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. *Hepatology.* 2006; 43(2): 233–40. <https://doi.org/10.1002/hep.21024>.
- [53] Park JW, Park KW, Cho SH, Park HS, Lee WJ, Lee DH, et al. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. *Am J Gastroenterol.* 2005; 100(10): 2194–200. <https://doi.org/10.1111/j.1572-0241.2005.00232.x>.
- [54] Nagamatsu H, Itano S, Nagaoka S, Akiyoshi J, Matsugaki S, Kurogi J, et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. *Am J Gastroenterol.* 2004; 99(12): 2369–75. <https://doi.org/10.1111/j.1572-0241.2004.40069.x>.
- [55] Tamori A, Nishiguchi S, Tanaka M, Kurooka H, Fujimoto S, Nakamura K, et al. Lamivudine therapy for hepatitis B virus reactivation in a patient receiving intra-arterial chemotherapy for advanced hepatocellular carcinoma. *Hepatol Res.* 2003; 26(1): 77–80. [https://doi.org/10.1016/s1386-6346\(03\)00002-0](https://doi.org/10.1016/s1386-6346(03)00002-0).
- [56] Kim JH, Park JW, Kim TH, Koh DW, Lee WJ, Kim CM. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2007; 69(3): 813–9. <https://doi.org/10.1016/j.ijrobp.2007.04.005>.
- [57] Huang W, Zhang W, Fan M, Lu Y, Zhang J, Li H, et al. Risk factors for hepatitis B virus reactivation after conformal radiotherapy in patients with hepatocellular carcinoma. *Cancer Sci.* 2014; 105(6): 697–703. <https://doi.org/10.1111/cas.12400>.
- [58] Jun BG, Kim YD, Kim SG, Kim YS, Jeong SW, Jang JY, et al. Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: a multicenter study. *PLoS One.* 2018; 13(7): e0201316. <https://doi.org/10.1371/journal.pone.0201316>.
- [59] Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. *Ann Oncol.* 2004; 15(11): 1661–6. <https://doi.org/10.1093/annonc/mdh430>.
- [60] Lim S, Han J, Kim GM, Han KH, Choi HJ. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. *J Gastroenterol Hepatol.* 2015; 30(6): 1024–31. <https://doi.org/10.1111/jgh.12898>.
- [61] Yoo SH, Jang JW, Kwon JH, Jung SM, Jang B, Choi JY. Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization. *Clin Mol Hepatol.* 2016; 22(4): 458–65. <https://doi.org/10.3350/cmh.2016.0054>.
- [62] Jang JW, Yoo SH, Nam HC, Jang BH, Sung Sung PS, Lee W, et al. Association of prophylactic anti-hepatitis B virus therapy with improved long-term survival in patients with hepatocellular carcinoma undergoing transarterial therapy. *Clin Infect Dis.* 2020; 71(3): 546–55. <https://doi.org/10.1093/cid/ciz860>.
- [63] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. *J Hepatol.* 2018; 69(2): 461–511. <https://doi.org/10.1016/j.jhep.2018.03.026>.
- [64] Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. *Clin Mol Hepatol.* 2014; 20(2): 89–136. <https://doi.org/10.3350/cmh.2014.20.2.89>.
- [65] Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. *Gastroenterology.* 2010; 139(5): 1593–601. <https://doi.org/10.1053/j.gastro.2010.07.009>.
- [66] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series ☆. *J Hepatol.* 2020; <https://doi.org/10.1016/j.jhep.2020.08.018>.
- [67] Korean Association for the Study of the Liver. 2017 KASL clinical practice guidelines management of hepatitis C: treatment of chronic hepatitis C. *Clin Mol Hepatol.* 2018; 24(3): 169–229. <https://doi.org/10.3350/cmh.2018.1004>.
- [68] Ghany MG, Morgan TR, Panel A-IHCG. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. *Hepatology.* 2020; 71(2): 686–721. <https://doi.org/10.1002/hep.31060>.
- [69] Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, Ioannou GN. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. *J Hepatol.* 2017; 67(1): 32–9. <https://doi.org/10.1016/j.jhep.2017.02.027>.
- [70] Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, Kulik L. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. *J Hepatol.* 2017; 66(6): 1173–81. <https://doi.org/10.1016/j.jhep.2017.01.020>.
- [71] Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, et al. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma:

- a systematic review and meta-analysis. *J Hepatol.* 2019; 71(3): 473–85. <https://doi.org/10.1016/j.jhep.2019.04.017>.
- [72] He S, Lockart I, Alavi M, Danta M, Hajarizadeh B, Dore GJ. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. *Aliment Pharmacol Ther.* 2020; 51(1): 34–52. <https://doi.org/10.1111/apt.15598>.
- [73] Yen YH, Chen CH, Hung CH, Wang JH, Lu SN, Kee KM, et al. Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: a retrospective study with prospectively collected data. *PLoS One.* 2019; 14(10): e0222605. <https://doi.org/10.1371/journal.pone.0222605>.
- [74] Ogawa E, Toyoda H, Iio E, Jun DW, Huang CF, Enomoto M, et al. HCV cure rates are reduced in patients with active but not inactive hepatocellular carcinoma: a practice implication. *Clin Infect Dis.* 2019; <https://doi.org/10.1093/cid/ciz1160>.
- [75] Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, et al. Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study. *BMJ Open.* 2019; 9(5): e026703. <https://doi.org/10.1136/bmjopen-2018-026703>.
- [76] Singal AG, Lim JK, Kanwal F. AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review. *Gastroenterology.* 2019; 156(8): 2149–57. <https://doi.org/10.1053/j.gastro.2019.02.046>.
- [77] Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. *Ann Intern Med.* 2013; 158(5 Pt 1): 329–37. <https://doi.org/10.7326/0003-4819-158-5-201303050-00005>.
- [78] Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. *Clin Gastroenterol Hepatol.* 2010; 8(3) <https://doi.org/10.1016/j.cgh.2009.11.018>.
- [79] Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. *J Hepatol.* 2017; 67(6): 1204–12. <https://doi.org/10.1016/j.jhep.2017.07.025>.
- [80] Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. *J Hepatol.* 2018; 68(1): 25–32. <https://doi.org/10.1016/j.jhep.2017.08.030>.
- [81] Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. *Gastroenterology.* 2018; 155(2): 411–21. <https://doi.org/10.1053/j.gastro.2018.04.008>.
- [82] Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. *Gastroenterology.* 2017; 153(4): 996–1005. <https://doi.org/10.1053/j.gastro.2017.06.012>.
- [83] Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study. *J Hepatol.* 2018; 69(2): 345–52. <https://doi.org/10.1016/j.jhep.2018.03.009>.
- [84] Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. *Gastroenterology.* 2017; 152(1): 142–56. <https://doi.org/10.1053/j.gastro.2016.09.009>.
- [85] El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. *Hepatology.* 2016; 64(1): 130–7. <https://doi.org/10.1002/hep.28535>.
- [86] Ioannou GN, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. *Gastroenterology.* 2019; 157(5): 1264–78. <https://doi.org/10.1053/j.gastro.2019.07.033>.
- [87] Hamdane N, Juhling F, Crouchet E, El Saghire H, Thumann C, Oudot MA, et al. HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response. *Gastroenterology.* 2019; 156(8): 2313–29. <https://doi.org/10.1053/j.gastro.2019.02.038>.
- [88] Perez S, Kaspi A, Domovitz T, Davidovich A, Lavi-Itzkovitz A, Meirson T, et al. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. *PLoS Genet.* 2019; 15(6): e1008181. <https://doi.org/10.1371/journal.pgen.1008181>.
- [89] Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. *Aliment Pharmacol Ther.* 2010; 32(7): 851–8. <https://doi.org/10.1111/j.1365-2036.2010.04414.x>.
- [90] Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. *J Hepatol.* 2016; 65(4): 719–26. <https://doi.org/10.1016/j.jhep.2016.04.008>.
- [91] ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. *J Hepatol.* 2016; 65(4): 734–40. <https://doi.org/10.1016/j.jhep.2016.05.045>.
- [92] Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, et al. Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter north American Cohort Study. *Gastroenterology.* 2019; 156(6): 1683–92. <https://doi.org/10.1053/j.gastro.2019.01.027>.
- [93] Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavò MR, Madonia S, et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. *Aliment Pharmacol Ther.* 2017; 46(7): 688–95. <https://doi.org/10.1111/apt.14256>.
- [94] Nishibatake Kinoshita M, Minami T, Tateishi R, Wake T, Nakagomi R, Fujiwara N, et al. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: comparison with interferon-based therapy. *J Hepatol.* 2019; 70(1): 78–86. <https://doi.org/10.1016/j.jhep.2018.09.029>.
- [95] Cabibbo G, Celsa C, Calvaruso V, Petta S, Cacciola I, Cannavò MR, et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. *J Hepatol.* 2019; 71(2): 265–73. <https://doi.org/10.1016/j.jhep.2019.03.027>.
- [96] Petta S, Cabibbo G, Barbara M, Attardo S, Bucci L, Farinati

- F, et al. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. *Aliment Pharmacol Ther.* 2017; 45(1): 160–8. <https://doi.org/10.1111/apt.13821>.
- [97] Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, et al. Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma. *Gastroenterology.* 2019; 157(5): 1253–63. <https://doi.org/10.1053/j.gastro.2019.07.040>.
- [98] Kamp WM, Sellers CM, Stein S, Lim JK, Kim HS. Impact of direct acting antivirals on survival in patients with chronic hepatitis C and hepatocellular carcinoma. *Sci Rep.* 2019; 9(1): 17081. <https://doi.org/10.1038/s41598-019-53051-2>.
- [99] Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, Landis C, et al. Cure with interferon-free direct-acting antiviral is associated with increased survival in patients with hepatitis C virus-related hepatocellular carcinoma from both east and west. *Hepatology.* 2020; 71(6): 1910–22. <https://doi.org/10.1002/hep.30988>.
- [100] Sung PS, Bae SH, Jang JW, Song DS, Kim HY, Yoo SH, et al. Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization. *Korean J Hepatol.* 2011; 17(4): 299–306. <https://doi.org/10.3350/kjhep.2011.17.4.299>.

- [1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018; 68(6): 394–424.
- [2] Delis SG, Dervenis C. Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease. *World J Gastroenterol.* 2008; 14(22): 3452–60.
- [3] Couto OF, Dvorchik I, Carr BI. Causes of death in patients with unresectable hepatocellular carcinoma. *Dig Dis Sci.* 2007; 52(11): 3285–9.
- [4] Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. *Int J Radiat Oncol Biol Phys.* 1995; 31(5): 1237–48.
- [5] Ben-Josef E, Normolle D, Ensminger WD, Walker S, Tatro D, Haken RKT, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. *J Clin Oncol.* 2005; 23(34): 8739–47.
- [6] Mornex F, Girard N, Beziat C, Kubas A, Khodri M, Trepo C, et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies—mature results of the French Phase II RTF-1 trial. *Int J Radiat Oncol Biol Phys.* 2006; 66(4): 1152–8.
- [7] Yoon HI, Lee IJ, Han KH, Seong J. Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma. *J Cancer Res Clin Oncol.* 2014; 140(9): 1595–605.
- [8] Hou JZ, Zeng ZC, Wang BL, Yang P, Zhang JY, Mo HF. High dose radiotherapy with image-guided hypo-IMRT for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombi is more feasible and efficacious than conventional 3D-CRT. *Jpn J Clin Oncol.* 2016; 46(4): 357–62.
- [9] Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, Ayuso JR, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. *Hepatology (Baltimore, MD).* 2008; 47(1): 97–104.
- [10] Voroney JP, Brock KK, Eccles C, Haider M, Dawson LA. Prospective comparison of computed tomography and magnetic resonance imaging for liver cancer delineation using deformable image registration. *Int J Radiat Oncol Biol Phys.* 2006; 66(3): 780–91.
- [11] Wang H, Krishnan S, Wang X, Beddar AS, Briere TM, Crane CH, et al. Improving soft-tissue contrast in four-dimensional computed tomography images of liver cancer patients using a deformable image registration method. *Int J Radiat Oncol Biol Phys.* 2008; 72(1): 201–9.
- [12] Keall PJ, Mageras GS, Balter JM, Emery RS, Forster KM, Jiang SB, et al. The management of respiratory motion in radiation oncology report of AAPM Task Group 76. *Med Phys.* 2006; 33(10): 3874–900.
- [13] Tsai YL, Wu CJ, Shaw S, Yu PC, Nien HH, Lui LT. Quantitative analysis of respiration-induced motion of each liver segment with helical computed tomography and 4-dimensional computed tomography. *Radiat Oncol (London, Engl).* 2018; 13(1): 59.
- [14] Oh SA, Yea JW, Kim SK, Park JW. Optimal gating window for respiratory-gated radiotherapy with real-time position management and respiration guiding system for liver cancer treatment. *Sci Rep.* 2019; 9(1): 4384.
- [15] Eccles C, Brock KK, Bissonnette JP, Hawkins M, Dawson LA. Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy. *Int J Radiat Oncol Biol Phys.* 2006; 64(3): 751–9.
- [16] Herfarth KK, Debus J, Lohr F, Bahner ML, Fritz P, Höss A, et al. Extracranial stereotactic radiation therapy: set-up accuracy of patients treated for liver metastases. *Int J Radiat Oncol Biol Phys.* 2000; 46(2): 329–35.
- [17] Wagman R, Yorke E, Ford E, Giraud P, Mageras G, Minsky B, et al. Respiratory gating for liver tumors: use in dose escalation. *Int J Radiat Oncol Biol Phys.* 2003; 55(3): 659–68.
- [18] Beddar AS, Kainz K, Briere TM, Tsunashima Y, Pan T, Prado K, et al. Correlation between internal fiducial tumor motion and external marker motion for liver tumors imaged with 4D-CT. *Int J Radiat Oncol Biol Phys.* 2007; 67(2): 630–8.
- [19] Park SH, Won HJ, Kim SY, Shin YM, Kim PN, Yoon SM, et al. Efficacy and safety of ultrasound-guided implantation of fiducial markers in the liver for stereotactic body radiation therapy. *PLoS One.* 2017; 12(6): e0179676.
- [20] Hawkins MA, Brock KK, Eccles C, Moseley D, Jaffray D, Dawson LA. Assessment of residual error in liver position using kV cone-beam computed tomography for liver cancer high-precision radiation therapy. *Int J Radiat Oncol Biol Phys.* 2006; 66(2): 610–9.
- [21] Yang J, Cai J, Wang H, Chang Z, Czito BG, Bashir MR, et al. Is diaphragm motion a good surrogate for liver tumor motion? *Int J Radiat Oncol Biol Phys.* 2014; 90(4): 952–8.
- [22] Fahmi S, Simonis FFJ, Abayazid M. Respiratory motion estimation of the liver with abdominal motion as a surrogate. *Int J Med Robot.* 2018; 14(6): e1940.
- [23] Seiler PG, Blattmann H, Kirsch S, Muench RK, Schilling C. A novel tracking technique for the continuous precise measurement of tumour positions in conformal radiotherapy.

- Phys Med Biol. 2000; 45(9): N103–10.
- [24] Balter JM, Wright JN, Newell LJ, Friemel B, Dimmer S, Cheng Y, et al. Accuracy of a wireless localization system for radiotherapy. *Int J Radiat Oncol Biol Phys.* 2005; 61(3): 933–7.
- [25] Eccles CL, Tse RV, Hawkins MA, Lee MT, Moseley DJ, Dawson LA. Intravenous contrast-enhanced cone beam computed tomography (IVCBCT) of intrahepatic tumors and vessels. *Adv Radiat Oncol.* 2016; 1(1): 43–50.
- [26] Scherthaner RE, Haroun RR, Duran R, Lee H, Sahu S, Sohn JH, et al. Improved visibility of metastatic disease in the liver during intra-arterial therapy using delayed arterial phase cone-beam CT. *Cardiovasc Intervent Radiol.* 2016; 39(10): 1429–37.
- [27] Price RG, Apisarnthanarax S, Schaub SK, Nyflot MJ, Chapman TR, Matesan M, et al. Regional radiation dose-response modeling of functional liver in hepatocellular carcinoma patients with longitudinal sulfur colloid SPECT/CT: a proof of concept. *Int J Radiat Oncol Biol Phys.* 2018; 102(4): 1349–56.
- [28] Schaub SK, Apisarnthanarax S, Price RG, Nyflot MJ, Chapman TR, Matesan M, et al. Functional liver imaging and dosimetry to predict hepatotoxicity risk in cirrhotic patients with primary liver cancer. *Int J Radiat Oncol Biol Phys.* 2018; 102(4): 1339–48.
- [29] Qi WX, Fu S, Zhang Q, Guo XM. Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. *Radiation Oncol.* 2015; 114(3): 289–95.
- [30] Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. *JAMA Oncol.* 2018; 4(5): 661–9.
- [31] Schae D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. *Int J Radiat Oncol Biol Phys.* 2012; 83(4): 1306–10.
- [32] Wen N, Kim J, Doemer A, Glide-Hurst C, Chetty IJ, Liu C, et al. Evaluation of a magnetic resonance guided linear accelerator for stereotactic radiosurgery treatment. *Radiation Oncol J Eur Soc Therap Radiol Oncol.* 2018; 127(3): 460–6.
- [33] Fast M, van de Schoot A, van de Lindt T, Carbaat C, van der Heide U, Sonke JJ. Tumor trailing for liver SBRT on the MR-linac. *Int J Radiat Oncol Biol Phys.* 2019; 103(2): 468–78.
- [34] Feldman AM, Modh A, Glide-Hurst C, Chetty IJ, Movsas B. Real-time magnetic resonance-guided liver stereotactic body radiation therapy: an institutional report using a magnetic resonance-linac system. *Cureus.* 2019; 11(9): e5774.
- [35] Newhauser WD, Zhang R. The physics of proton therapy. *Phys Med Biol.* 2015; 60(8): R155–209.
- [36] Munoz-Schuffenegger P, Ng S, Dawson LA. Radiation-induced liver toxicity. *Semin Radiat Oncol.* 2017; 27(4): 350–7.
- [37] Dionisi F, Widesott L, Lorentini S, Amichetti M. Is there a role for proton therapy in the treatment of hepatocellular carcinoma? A systematic review. *Radiation Oncol.* 2014; 111(1): 1–10.
- [38] Skinner HD, Hong TS, Krishnan S. Charged-particle therapy for hepatocellular carcinoma. *Semin Radiat Oncol.* 2011; 21(4): 278–86.
- [39] Langen K, Zhu M. Concepts of PTV and robustness in passively scattered and pencil beam scanning proton therapy. *Semin Radiat Oncol.* 2018; 28(3): 248–55.
- [40] Fukumitsu N, Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Abei M, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2009; 74(3): 831–6.
- [41] Bush DA, Kayali Z, Grove R, Slater JD. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. *Cancer.* 2011; 117(13): 3053–9.
- [42] Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *J Clin Oncol.* 2016; 34(5): 460–8.
- [43] Robbins JR, Schmid RK, Hammad AY, Gamblin TC, Erickson BA. Stereotactic body radiation therapy for hepatocellular carcinoma: practice patterns, dose selection and factors impacting survival. *Cancer Med.* 2019; 8(3): 928–38.
- [44] Holliday EB, Tao R, Brownlee Z, Das P, Krishnan S, Taniguchi C, et al. Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus. *Clin Transl Radiat Oncol.* 2017; 4: 39–45.
- [45] Lausch A, Sinclair K, Lock M, Fisher B, Jensen N, Gaede S, et al. Determination and comparison of radiotherapy dose responses for hepatocellular carcinoma and metastatic colorectal liver tumours. *Br J Radiol.* 2013; 86(1027): 20130147.
- [46] Jang WI, Kim M-S, Bae SH, Cho CK, Yoo HJ, Seo YS, et al. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. *Radiat Oncol.* 2013; 8(1): 250.
- [47] Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C, et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). *J Cancer Res Clin Oncol.* 2015; 141(7): 1301–9.
- [48] Chadha AS, Gunther JR, Hsieh CE, Aliru M, Mahadevan LS, Venkatesulu BP, et al. Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. *Radiation Oncol J Eur Soc Therap Radiol Oncol.* 2019; 133: 54–61.
- [49] Pursley J, El Naqa I, Sanford NN, Noe B, Wo JY, Eyler CE, et al. Dosimetric analysis and normal tissue complication probability modeling of Child-Pugh score and Albumin-Bilirubin grade increase after hepatic irradiation. *Int J Radiat Oncol Biol Phys.* 2020; 107(5): 986–95.
- [50] Son SH, Kay CS, Song JH, Lee S-W, Choi BO, Kang YN, et al. Dosimetric parameter predicting the deterioration of hepatic function after helical tomotherapy in patients with unresectable locally advanced hepatocellular carcinoma. *Radiat Oncol.* 2013; 8(1): 11.
- [51] Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. *Int J Radiat Oncol Biol Phys.* 2010; 76(3 Suppl): S94–S100.
- [52] Hsieh C-E, Venkatesulu BP, Lee C-H, Hung S-P, Wong P-F, Aithala SP, et al. Predictors of radiation-induced liver disease in eastern and western patients with hepatocellular carcinoma undergoing proton beam therapy. *Int J Radiat Oncol Biol Phys.* 2019; 105: 73–86.
- [53] Gandhi SJ, Liang X, Ding X, Zhu TC, Ben-Josef E, Plastaras JP, et al. Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: Photons versus protons. *Pract Radiat Oncol.* 2015; 5(4): 209–18.
- [54] Toramatsu C, Katoh N, Shimizu S, Nihongi H, Matsuura T,

- Takao S, et al. What is the appropriate size criterion for proton radiotherapy for hepatocellular carcinoma? A dosimetric comparison of spot-scanning proton therapy versus intensity-modulated radiation therapy. *Radiat Oncol (London, Engl)*. 2013; 8: 48.
- [55] Wang X, Krishnan S, Zhang X, Dong L, Briere T, Crane CH, et al. Proton radiotherapy for liver tumors: dosimetric advantages over photon plans. *Med Dosim*. 2008; 33(4): 259–67.
- [56] Sanford NN, Pursley J, Noe B, Yeap BY, Goyal L, Clark JW, et al. Protons versus photons for unresectable hepatocellular carcinoma: liver decompensation and overall survival. *Int J Radiat Oncol Biol Phys*. 2019; 105(1): 64–72.
- [57] Hasan S, Abel S, Verma V, Webster P, Arscott WT, Wegner RE, et al. Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation. *J Gastrointest Oncol*. 2019; 10(5): 999–1009.
- [58] Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. *J Clin Oncol Off J Am Soc Clin Oncol*. 2016; 34(3): 219–26.
- [59] Hung S-P, Huang B-S, Hsieh C-E, Lee C-H, Tsang N-M, Chang JT-C, et al. Clinical outcomes of patients with unresectable cholangiocarcinoma treated with proton beam therapy. *Am J Clin Oncol*. 2020; 43(3): 180–6.
- [60] Makita C, Nakamura T, Takada A, Takayama K, Suzuki M, Ishikawa Y, et al. Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma. *Radiat Oncol*. 2014; 9(1): 26.
- [61] Ohkawa A, Mizumoto M, Ishikawa H, Abei M, Fukuda K, Hashimoto T, et al. Proton beam therapy for unresectable intrahepatic cholangiocarcinoma. *J Gastroenterol Hepatol*. 2015; 30(5): 957–63.
- [62] Hong TS, Wo JY, Borger DR, Yeap BY, McDonnell EI, Willers H, et al. Phase II study of proton-based stereotactic body radiation therapy for liver metastases: importance of tumor genotype. *J Natl Cancer Inst*. 2017. 109(9) <https://doi.org/10.1093/jnci/djx031>.
- [63] Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. *J Clin Oncol Off J Am Soc Clin Oncol*. 2009; 27(10): 1585–91.
- [64] Komatsu S, Fukumoto T, Demizu Y, Miyawaki D, Terashima K, Sasaki R, et al. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. *Cancer*. 2011; 117(21): 4890–904.
- [65] Nakayama H, Sugahara S, Tokita M, Fukuda K, Mizumoto M, Abei M, et al. Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. *Cancer*. 2009; 115(23): 5499–506.
- [66] Kawashima M, Kohno R, Nakachi K, Nishio T, Mitsunaga S, Ikeda M, et al. Dose-volume histogram analysis of the safety of proton beam therapy for unresectable hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2011; 79(5): 1479–86.
- [67] Fukumitsu N, Okumura T, Takizawa D, Numajiri H, Ohnishi K, Mizumoto M, et al. Proton beam therapy for liver metastases from gastric cancer. *J Radiat Res*. 2017; 58(3): 357–62.
- [68] Moreno AC, Frank SJ, Garden AS, Rosenthal DI, Fuller CD, Gunn GB, et al. Intensity modulated proton therapy (IMPT) – The future of IMRT for head and neck cancer. *Oral Oncol*. 2019; 88: 66–74.
- [69] Pugh TJ, Amos RA, John Baptiste S, Choi S, Nhu Nguyen Q, Ronald Zhu X, et al. Multifield optimization intensity-modulated proton therapy (MFO-IMPT) for prostate cancer: robustness analysis through simulation of rotational and translational alignment errors. *Med Dosim*. 2013; 38(3): 344–50.
- [70] Park PC, Zhu XR, Lee AK, Sahoo N, Melancon AD, Zhang L, et al. A beam-specific planning target volume (PTV) design for proton therapy to account for setup and range uncertainties. *Int J Radiat Oncol Biol Phys*. 2012; 82(2): e329–e36.
- [71] Grassberger C, Dowdell S, Lomax A, Sharp G, Shackelford J, Choi N, et al. Motion interplay as a function of patient parameters and spot size in spot scanning proton therapy for lung cancer. *Int J Radiat Oncol Biol Phys*. 2013; 86(2): 380–6.
- [72] Knopf A-C, Lomax AJ. In the context of radiosurgery – pros and cons of rescanning as a solution for treating moving targets with scanned particle beams. *Phys Med*. 2014; 30(5): 551–4.
- [73] Dolde K, Zhang Y, Chaudhri N, Dávid C, Kachelrieß M, Lomax AJ, et al. 4DMRI-based investigation on the interplay effect for pencil beam scanning proton therapy of pancreatic cancer patients. *Radiat Oncol*. 2019; 14(1): 30.
- [74] Yoo GS, Yu JI, Cho S, Jung SH, Han Y, Park S, et al. Comparison of clinical outcomes between passive scattering versus pencil-beam scanning proton beam therapy for hepatocellular carcinoma. *Radiation Oncol*. 2020; 146: 187–93.
- [75] Dionisi F, Brolese A, Siniscalchi B, Giacomelli I, Fracchiolla F, Righetto R, et al. Clinical results of active scanning proton therapy for primary liver tumors. *Tumori J*. 2020; <https://doi.org/10.1177/0300891620937809>.
- [76] Akino Y, Wu H, Oh R-J, Das IJ. An effective method to reduce the interplay effects between respiratory motion and a uniform scanning proton beam irradiation for liver tumors: a case study. *J Appl Clin Med Phys*. 2019; 20(1): 220–8.
- [77] Lambert J, Suchowerska N, McKenzie DR, Jackson M. Intrafractional motion during proton beam scanning. *Phys Med Biol*. 2005; 50(20): 4853–62.
- [78] Ray S, Cekanaviciute E, Lima IP, Sørensen BS, Costes SV. Comparing photon and charged particle therapy using DNA damage biomarkers. *Int J Part Ther*. 2018; 5(1): 15–24.
- [79] Ebner DK, Tsuji H, Yasuda S, Yamamoto N, Mori S, Kamada T. Respiration-gated fast-rescanning carbon-ion radiotherapy. *Jpn J Clin Oncol*. 2017; 47(1): 80–3.
- [80] Zeitlin C, La Tessa C. The role of nuclear fragmentation in particle therapy and space radiation protection. *Front Oncol*. 2016; 6: 65.
- [81] Tsujii H, Kamada T. A review of update clinical results of carbon ion radiotherapy. *Jpn J Clin Oncol*. 2012; 42(8): 670–85.
- [82] Karger CP, Peschke P. RBE and related modeling in carbon-ion therapy. *Phys Med Biol*. 2017; 63(1): 01TR02.
- [83] Choi J, Kang JO. Basics of particle therapy II: relative biological effectiveness. *Radiat Oncol J*. 2012; 30(1): 1–13.
- [84] Mohamad O, Makishima H, Kamada T. Evolution of carbon ion radiotherapy at the national institute of radiological sciences in Japan. *Cancers (Basel)*. 2018; 10(3): 66.
- [85] Fossati P, Matsufoji N, Kamada T, Karger CP. Radiobiological issues in prospective carbon ion therapy trials. *Med Phys*. 2018; 45(11): e1096–e110.
- [86] Fossati P, Molinelli S, Matsufoji N, Ciocca M, Mirandola A, Mairani A, et al. Dose prescription in carbon ion radiotherapy:

- a planning study to compare NIRS and LEM approaches with a clinically-oriented strategy. *Phys Med Biol.* 2012; 57: 7543–54.
- [87] Kagawa K, Murakami M, Hishikawa Y, Abe M, Akagi T, Yanou T, et al. Preclinical biological assessment of proton and carbon ion beams at Hyogo Ion Beam Medical Center. *Int J Radiat Oncol Biol Phys.* 2002; 54: 928–38.
- [88] Wang W, Huang Z, Sheng Y, Zhao J, Shahnazi K, Zhang Q, et al. RBE-weighted dose conversions for carbon ionradiotherapy between microdosimetric kinetic model and local effect model for the targets and organs at risk in prostate carcinoma. *Radiother Oncol.* 2020; 144: 30–6.
- [89] Yasuda S, Kato H, Imada H, Isozaki Y, Kasuya G, Makishima H, et al. Long-term results of high-dose 2-fraction carbon ion radiation therapy for hepatocellular carcinoma. *Adv Radiat Oncol.* 2020; 5(2): 196–203.
- [90] Shiba S, Shibuya K, Kawashima M, Okano N, Kaminuma T, Okamoto M, et al. Comparison of dose distributions when using carbon ion radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with macroscopic vascular invasion: a retrospective analysis. *Anticancer Res.* 2020; 40(1): 459–64.
- [91] Abe T, Saitoh J-I, Kobayashi D, Shibuya K, Koyama Y, Shimada H, et al. Dosimetric comparison of carbon ion radiotherapy and stereotactic body radiotherapy with photon beams for the treatment of hepatocellular carcinoma. *Radiat Oncol (London, Engl).* 2015; 10: 187.
- [92] Hsu C-Y, Wang C-W, Cheng A-L, Kuo S-H. Hypofractionated particle beam therapy for hepatocellular carcinoma: a brief review of clinical effectiveness. *World J Gastrointest Oncol.* 2019; 11(8): 579–88.
- [93] Kasuya G, Kato H, Yasuda S, Tsuji H, Yamada S, Haruyama Y, et al. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: combined analyses of 2 prospective trials. *Cancer.* 2017; 123(20): 3955–65.
- [94] Kato H, Tsujii H, Miyamoto T, Mizoe J-E, Kamada T, Tsuji H, et al. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. *Int J Radiat Oncol Biol Phys.* 2004; 59(5): 1468–76.
- [95] Shibuya K, Ohno T, Katoh H, Okamoto M, Shiba S, Koyama Y, et al. A feasibility study of high-dose hypofractionated carbon ion radiation therapy using four fractions for localized hepatocellular carcinoma measuring 3 cm or larger. *Radiother Oncol.* 2019; 132: 230–5.
- [96] Shibuya K, Ohno T, Terashima K, Toyama S, Yasuda S, Tsuji H, et al. Short-course carbon-ion radiotherapy for hepatocellular carcinoma: a multi-institutional retrospective study. *Liver Int.* 2018; 38(12): 2239–47.
- [97] Imada H, Kato H, Yasuda S, Yamada S, Yanagi T, Kishimoto R, et al. Comparison of efficacy and toxicity of short-course carbon ion radiotherapy for hepatocellular carcinoma depending on their proximity to the porta hepatis. *Radiother Oncol.* 2010; 96(2): 231–5.

消融放射治疗基础：肝细胞癌立体定向放射治疗的背景知识

7

Basics of Ablative Radiotherapy: The Background Knowledge Necessary to Practicing Stereotactic Body Radiotherapy for Hepatocellular Carcinoma

- [1] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. *J Hepatol.* 2018; 69(1): 182–236.
- [2] Schuppan D, Afdhal NH. Liver cirrhosis. *Lancet.* 2008; 371(9615): 838–51.
- [3] Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int.* 2017; 11(4): 317–70.
- [4] Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. *Hepatology.* 2018; 68(2): 723–50.
- [5] Borgelt BB, Gelber R, Brady LW, Griffin T, Hendrickson FR. The palliation of hepatic metastases: results of the Radiation Therapy Oncology Group pilot study. *Int J Radiat Oncol Biol Phys.* 1981; 7(5): 587–91.
- [6] Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. *Int J Radiat Oncol Biol Phys.* 1991; 21(1): 109–22.
- [7] Lax I, Blomgren H, Naslund I, Svanstrom R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. *Acta Oncol.* 1994; 33(6): 677–83.
- [8] McGinn CJ, Ten Haken RK, Ensminger WD, Walker S, Wang S, Lawrence TS. Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. *J Clin Oncol.* 1998; 16(6): 2246–52.
- [9] Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. *Int J Radiat Oncol Biol Phys.* 2002; 53(4): 810–21.
- [10] Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. *J Clin Oncol.* 2001; 19(1): 164–70.
- [11] Wulf J, Hadinger U, Oppitz U, Thiele W, Ness-Dourdoumas R, Flentje M. Stereotactic radiotherapy of targets in the lung and liver. *Strahlenther Onkol.* 2001; 177(12): 645–55.
- [12] Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2011; 81(4): e447–53.
- [13] Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. *J Clin Oncol.* 2013; 31(13): 1631–9.
- [14] Cardenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. *Clin Transl Oncol.* 2010; 12(3): 218–25.
- [15] Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. *Cancer.* 2012; 118(21): 5424–31.
- [16] Louis C, Dewas S, Mirabel X, Lacornerie T, Adenis A, Bonodeau F, et al. Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. *Technol Cancer Res Treat.* 2010; 9(5): 479–87.
- [17] Mendez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study. *Acta Oncol.* 2006; 45(7): 831–7.
- [18] Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, Eriguchi T, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. *Acta Oncol.* 2014; 53(3): 399–404.
- [19] Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, Ebinuma H, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. *Cancer.* 2016; 122(13): 2041–9.
- [20] Hara K, Takeda A, Tsurugai Y, Saigusa Y, Sanuki N, Eriguchi T, et al. Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis. *Hepatology.* 2019; 69(6): 2533–45.
- [21] Kim N, Cheng J, Jung I, Liang J, Shih YL, Huang WY, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. *J Hepatol.* 2020; 73(1): 121–9.
- [22] Kim TH, Koh YH, Kim BH, Kim MJ, Lee JH, Park B, et al. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial. *J Hepatol.* 2020; 74(3): 603–12.

- [23] Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. *JAMA Oncol.* 2017; 3(12): 1683–91.
- [24] Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. *Hepatology.* 2011; 53(3): 1020–2.
- [25] Balakrishnan M, El-Serag HB. Editorial: NAFLD-related hepatocellular carcinoma—increasing or not? With or without cirrhosis? *Aliment Pharmacol Ther.* 2018; 47(3): 437–8.
- [26] White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. *Clin Gastroenterol Hepatol.* 2012; 10(12): 1342–59.e2.
- [27] Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. *Gastroenterology.* 2019; 156(2): 477–91.e1.
- [28] Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. *Lancet.* 1992; 339(8799): 943–6.
- [29] Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. *Cancer.* 2016; 122(22): 3430–46.
- [30] Lurje I, Czigan Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, et al. Treatment strategies for hepatocellular carcinoma (-) a multidisciplinary approach. *Int J Mol Sci.* 2019; 20(6): 1465.
- [31] Montalti R, Mimmo A, Rompianesi G, Di Gregorio C, Serra V, Cautero N, et al. Absence of viable HCC in the native liver is an independent protective factor of tumor recurrence after liver transplantation. *Transplantation.* 2014; 97(2): 220–6.
- [32] Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet.* 2002; 359(9319): 1734–9.
- [33] Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology.* 2002; 35(5): 1164–71.
- [34] Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. *Gastroenterology.* 2016; 151(6): 1155–63.e2.
- [35] Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. *Gastroenterology.* 2011; 140(2): 497–507.e2.
- [36] Durand-Labrunie J, Baumann AS, Ayav A, Laurent V, Boleslawski E, Cattan S, et al. Curative irradiation treatment of hepatocellular carcinoma: a multicenter phase 2 trial. *Int J Radiat Oncol Biol Phys.* 2020; 107(1): 116–25.
- [37] Gkika E, Schultheiss M, Bettinger D, Maruschke L, Neeff HP, Schulenburg M, et al. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma. *Radiat Oncol.* 2017; 12(1): 116.
- [38] Jang WI, Bae SH, Kim MS, Han CJ, Park SC, Kim SB, et al. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: safety and efficacy. *Cancer.* 2020; 126(2): 363–72.
- [39] Loi M, Comito T, Franzese C, Dominici L, Lo Faro L, Clerici E, et al. Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity. *J Cancer Res Clin Oncol.* 2020; 147(3): 927–36.
- [40] Yeung R, Beaton L, Rackley T, Weber B, Hamm J, Lee R, et al. Stereotactic body radiotherapy for small unresectable hepatocellular carcinomas. *Clin Oncol (R Coll Radiol).* 2019; 31(6): 365–73.
- [41] Facciuto ME, Singh MK, Rochon C, Sharma J, Gimenez C, Katta U, et al. Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response. *J Surg Oncol.* 2012; 105(7): 692–8.
- [42] Katz AW, Chawla S, Qu Z, Kashyap R, Milano MT, Hezel AF. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation. *Int J Radiat Oncol Biol Phys.* 2012; 83(3): 895–900.
- [43] O'Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, Goldstein RM. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. *Liver Transpl.* 2012; 18(8): 949–54.
- [44] Mannina EM, Cardenes HR, Lasley FD, Goodman B, Zook J, Althouse S, et al. Role of stereotactic body radiation therapy before orthotopic liver transplantation: retrospective evaluation of pathologic response and outcomes. *Int J Radiat Oncol Biol Phys.* 2017; 97(5): 931–8.
- [45] Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. *J Hepatol.* 2017; 67(1): 92–9.
- [46] Uemura T, Kirichenko A, Bunker M, Vincent M, Machado L, Thai N. Stereotactic body radiation therapy: a new strategy for loco-regional treatment for hepatocellular carcinoma while awaiting liver transplantation. *World J Surg.* 2019; 43(3): 886–93.
- [47] Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, Brade A, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. *Radiother Oncol.* 2014; 111(3): 412–7.
- [48] Valakh V, Gresswell S, Kirichenko A. Outcomes of stereotactic body radiotherapy for hepatocellular carcinoma with severe cirrhosis and ineligibility for transplant. *Anticancer Res.* 2018; 38(12): 6815–20.
- [49] Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. *Int J Radiat Oncol Biol Phys.* 2010; 78(2): 486–93.
- [50] Kimura T, Aikata H, Takahashi S, Takahashi I, Nishibuchi I, Doi Y, et al. Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. *Hepatol Res.* 2015; 45(4): 378–86.
- [51] Park JH, Yoon SM, Lim YS, Kim SY, Shim JH, Kim KM, et al. Two-week schedule of hypofractionated radiotherapy as a local salvage treatment for small hepatocellular carcinoma. *J Gastroenterol Hepatol.* 2013; 28(10): 1638–42.

- [52] Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C, et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). *J Cancer Res Clin Oncol*. 2015; 141(7): 1301–9.
- [53] Kim N, Cheng J, Huang WY, Kimura T, Zeng ZC, Lee VHF, et al. Dose-response relationship in stereotactic body radiation therapy for hepatocellular carcinoma: a pooled analysis of an Asian liver radiation therapy group study. *Int J Radiat Oncol Biol Phys*. 2020; 109(2): 464–73.
- [54] Ohri N, Tome WA, Mendez Romero A, Miften M, Ten Haken RK, Dawson LA, et al. Local control after stereotactic body radiation therapy for liver tumors. *Int J Radiat Oncol Biol Phys*. 2018; <https://doi.org/10.1016/j.ijrobp.2017.12.288>.
- [55] Kim N, Kim HJ, Won JY, Kim DY, Han KH, Jung I, et al. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. *Radiother Oncol*. 2019; 131: 81–7.
- [56] Rajyaguru DJ, Borgert AJ, Smith AL, Thomes RM, Conway PD, Halfdanarson TR, et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the national cancer database. *J Clin Oncol*. 2018; 36(6): 600–8.
- [57] Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. *J Clin Oncol*. 2016; 34(5): 452–9.
- [58] Sapir E, Tao Y, Schipper MJ, Bazzi L, Novelli PM, Devlin P, et al. Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2018; 100(1): 122–30.
- [59] Honda Y, Kimura T, Aikata H, Kobayashi T, Fukuhara T, Masaki K, et al. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. *J Gastroenterol Hepatol*. 2013; 28(3): 530–6.
- [60] Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. *Int J Radiat Oncol Biol Phys*. 2010; 76(3 Suppl): S94–100.
- [61] Cheng JC, Wu JK, Lee PC, Liu HS, Jian JJ, Lin YM, et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. *Int J Radiat Oncol Biol Phys*. 2004; 60(5): 1502–9.
- [62] Liang SX, Zhu XD, Xu ZY, Zhu J, Zhao JD, Lu HJ, et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. *Int J Radiat Oncol Biol Phys*. 2006; 65(2): 426–34.
- [63] Jang JW, Kwon JH, You CR, Kim JD, Woo HY, Bae SH, et al. Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma. *Antivir Ther*. 2011; 16(7): 969–77.
- [64] Miften M, Vinogradskiy Y, Moiseenko V, Grimm J, Yorke E, Jackson A, et al. Radiation dose-volume effects for liver SBRT. *Int J Radiat Oncol Biol Phys*. 2018; <https://doi.org/10.1016/j.ijrobp.2017.12.290>.
- [65] Velec M, Haddad CR, Craig T, Wang L, Lindsay P, Brierley J, et al. Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2017; 97(5): 939–46.
- [66] Son SH, Choi BO, Ryu MR, Kang YN, Jang JS, Bae SH, et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. *Int J Radiat Oncol Biol Phys*. 2010; 78(4): 1073–80.
- [67] Mendez Romero A, de Man RA. Stereotactic body radiation therapy for primary and metastatic liver tumors: from technological evolution to improved patient care. *Best Pract Res Clin Gastroenterol*. 2016; 30(4): 603–16.
- [68] Xu MJ, Feng M. Radiation therapy in HCC: what data exist and what data do we need to incorporate into guidelines? *Semin Liver Dis*. 2019; 39(1): 43–52.
- [69] Sanuki N, Takeda A, Oku Y, Eriguchi T, Nishimura S, Aoki Y, et al. Influence of liver toxicities on prognosis after stereotactic body radiation therapy for hepatocellular carcinoma. *Hepatol Res*. 2015; 45(5): 540–7.
- [70] Lasley FD, Mannina EM, Johnson CS, Perkins SM, Althouse S, Maluccio M, et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. *Pract Radiat Oncol*. 2015; 5(5): e443–e9.
- [71] Choi SH, Seong J. Stereotactic body radiotherapy: does it have a role in management of hepatocellular carcinoma? *Yonsei Med J*. 2018; 59(8): 912–22.
- [72] Beddar AS, Briere TM, Balter P, Pan T, Tolani N, Ng C, et al. 4D-CT imaging with synchronized intravenous contrast injection to improve delineation of liver tumors for treatment planning. *Radiother Oncol*. 2008; 87(3): 445–8.
- [73] Jensen NK, Mulder D, Lock M, Fisher B, Zener R, Beech B, et al. Dynamic contrast enhanced CT aiding gross tumor volume delineation of liver tumors: an interobserver variability study. *Radiother Oncol*. 2014; 111(1): 153–7.
- [74] Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, Heimbach JK, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. *Hepatology*. 2018; 67(1): 401–21.
- [75] Jabbour SK, Hashem SA, Bosch W, Kim TK, Finkelstein SE, Anderson BM, et al. Upper abdominal normal organ contouring guidelines and atlas: a Radiation Therapy Oncology Group consensus. *Pract Radiat Oncol*. 2014; 4(2): 82–9.
- [76] Dawson LA, Eccles C, Craig T. Individualized image guided iso-NTCP based liver cancer SBRT. *Acta Oncol*. 2006; 45(7): 856–64.
- [77] Kavanagh BD, Pan CC, Dawson LA, Das SK, Li XA, Ten Haken RK, et al. Radiation dose-volume effects in the stomach and small bowel. *Int J Radiat Oncol Biol Phys*. 2010; 76(3 Suppl): S101–7.
- [78] Kong FM, Ritter T, Quint DJ, Senan S, Gaspar LE, Komaki RU, et al. Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. *Int J Radiat Oncol Biol Phys*. 2011; 81(5): 1442–57.
- [79] Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. *Int J Radiat Oncol Biol Phys*. 2005; 62(5): 1371–8.
- [80] Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and

- intrahepatic cholangiocarcinoma. *J Clin Oncol*. 2016; 34(5): 460–8.
- [81] Sanford NN, Pursley J, Noe B, Yeap BY, Goyal L, Clark JW, et al. Protons versus photons for unresectable hepatocellular carcinoma: liver decompensation and overall survival. *Int J Radiat Oncol Biol Phys*. 2019; 105(1): 64–72.
- [82] Chin PL, Chu DZ, Clarke KG, Odom-Maryon T, Yen Y, Wagman LD. Ethnic differences in the behavior of hepatocellular carcinoma. *Cancer*. 1999; 85(9): 1931–6.
- [83] Xu ZY, Liang SX, Zhu J, Zhu XD, Zhao JD, Lu HJ, et al. Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. *Int J Radiat Oncol Biol Phys*. 2006; 65(1): 189–95.

- [1] Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. *Lancet*. 2019; 393(10185): 2051–8.
- [2] Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. *J Clin Oncol*. 2020; 38(25): 2830–8.
- [3] Jaffray DA, Langen KM, Mageras G, Dawson LA, Yan D, Ed DR, et al. Safety considerations for IGRT: executive summary. *Pract Radiat Oncol*. 2013; 3(3): 167–70.
- [4] Helou J, Karotki A, Milot L, Chu W, Erler D, Chung HT. 4DCT simulation with synchronized contrast injection in liver SBRT patients. *Technol Cancer Res Treat*. 2016; 15(1): 55–9.
- [5] Voroney JP, Brock KK, Eccles C, Haider M, Dawson LA. Prospective comparison of computed tomography and magnetic resonance imaging for liver cancer delineation using deformable image registration. *Int J Radiat Oncol Biol Phys*. 2006; 66(3): 780–91.
- [6] Hong TS, Bosch WR, Krishnan S, Kim TK, Mamon HJ, Shyn P, et al. Interobserver variability in target definition for hepatocellular carcinoma with and without portal vein thrombus: radiation therapy oncology group consensus guidelines. *Int J Radiat Oncol Biol Phys*. 2014; 89(4): 804–13.
- [7] Langen KM, Jones DT. Organ motion and its management. *Int J Radiat Oncol Biol Phys*. 2001; 50(1): 265–78.
- [8] Balter JM, Dawson LA, Kazanjian S, McGinn C, Brock KK, Lawrence T, et al. Determination of ventilatory liver movement via radiographic evaluation of diaphragm position. *Int J Radiat Oncol Biol Phys*. 2001; 51(1): 267–70.
- [9] Beddar AS, Briere TM, Balter P, Pan T, Tolani N, Ng C, et al. 4D-CT imaging with synchronized intravenous contrast injection to improve delineation of liver tumors for treatment planning. *Radiother Oncol*. 2008; 87(3): 445–8.
- [10] Kirilova A, Lockwood G, Choi P, Bana N, Haider MA, Brock KK, et al. Three-dimensional motion of liver tumors using cine-magnetic resonance imaging. *Int J Radiat Oncol Biol Phys*. 2008; 71(4): 1189–95.
- [11] Shimizu S, Shirato H, Xo B, Kagei K, Nishioka T, Hashimoto S, et al. Three-dimensional movement of a liver tumor detected by high-speed magnetic resonance imaging. *Radiother Oncol*. 1999; 50(3): 367–70.
- [12] Eccles CL, Patel R, Simeonov AK, Lockwood G, Haider M, Dawson LA. Comparison of liver tumor motion with and without abdominal compression using cine-magnetic resonance imaging. *Int J Radiat Oncol Biol Phys*. 2011; 79(2): 602–8.
- [13] Tsang DS, Voncken FE, Tse RV, Sykes J, Wong RK, Dinniwell RE, et al. A randomized controlled trial of lorazepam to reduce liver motion in patients receiving upper abdominal radiation therapy. *Int J Radiat Oncol Biol Phys*. 2013; 87(5): 881–7.
- [14] Eccles C, Brock KK, Bissonnette JP, Hawkins M, Dawson LA. Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy. *Int J Radiat Oncol Biol Phys*. 2006; 64(3): 751–9.
- [15] Fast M, van de Schoot A, van de Lindt T, Carbaat C, van der Heide U, Sonke JJ. Tumor trailing for liver SBRT on the MR-Linac. *Int J Radiat Oncol Biol Phys*. 2019; 103(2): 468–78.
- [16] Yoon SS, Aloia TA, Haynes AB, Kambadakone A, Kaur H, Vauthey JN, et al. Surgical placement of biologic mesh spacers to displace bowel away from unresectable liver tumors followed by delivery of dose-intensive radiation therapy. *Pract Radiat Oncol*. 2014; 4(3): 167–73.
- [17] Llovet JM, Vilana R, Bru C, Bianchi L, Salmeron JM, Boix L, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. *Hepatology*. 2001; 33(5): 1124–9.
- [18] Dawson LA, Eccles C, Craig T. Individualized image guided iso-NTCP based liver cancer SBRT. *Acta Oncol*. 2006; 45(7): 856–64.
- [19] Hawkins MA, Brock KK, Eccles C, Moseley D, Jaffray D, Dawson LA. Assessment of residual error in liver position using kV cone-beam computed tomography for liver cancer high-precision radiation therapy. *Int J Radiat Oncol Biol Phys*. 2006; 66(2): 610–9.
- [20] Shirato H, Oita M, Fujita K, Shimizu S, Onimaru R, Uegaki S, et al. Three-dimensional conformal setup (3D-CSU) of patients using the coordinate system provided by three internal fiducial markers and two orthogonal diagnostic X-ray systems in the treatment room. *Int J Radiat Oncol Biol Phys*. 2004; 60(2): 607–12.
- [21] Yue J, Sun X, Cai J, Yin FF, Yin Y, Zhu J, et al. Lipiodol: a potential direct surrogate for cone-beam computed tomography image guidance in radiotherapy of liver tumor. *Int J Radiat Oncol Biol Phys*. 2012; 82(2): 834–41.
- [22] Engels B, Everaert H, Gevaert T, Duchateau M, Neyns B, Sermeus A, et al. Phase II study of helical tomotherapy for oligometastatic colorectal cancer. *Ann Oncol*. 2011; 22(2): 362–8.
- [23] Wunderink W, Mendez Romero A, Vasquez Osorio EM, de Boer HC, Brandwijk RP, Levendag PC, et al. Target coverage in image-guided stereotactic body radiotherapy of liver tumors. *Int J Radiat Oncol Biol Phys*. 2007; 68(1): 282–90.

- [24] Court L, Rosen I, Mohan R, Dong L. Evaluation of mechanical precision and alignment uncertainties for an integrated CT/LINAC system. *Med Phys*. 2003; 30(6): 1198–210.
- [25] Jaffray DA, Siewerdsen JH, Wong JW, Martinez AA. Flat-panel cone-beam computed tomography for image-guided radiation therapy. *Int J Radiat Oncol Biol Phys*. 2002; 53(5): 1337–49.
- [26] Wong JW, Sharpe MB, Jaffray DA, Kini VR, Robertson JM, Stromberg JS, et al. The use of active breathing control (ABC) to reduce margin for breathing motion. *Int J Radiat Oncol Biol Phys*. 1999; 44(4): 911–9.
- [27] Sonke JJ, Zipp L, Remeijer P, van Herk M. Respiratory correlated cone beam CT. *Med Phys*. 2005; 32(4): 1176–86.
- [28] Raaymakers BW, Jurgenliemk-Schulz IM, Bol GH, Glitzner M, Kotte A, van Asselen B, et al. First patients treated with a 1.5 T MRI-Linac: clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment. *Phys Med Biol*. 2017; 62(23): L41–50.
- [29] Kluter S. Technical design and concept of a 0.35 T MR-Linac. *Clin Transl Radiat Oncol*. 2019; 18: 98–101.
- [30] Keall PJ, Barton M, Crozier S. Australian Mri-Linac program icfIIICCCCLHSUUoNQSWS, Wollongong. The Australian magnetic resonance imaging-linac program. *Semin Radiat Oncol*. 2014; 24(3): 203–6.
- [31] Fallone BG. The rotating biplanar linac-magnetic resonance imaging system. *Semin Radiat Oncol*. 2014; 24(3): 200–2.
- [32] Bertholet J, Knopf A, Eiben B, McClelland J, Grimwood A, Harris E, et al. Real-time intrafraction motion monitoring in external beam radiotherapy. *Phys Med Biol*. 2019; 64(15): 15TR01.
- [33] Paulson ES, Ahunbay E, Chen X, Mickevicius NJ, Chen GP, Schultz C, et al. 4D-MRI driven MR-guided online adaptive radiotherapy for abdominal stereotactic body radiation therapy on a high field MR-Linac: implementation and initial clinical experience. *Clin Transl Radiat Oncol*. 2020; 23: 72–9.
- [34] Stemkens B, Paulson ES, Tijssen RHN. Nuts and bolts of 4D-MRI for radiotherapy. *Phys Med Biol*. 2018; 63(21): 21TR01.
- [35] Eccles CL, Haider EA, Haider MA, Fung S, Lockwood G, Dawson LA. Change in diffusion weighted MRI during liver cancer radiotherapy: preliminary observations. *Acta Oncol*. 2009; 48(7): 1034–43.
- [36] Lukovic J, Henke L, Gani C, Kim TK, Stanescu T, Hosni A, et al. MRI-based upper abdominal organs-at-risk atlas for radiation oncology. *Int J Radiat Oncol Biol Phys*. 2020; 106(4): 743–53.
- [37] Jabbour SK, Hashem SA, Bosch W, Kim TK, Finkelstein SE, Anderson BM, et al. Upper abdominal normal organ contouring guidelines and atlas: a Radiation Therapy Oncology Group consensus. *Pract Radiat Oncol*. 2014; 4(2): 82–9.
- [38] Vilgrain V, Esvan M, Ronot M, Caumont-Prim A, Aube C, Chatellier G. A meta-analysis of diffusion-weighted and gadoteric acid-enhanced MR imaging for the detection of liver metastases. *Eur Radiol*. 2016; 26(12): 4595–615.
- [39] Rosenberg SA, Henke LE, Shaverdian N, Mittauer K, Wojcieszynski AP, Hullett CR, et al. A multi-institutional experience of MR-guided liver stereotactic body radiation therapy. *Adv Radiat Oncol*. 2019; 4(1): 142–9.
- [40] Feldman AM, Modh A, Glide-Hurst C, Chetty IJ, Movsas B. Real-time magnetic resonance-guided liver stereotactic body radiation therapy: an institutional report using a magnetic resonance-Linac system. *Cureus*. 2019; 11(9): e5774.
- [41] Henke L, Kashani R, Robinson C, Curcuru A, DeWees T, Bradley J, et al. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. *Radiother Oncol*. 2018; 126(3): 519–26.

粒子束放射治疗

Particle Beam Radiotherapy

9

- [1] Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M. Tolerance of normal tissue to therapeutic irradiation. *Int J Radiat Oncol Biol Phys.* 1991; 21: 109–22.
- [2] The American Society for Radiation Oncology. Proton beam therapy model policy issued by ASTRO 2014.
- [3] Breuer H, Smit BJ. Proton therapy and radio-surgery. 1st ed. Berlin: Springer; 2000.
- [4] Paganetti H, Niemierko A, Ancukiewicz M, Gerweck LE, Goitein M, Loeffler JS, Suit HD. Relative biological effectiveness (RBE) values for proton beam therapy. *Int J Radiat Oncol Biol Phys.* 2002; 53: 407–21.
- [5] Wambersie A. RBE, reference RBE and clinical RBE: applications of these concepts in hadron therapy. *Strahlenther Onkol.* 1999; 175(Suppl 2): 39–43.
- [6] Di Pietro C, Piro S, Tabbi G, Ragusa M, Di Pietro V, Zimmiti V, Cuda F, Anello M, Consoli U, Salinaro ET, Caruso M, Vancheri C, Crimi N, Sabini MG, Cirrone GA, Raffaele L, Privitera G, Pulvirenti A, Giugno R, Ferro A, Cuttone G, Lo Nigro S, Purrello R, Purrello F, Purrello M. Cellular and molecular effects of protons: apoptosis induction and potential implications for cancer therapy. *Apoptosis.* 2006; 11: 57–66.
- [7] Gerelchuluun A, Hong Z, Sun L, Suzuki K, Terunuma T, Yasuoka K, Sakae T, Moritake T, Tsuboi K. Induction of in situ DNA double-strand breaks and apoptosis by 200 MeV protons and 10 MV X-rays in human tumour cell lines. *Int J Radiat Biol.* 2011; 87: 57–70.
- [8] Rutherford E. Collisions of alpha particles with light atoms. II. Nitrogen and oxygen atoms. *The Philosophical Magazine.* 1919; 37: 571–80.
- [9] Rutherford E. Collision of a particle with light atoms. IV. An anomalous effect in nitrogen (Reprint from philosophical Magazine Series 6, Vol 37, pg 581–587. 1919). *Philos Mag.* 2010; 90: 31–7.
- [10] Wilson RR. Radiological use of fast protons. *Radiology.* 1946; 47: 487–91.
- [11] Gragoudas ES, Goitein M, Koehler AM, Verhey L, Tepper J, Suit HD, Brockhurst R, Constable IJ. Proton irradiation of small choroidal malignant melanomas. *Am J Ophthalmol.* 1977; 83: 665–73.
- [12] Matsuzaki Y, Osuga T, Saito Y, Chuganji Y, Tanaka N, Shoda J, Tsuji H, Tsujii H. A new, effective, and safe therapeutic option using proton irradiation for hepatocellular carcinoma. *Gastroenterology.* 1994; 106: 1032–41.
- [13] Tsujii H, Inada T, Maruhashi A, Hayakawa Y, Tsuji H, Ohara K, Akisada M, Kitagawa T. [Field localization and verification system for proton beam radiotherapy in deep-seated tumors]. *Nihon Igaku Hoshasen Gakkai Zasshi.* 1989; 49: 622–29.
- [14] Arimoto T, Takase Y, Ishikawa N, Yoshii Y, Ishikawa S, Otani M, Kaneko M, Nishida M, Kitagawa T. [Investigation of marking procedure for markers in deep-seated organs by proton beam therapy]. *Gan No Rinsho.* 1988; 34: 395–403.
- [15] Ohara K, Okumura T, Akisada M, Inada T, Mori T, Yokota H, Calaguas MJB. Irradiation synchronized with respiration gate. *Int J Radiat Oncol.* 1989; 17: 853–7.
- [16] Kooy HM, Grassberger C. Intensity modulated proton therapy. *Br J Radiol.* 2015; 88: 20150195.
- [17] Bush DA, Smith JC, Slater JD, Volk ML, Reeves ME, Cheng J, Grove R, de Vera ME. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. *Int J Radiat Oncol Biol Phys.* 2016; 95: 477–82.
- [18] Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. *Gastroenterology.* 2004; 127: S189–93.
- [19] Bush DA, Kayali Z, Grove R, Slater JD. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. *Cancer.* 2011; 117: 3053–9.
- [20] Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, Nagase M, Nihei K, Ogino T. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. *J Clin Oncol.* 2005; 23: 1839–46.
- [21] Chiba T, Tokuuye K, Matsuzaki Y, Sugahara S, Chuganji Y, Kagei K, Shoda J, Hata M, Abei M, Igaki H, Tanaka N, Akine Y. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. *Clin Cancer Res.* 2005; 11: 3799–805.
- [22] Hata M, Tokuuye K, Sugahara S, Fukumitsu N, Hashimoto T, Ohnishi K, Nemoto K, Ohara K, Matsuzaki Y, Akine Y. Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis. *Strahlenther Onkol.* 2006; 182: 713–20.
- [23] Fukumitsu N, Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Abei M, Shoda J, Thono E, Tsuboi K, Tokuuye K. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2009; 74: 831–6.
- [24] Mizumoto M, Tokuuye K, Sugahara S, Nakayama H, Fukumitsu N, Ohara K, Abei M, Shoda J, Tohno E, Minami M. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. *Int J Radiat Oncol Biol Phys.* 2008; 71: 462–7.
- [25] Mizumoto M, Okumura T, Hashimoto T, Fukuda K, Oshiro Y,

- Fukumitsu N, Abei M, Kawaguchi A, Hayashi Y, Ookawa A, Hashii H, Kanemoto A, Moritake T, Tohno E, Tsuboi K, Sakae T, Sakurai H. Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. *Int J Radiat Oncol Biol Phys.* 2011; 81: 1039–45.
- [26] Hong TS, DeLaney TF, Mamon HJ, Willett CG, Yeap BY, Niemierko A, Wolfgang JA, Lu HM, Adams J, Weyman EA, Arellano RS, Blaszkowsky LS, Allen JN, Tanabe KK, Ryan DP, Zhu AX. A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. *Pract Radiat Oncol.* 2014; 4: 316–22.
- [27] Kim TH, Park JW, Kim YJ, Kim BH, Woo SM, Moon SH, Kim SS, Koh YH, Lee WJ, Park SJ, Kim JY, Kim DY, Kim CM. Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. *Cancer Res Treat.* 2015; 47: 34–45.
- [28] Chadha AS, Gunther JR, Hsieh CE, Aliru M, Mahadevan LS, Venkatesulu BP, Crane CH, Das P, Herman JM, Koay EJ, Taniguchi C, Holliday EB, Minsky BD, Suh Y, Park P, Sawakuchi G, Beddar S, Odisio BC, Gupta S, Loyer E, Kaur H, Raghav K, Javle MM, Kaseb AO, Krishnan S. Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. *Radiother Oncol.* 2019; 133: 54–61.
- [29] Komatsu S, Fukumoto T, Demizu Y, Miyawaki D, Terashima K, Sasaki R, Hori Y, Hishikawa Y, Ku Y, Murakami M. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. *Cancer.* 2011; 117: 4890–904.
- [30] Sanford NN, Pursley J, Noe B, Yeap BY, Goyal L, Clark JW, Allen JN, Blaszkowsky LS, Ryan DP, Ferrone CR, Tanabe KK, Qadan M, Crane CH, Koay EJ, Eyer C, DeLaney TF, Zhu AX, Wo JY, Grassberger C, Hong TS. Protons versus photons for unresectable hepatocellular carcinoma: liver decompensation and overall survival. *Int J Radiat Oncol Biol Phys.* 2019; 105: 64–72.
- [31] Sumiya T, Mizumoto M, Oshiro Y, Baba K, Murakami M, Shimizu S, Nakamura M, Hiroshima Y, Ishida T, Iizumi T, Saito T, Numajiri H, Nakai K, Okumura T, Sakurai H. Transitions of liver and biliary enzymes during proton beam therapy for hepatocellular carcinoma. *Cancers (Basel).* 2020; 12: 1840.
- [32] Blum HE. Treatment of hepatocellular carcinoma. *Best Pract Res Clin Gastroenterol.* 2005; 19: 129–45.
- [33] Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Bru C, Rodes J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. *Hepatology.* 1999; 29: 62–7.
- [34] Markovic S, Gadzijev E, Stabuc B, Croce LS, Masutti F, Surlan M, Berden P, Brencic E, Visnar-Perovic A, Sasso F, Ferlan-Marolt V, Mucelli FP, Cesar R, Sponza M, Tiribelli C. Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients. *J Hepatol.* 1998; 29: 650–9.
- [35] Chan LC, Chiu SK, Chan SL. Stereotactic radiotherapy for hepatocellular carcinoma: report of a local single-centre experience. *Hong Kong Med J.* 2011; 17: 112–8.
- [36] Cardenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, Henderson MA, Schefter TE, Tudor K, Deluca J, Johnstone PA. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. *Clin Transl Oncol.* 2010; 12: 218–25.
- [37] Mizumoto M, Oshiro Y, Okumura T, Fukuda K, Fukumitsu N, Abei M, Ishikawa H, Ohnishi K, Numajiri H, Tsuboi K, Sakurai H. Association between pretreatment retention rate of indocyanine green 15 min after administration and life prognosis in patients with HCC treated by proton beam therapy. *Radiother Oncol.* 2014; 113: 54–9.
- [38] Hata M, Tokuyue K, Sugahara S, Fukumitsu N, Hashimoto T, Ohnishi K, Nemoto K, Ohara K, Matsuzaki Y, Akine Y. Proton beam therapy for hepatocellular carcinoma with limited treatment options. *Cancer.* 2006; 107: 591–8.
- [39] Hata M, Tokuyue K, Sugahara S, Tohno E, Nakayama H, Fukumitsu N, Mizumoto M, Abei M, Shoda J, Minami M, Akine Y. Proton beam therapy for aged patients with hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2007; 69: 805–12.
- [40] Fukuda K, Okumura T, Abei M, Fukumitsu N, Ishige K, Mizumoto M, Hasegawa N, Numajiri H, Ohnishi K, Ishikawa H, Tsuboi K, Sakurai H, Hyodo I. Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma. *Cancer Sci.* 2017; 108: 497–503.
- [41] Sitruk V, Seror O, Grando-Lemaire V, Mohand D, N'Kontchou G, Ganne-Carrie N, Beaugrand M, Sellier N, Trinchet JC. [Percutaneous ablation of hepatocellular carcinoma]. *Gastroenterol Clin Biol.* 2003; 27: 381–90.
- [42] Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, Frings H, Laubenberger J, Zuber I, Blum HE, Bartolozzi C. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. *Radiology.* 2003; 228: 235–40.
- [43] Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. *Gastroenterology.* 2004; 127: 1714–23.
- [44] Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, Ishikawa T, Koike Y, Yoshida H, Kawabe T, Omata M. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. *Gastroenterology.* 2005; 129: 122–30.
- [45] Ohara K, Okumura T, Tsuji H, Chiba T, Min M, Tatsuzaki H, Tsujii H, Akine Y, Itai Y. Radiation tolerance of cirrhotic livers in relation to the preserved functional capacity: analysis of patients with hepatocellular carcinoma treated by focused proton beam radiotherapy. *Int J Radiat Oncol Biol Phys.* 1997; 38: 367–72.
- [46] Kimura K, Nakamura T, Ono T, Azami Y, Suzuki M, Wada H, Takayama K, Endo H, Takeyama T, Hirose K, Takai Y, Kikuchi Y. Clinical results of proton beam therapy for hepatocellular carcinoma over 5 cm. *Hepatol Res.* 2017; 47: 1368–74.
- [47] Sugahara S, Oshiro Y, Nakayama H, Fukuda K, Mizumoto M, Abei M, Shoda J, Matsuzaki Y, Thono E, Tokita M, Tsuboi K, Tokuyue K. Proton beam therapy for large hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2010; 76: 460–6.
- [48] Nakamura M, Fukumitsu N, Kamizawa S, Numajiri H, Nemoto Murofushi K, Ohnishi K, Aihara T, Ishikawa H, Okumura T, Tsuboi K, Sakurai H. A validated proton beam therapy patch-field protocol for effective treatment of large hepatocellular carcinoma. *J Radiat Res.* 2018; 59: 632–8.
- [49] Nakayama H, Sugahara S, Fukuda K, Abei M, Shoda J, Sakurai H, Tsuboi K, Matsuzaki Y, Tokuyue K. Proton beam therapy for hepatocellular carcinoma located adjacent to the alimentary tract. *Int J Radiat Oncol Biol Phys.* 2011; 80: 992–5.
- [50] Kanemoto A, Mizumoto M, Okumura T, Takahashi H,

- Hashimoto T, Oshiro Y, Fukumitsu N, Moritake T, Tsuboi K, Sakae T, Sakurai H. Dose-volume histogram analysis for risk factors of radiation-induced rib fracture after hypofractionated proton beam therapy for hepatocellular carcinoma. *Acta Oncol.* 2013; 52: 538–44.
- [51] Pirisi M, Avellini C, Fabris C, Scott C, Bardus P, Soardo G, Beltrami CA, Bartoli E. Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study. *J Cancer Res Clin Oncol.* 1998; 124: 397–400.
- [52] Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. *Ann Surg.* 1999; 229: 790–9. discussion 799–800
- [53] Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. *Cancer.* 1996; 77: 2217–22.
- [54] Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. *Cancer.* 1997; 79: 2087–94.
- [55] Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. *Cancer.* 1985; 56: 918–28.
- [56] Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. *Am J Clin Oncol.* 1998; 21: 386–91.
- [57] Nagasue N, Yukaya H, Hamada T, Hirose S, Kanashima R, Inokuchi K. The natural history of hepatocellular carcinoma. A study of 100 untreated cases. *Cancer.* 1984; 54: 1461–5.
- [58] Ishikura S, Ogino T, Furuse J, Satake M, Baba S, Kawashima M, Nihei K, Ito Y, Maru Y, Ikeda H. Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. *Am J Clin Oncol.* 2002; 25: 189–93.
- [59] Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, Tateishi R, Teratani T, Shiina S, Omata M. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. *Cancer.* 2006; 106: 1990–7.
- [60] Hsu WC, Chan SC, Ting LL, Chung NN, Wang PM, Ying KS, Shin JS, Chao CJ, Lin GD. Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma. *Jpn J Clin Oncol.* 2006; 36: 93–9.
- [61] Nakagawa K, Yamashita H, Shiraishi K, Nakamura N, Tago M, Igaki H, Hosoi Y, Shiina S, Omata M, Makuuchi M, Ohtomo K. Radiation therapy for portal venous invasion by hepatocellular carcinoma. *World J Gastroenterol.* 2005; 11: 7237–41.
- [62] Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Nakamura M, Damdinsuren B, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Wakasa K, Monden M. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. *Br J Cancer.* 2005; 93: 557–64.
- [63] Hata M, Tokuyue K, Sugahara S, Kagei K, Igaki H, Hashimoto T, Ohara K, Matsuzaki Y, Tanaka N, Akine Y. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. *Cancer.* 2005; 104: 794–801.
- [64] Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, Shoda J, Matsuzaki Y, Thono E, Tsuboi K, Tokuyue K. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. *Strahlenther Onkol.* 2009; 185: 782–8.
- [65] Lee SU, Park JW, Kim TH, Kim YJ, Woo SM, Koh YH, Lee WJ, Park SJ, Kim DY, Kim CM. Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. *Strahlenther Onkol.* 2014; 190: 806–14.
- [66] Kim TH, Park JW, Kim BH, Kim DY, Moon SH, Kim SS, Lee JH, Woo SM, Koh YH, Lee WJ, Kim CM. Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma. *Oncotarget.* 2018; 9: 4034–43.
- [67] Mizumoto M, Tokuyue K, Sugahara S, Hata M, Fukumitsu N, Hashimoto T, Ohnishi K, Nemoto K, Ohara K, Matsuzaki Y, Tohno E, Akine Y. Proton beam therapy for hepatocellular carcinoma with inferior vena cava tumor thrombus: report of three cases. *Jpn J Clin Oncol.* 2007; 37: 459–62.
- [68] Komatsu S, Fukumoto T, Demizu Y, Miyawaki D, Terashima K, Niwa Y, Mima M, Fujii O, Sasaki R, Yamada I, Hori Y, Hishikawa Y, Abe M, Ku Y, Murakami M. The effectiveness of particle radiotherapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. *J Gastroenterol.* 2011; 46: 913–20.
- [69] Sekino Y, Okumura T, Fukumitsu N, Iizumi T, Numajiri H, Mizumoto M, Nakai K, Nonaka T, Ishikawa H, Sakurai H. Proton beam therapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. *J Cancer Res Clin Oncol.* 2020; 146: 711–20.
- [70] Lawrence TS, Ten Haken RK, Kessler ML, Robertson JM, Lyman JT, Lavigne ML, Brown MB, DuRoss DJ, Andrews JC, Ensminger WD, et al. The use of 3-D dose volume analysis to predict radiation hepatitis. *Int J Radiat Oncol Biol Phys.* 1992; 23: 781–8.
- [71] Dawson LA, Ten Haken RK, Lawrence TS. Partial irradiation of the liver. *Semin Radiat Oncol.* 2001; 11: 240–6.
- [72] Hashimoto T, Tokuyue K, Fukumitsu N, Igaki H, Hata M, Kagei K, Sugahara S, Ohara K, Matsuzaki Y, Akine Y. Repeated proton beam therapy for hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2006; 65: 196–202.
- [73] Oshiro Y, Mizumoto M, Okumura T, Fukuda K, Fukumitsu N, Abei M, Ishikawa H, Takizawa D, Sakurai H. Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma. *Radiother Oncol.* 2017; 123: 240–5.
- [74] Tsujii H, Mizoe J, Kamada T, Baba M, Tsuji H, Kato H, Kato S, Yamada S, Yasuda S, Ohno T, Yanagi T, Imai R, Kagei K, Kato H, Hara R, Hasegawa A, Nakajima M, Sugane N, Tamaki N, Takagi R, Kandatsu S, Yoshikawa K, Kishimoto R, Miyamoto T. Clinical results of carbon ion radiotherapy at NIRS. *J Radiat Res.* 2007; 48(Suppl A): A1–A13.
- [75] Kato H, Tsujii H, Miyamoto T, Mizoe JE, Kamada T, Tsuji H, Yamada S, Kandatsu S, Yoshikawa K, Obata T, Ezawa H, Morita S, Tomizawa M, Morimoto N, Fujita J, Ohto M. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. *Int J Radiat Oncol Biol Phys.* 2004; 59: 1468–76.
- [76] Kasuya G, Kato H, Yasuda S, Tsuji H, Yamada S, Haruyama Y, Kobashi G, Ebner DK, Okada NN, Makishima H, Miyazaki M,

- Kamada T, Tsujii H, Liver Cancer Working Group. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: combined analyses of 2 prospective trials. *Cancer*. 2017; 123: 3955–65.
- [77] Shibuya K, Ohno T, Terashima K, Toyama S, Yasuda S, Tsuji H, Okimoto T, Shioyama Y, Nemoto K, Kamada T, Nakano T, Japan Carbon Ion Radiotherapy Study Group. Short-course carbon-ion radiotherapy for hepatocellular carcinoma: a multi-institutional retrospective study. *Liver Int*. 2018; 38: 2239–47.
- [78] Shibuya K, Ohno T, Katoh H, Okamoto M, Shiba S, Koyama Y, Kakizaki S, Shirabe K, Nakano T. A feasibility study of high-dose hypofractionated carbon ion radiation therapy using four fractions for localized hepatocellular carcinoma measuring 3cm or larger. *Radiother Oncol*. 2019; 132: 230–5.
- [79] Yasuda S, Kato H, Imada H, Isozaki Y, Kasuya G, Makishima H, Tsuji H, Ebner DK, Yamada S, Kamada T, Tsujii H, Kato N, Miyazaki M, Working Group for Liver Tumor. Long-term results of high-dose 2-fraction carbon ion radiation therapy for hepatocellular carcinoma. *Adv Radiat Oncol*. 2020; 5: 196–203.
- [80] Shiba S, Abe T, Shibuya K, Katoh H, Koyama Y, Shimada H, Kakizaki S, Shirabe K, Kuwano H, Ohno T, Nakano T. Carbon ion radiotherapy for 80 years or older patients with hepatocellular carcinoma. *BMC Cancer*. 2017; 17: 721.
- [81] Shiba S, Shibuya K, Katoh H, Kaminuma T, Miyazaki M, Kakizaki S, Shirabe K, Ohno T, Nakano T. A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study. *Radiat Oncol*. 2019; 14: 137.

- [1] Ariel IM. Radioactive isotopes for adjuvant cancer therapy; animal experimentation and preliminary results in human application. *Arch Surg*. 1964; 89: 244–9.
- [2] Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting CW, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. *Int J Radiat Oncol Biol Phys*. 2007; 68: 13–23.
- [3] Reinders MTM, Smits MLJ, van Roekel C, Braat AJAT. Holmium-166 microsphere radioembolization of hepatic malignancies. *Semin Nucl Med*. 2019; 49(3): 237–43.
- [4] Braat AJAT, Bruijnen RCG, van Rooij R, et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLUS): a single-centre, single-arm, open-label, phase 2 study. *Lancet Oncol*. 2020; 21(4): 561–70.
- [5] Gray BN. Colorectal cancer: the natural history of disseminated disease—a review. *Aust N Z J Surg*. 1980; 50: 643–6.
- [6] Tong AKT, Kao YH, Too CW, Chin KFW, Ng DCE, Chow PKH. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. *Br J Radiol*. 2016; 89(1062): 20150943.
- [7] Teo JY, Allen JC Jr, Ng DC, et al. A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. *HPB (Oxford)*. 2016; 18(1): 7–12.
- [8] Tohme S, Sukato D, Chen HW, et al. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience. *J Vasc Interv Radiol*. 2013; 24(11): 1632–8.
- [9] Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. *Hepatology*. 1999; 29: 62–7.
- [10] Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. *Hepatology*. 2011; 54: 868–78.
- [11] Salem R, Gordon AC, Mouli S, et al. Y90 Radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. *Gastroenterology*. 2016; 151(6): 1155–63.
- [12] Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. *Am J Transplant*. 2009; 9(8): 1920–8.
- [13] Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. *Lancet Oncol*. 2017; 18(12): 1624–36.
- [14] Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. *J Clin Oncol*. 2018; 36(19): 1913–21.
- [15] Sposito C, Mazzaferro V. The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future. *Hepatobiliary Surg Nutr*. 2018; 7(6): 487–9.
- [16] Ricke J, Klumpen HJ, Amthauer H, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. *J Hepatol*. 2019; 71: 1164–74.
- [17] Venerito M, Pech M, Canbay A, et al. NEMESIS: non-inferiority, individual patient meta-analysis of selective internal radiation therapy with yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma. *J Nucl Med*. 2020; 61(12): 1736–42. <https://doi.org/10.2967/jnumed.120.242933>.
- [18] Garin E, Tzelikas L, Guiu B, et al. Major impact of personalized dosimetry using ⁹⁰Y loaded glass microspheres SIRT in HCC: final overall survival analysis of a multicentre randomized phase II study (DOSISPHERE-01). *J Clin Oncol*. 2020; 38(4 suppl): 516.
- [19] Kao YH, Hock Tan AE, Burgmans MC, Irani FG, Khoo LS, Gong Lo RH, et al. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective ⁹⁰Y radioembolization. *J Nucl Med*. 2012; 53: 559–66.
- [20] Rodriguez LS, Thang SP, Li H, et al. A descriptive analysis of remnant activity during (⁹⁰)Y resin microspheres radioembolization of hepatic tumors: technical factors and dosimetric implications. *Ann Nucl Med*. 2016; 30(3): 255–61.
- [21] Gnesin S, Canetti L, Adib S, et al. Partition model-based ^{99m}Tc-MAA SPECT/CT predictive dosimetry compared with ⁹⁰Y TOF PET/CT posttreatment dosimetry in radioembolization of hepatocellular carcinoma: a quantitative agreement comparison. *J Nucl Med*. 2016; 57(11): 1672–8.
- [22] Ho CL, Chen S, Cheung SK, et al. Radioembolization with Y-90 glass microspheres for hepatocellular carcinoma: significance of pretreatment C-11 acetate and FDG PET/CT and posttreatment Y-90 PET/CT in individualized dose prescription. *Eur J Nucl Med Mol Imaging*. 2018; 45(12): 2110–21.

- [23] Garin E, Lenoir L, Rolland Y, et al. Dosimetry based on ^{99m}Tc -macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with ^{90}Y -loaded glass microspheres: preliminary results. *J Nucl Med*. 2012; 53(2): 255–63.
- [24] Garin E, Rolland Y, Edeline J. ^{90}Y -loaded microsphere SIRT of HCC patients with portal vein thrombosis: high clinical impact of ^{99m}Tc -MAA SPECT/CT-based dosimetry. *Semin Nucl Med*. 2019; 49(3): 218–26.
- [25] Garin E, Lenoir L, Edeline J, et al. Boosted selective internal radiation therapy with ^{90}Y -loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. *Eur J Nucl Med Mol Imaging*. 2013; 40: 1057–68.
- [26] Levillain H, Duran Derijckere I, Ameye L, et al. Personalized radioembolization improves outcomes in refractory intrahepatic cholangiocarcinoma: a multicentre study. *Eur J Nucl Med Mol Imaging*. 2019; 46(11): 2270–9.
- [27] Lau WY, Kennedy AS, Kim YH, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. *Int J Radiat Oncol Biol Phys*. 2012; 82: 401–7.
- [28] Lam MG, Goris ML, Iagaru AH, et al. Prognostic utility of ^{90}Y radioembolization dosimetry based on fusion ^{99m}Tc -macroaggregated albumin- ^{99m}Tc -sulfur colloid SPECT. *J Nucl Med*. 2013; 54(12): 2055–61.
- [29] Lam MG, Louie JD, Iagaru AH, et al. Safety of repeated yttrium-90 radioembolization. *Cardiovasc Intervent Radiol*. 2013; 36: 1320–8.
- [30] Zarva A, Mohnike K, Damm R, et al. Safety of repeated radioembolizations in patients with advanced primary and secondary liver tumors and progressive disease after first selective internal radiotherapy. *J Nucl Med*. 2014; 55: 360–6.
- [31] Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. *Int J Radiat Oncol Biol Phys*. 2011; 79: 163–71.
- [32] Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicentre radiology-pathology correlation and survival of radiation segmentectomy. *Hepatology*. 2014; 60(1): 192–201.
- [33] Kao YH, Steinberg JD, Tay YS, Lim GK, Yan J, Townsend DW, et al. Post-radioembolization yttrium-90 PET/CT—part 2: dose-response and tumor predictive dosimetry for resin microspheres. *EJNMMI Res*. 2013; 3: 57.
- [34] Leung TW, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial ^{90}Y -microspheres for inoperable hepatic tumors. *Int J Radiat Oncol Biol Phys*. 1995; 33(4): 919–24.
- [35] Gil-Alzugaray B, Chopitea A, Inarrairaegui M, et al. Prognostic factors and prevention of radioembolization-induced liver disease. *Hepatology*. 2013; 57: 1078–87.
- [36] Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of Lu-177 Dotatate for midgut neuroendocrine tumours. *N Engl J Med*. 2017; 376: 125–35.
- [37] Kratochwil C, Lopez-Benitez R, Mier W, et al. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. *Endocr Relat Cancer*. 2011; 18(5): 595–602.
- [38] Murthy R, Kamat P, Nuñez R, Salem R. Radioembolization of yttrium-90 microspheres for hepatic malignancy. *Semin Intervent Radiol*. 2008; 25(1): 48–57.
- [39] Lam MG, Abdelmaksoud MH, Chang DT, et al. Safety of ^{90}Y radioembolization in patients who have undergone previous external beam radiation therapy. *Int J Radiat Oncol Biol Phys*. 2013; 87(2): 323–9.
- [40] Wang TH, Huang PI, Hu YW, et al. Combined yttrium-90 microsphere selective internal radiation therapy and external beam radiotherapy in patients with hepatocellular carcinoma: from clinical aspects to dosimetry. *PLoS One*. 2018; 13(1): e0190098.

放射肿瘤学家视角下的肝癌患者 治疗指南

11

Therapeutic Guidelines for Patients with Liver Cancer from the Perspective of Radiation Oncologists

- [1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018; 68(6): 394–424.
- [2] El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterology.* 2012; 142(6): 1264–73.e1.
- [3] Choo SP, Tan WL, Goh BK, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. *Cancer.* 2016; 122(22): 3430–46.
- [4] Sinn DH, Choi G-S, Park HC, Kim JM, Kim H, Song KD, et al. Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. *PLoS One.* 2019; 14(1): e0210730.
- [5] Rim CH, Kim CY, Yang DS, Yoon WS. The role of external beam radiotherapy for hepatocellular carcinoma patients with lymph node metastasis: a meta-analysis of observational studies. *Cancer Manag Res.* 2018; 10: 3305–15.
- [6] Kudo M. Management of hepatocellular carcinoma in Japan as a world-leading model. *Liver Cancer.* 2018; 7(2): 134–47.
- [7] Kudo M. Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. *Liver Cancer.* 2015; 4(1): 39–50.
- [8] KLCSG, NCCK. 2014 Korean Liver Cancer Study Group-National Cancer Center. Korea practice guideline for the management of hepatocellular carcinoma. *Korean J Radiol.* 2015; 16(3): 465–522.
- [9] Park S, Yoon WS, Rim CH. Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: diverse global viewpoints. *World J Gastroenterol.* 2020; 26(4): 393–403.
- [10] Jia J, Zhang D, Ludwig J, Kim H. Radiofrequency ablation versus resection for hepatocellular carcinoma in patients with Child–Pugh A liver cirrhosis: a meta-analysis. *Clin Radiol.* 2017; 72(12): 1066–75.
- [11] Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. *Liver Int.* 2015; 35(9): 2155–66.
- [12] Rim CH, Yim HJ, Park S, Seong J. Recent clinical applications of external beam radiotherapy for hepatocellular carcinoma according to guidelines, major trials and meta-analyses. *J Med Imaging Radiat Oncol.* 2019; 63(6): 812–21. <https://doi.org/10.1111/1754-9485.12948>.
- [13] Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med.* 2008; 359(4): 378–90.
- [14] Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2017; 389(10064): 56–66.
- [15] Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. *N Engl J Med.* 2018; 379(1): 54–63.
- [16] Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. *Gut.* 2002; 50(6): 881–5.
- [17] Subramaniam S, Kelley RK, Venook AP. A review of hepatocellular carcinoma (HCC) staging systems. *Chin Clin Oncol.* 2013; 2(4): 33.
- [18] Wang Y, Luo Q, Li Y, Wang H, Deng S, Wei S, et al. Quality assessment of clinical practice guidelines on the treatment of hepatocellular carcinoma or metastatic liver cancer. *PLoS One.* 2014; 9(8): e103939.
- [19] European Association for the Study of the Liver. EASL Clinical practice guidelines. <https://easl.eu/publications/clinical-practice-guidelines/>. Assessed 15 Dec 2019.
- [20] Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol.* 2018; 69(1): 182–236.
- [21] European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol.* 2012; 56(4): 908–43.
- [22] Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. *Int J Radiat Oncol Biol Phys.* 2010; 76(3): S94–S100.
- [23] Foerster F, Galle PR. Comparison of the current international guidelines on the management of HCC. *JHEP Rep.* 2019; 1(2): 114–9.
- [24] Chen S, Peng Z, Wei M, Liu W, Dai Z, Wang H, et al. Sorafenib versus transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis. *BMC Cancer.* 2018; 18(1): 392.
- [25] Omata M, Cheng A-L, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int.* 2017; 11(4): 317–70.
- [26] Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology.* 2011; 53(3): 1020–2.
- [27] Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of

- hepatocellular carcinoma. *Hepatology*. 2018; 67(1): 358–80.
- [28] Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis. *JAMA Oncol*. 2015; 1(6): 756–65.
- [29] Nakazawa T, Hidaka H, Shibuya A, Okuwaki Y, Tanaka Y, Takada J, et al. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. *BMC Gastroenterol*. 2014; 14(1): 84.
- [30] Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, et al. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: the Japanese Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). *Hepatol Res*. 2015; 45(2) <https://doi.org/10.1111/hepr.12464>.
- [31] Chow PK, Choo SP, Ng DC, Lo RH, Wang ML, Toh HC, et al. National cancer centre Singapore consensus guidelines for hepatocellular carcinoma. *Liver Cancer*. 2016; 5(2): 97–106.
- [32] Zhou J, Sun H-C, Wang Z, Cong W-M, Wang J-H, Zeng M-S, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition). *Liver Cancer*. 2018; 7(3): 235–60.
- [33] Korean Liver Cancer Association. 2018 Korean Liver Cancer Association–National Cancer Center. Korea practice guidelines for the management of hepatocellular carcinoma. *Gut Liver*. 2019; 13(3): 227–99.
- [34] Lu S-N, Wang J-H, Su C-W, Wang T-E, Dai C-Y, Chen C-H, et al. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. *J Formos Med Assoc*. 2018; 117(5): 381–403.
- [35] Cheung TT-T, Kwok PC-H, Chan S, Cheung C-C, Lee A-S, Lee V, et al. Hong Kong consensus statements for the management of unresectable hepatocellular carcinoma. *Liver Cancer*. 2018; 7(1): 40–54.
- [36] Gavriilidis P, Roberts KJ, Askari A, Sutcliffe RP, Liu P-H, Hidalgo E, et al. Evaluation of the current guidelines for resection of hepatocellular carcinoma using the Appraisal of Guidelines for Research and Evaluation II instrument. *J Hepatol*. 2017; 67(5): 991–8.
- [37] Yoon SM, Ryoo B-Y, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. *JAMA Oncol*. 2018; 4(5): 661–9.
- [38] Guyatt G, Oxman A, Vist G, GRADE Working Group. An emerging consensus on rating quality of evidence and strength of recommendations. *Br Med J*. 2007; 336(7650): 924–6.
- [39] Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, et al. The Indian National Association for Study of the Liver (INASL) consensus on prevention, diagnosis and management of hepatocellular carcinoma in India: the Puri recommendations. *J Clin Exp Hepatol*. 2014; 4: S3–S26.
- [40] Méndez-Sánchez N, Ridruejo E, de Mattos AA, Chávez-Tapia NC, Zapata R, Paraná R, et al. Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. *Ann Hepatol*. 2014; 13: S4–S40.
- [41] Wehrenberg-Klee E, Goyal L, Dugan M, Zhu AX, Ganguli S. Y-90 radioembolization combined with a PD-1 inhibitor for advanced hepatocellular carcinoma. *Cardiovasc Intervent Radiol*. 2018; 41(11): 1799–802.
- [42] Rim CH, Cheng J, Huang W-Y, Kimura T, Lee V, Zeng Z-C, et al. An evaluation of hepatocellular carcinoma practice guidelines from a radiation oncology perspective. *Radiother Oncol*. 2020; 2020(148): 73–81.
- [43] Rim CH, Seong J. Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. *Radiat Oncol J*. 2016; 34(3): 160–7.
- [44] Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. *CMAJ*. 2010; 182(18): E839–E42.
- [45] Holvoet T, Raevens S, Vandewynckel Y-P, Van Biesen W, Geboes K, Van Vlierberghe H. Systematic review of guidelines for management of intermediate hepatocellular carcinoma using the Appraisal of Guidelines Research and Evaluation II instrument. *Dig Liver Dis*. 2015; 47(10): 877–83.
- [46] Schmidt S, Follmann M, Malek N, Manns MP, Greten TF. Critical appraisal of clinical practice guidelines for diagnosis and treatment of hepatocellular carcinoma. *J Gastroenterol Hepatol*. 2011; 26(12): 1779–86.
- [47] National Cancer Comprehensive Network. Principle of locoregional therapy. NCCN guidelines version 3.2019, Hepatobiliary cancers. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Assessed 1 Dec 2019.

早期肝细胞癌的消融放射治疗

Ablative Radiation Therapy for Early Hepatocellular Carcinoma

12

- [1] Kanwal F, Singal AG. Surveillance for hepatocellular carcinoma: current best practice and future direction. *Gastroenterology*. 2019; 157(1): 54–64.
- [2] Sato T, Tateishi R, Yoshida H, Ohki T, Masuzaki R, Imamura J, et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. *Hepatol Int*. 2009; 3(4): 544–50.
- [3] Kudo M. Management of hepatocellular carcinoma in Japan: current trends. *Liver Cancer*. 2020; 9(1): 1–5.
- [4] Kudo M. Management of hepatocellular carcinoma in Japan as a world-leading model. *Liver Cancer*. 2018; 7(2): 134–47.
- [5] European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol*. 2018; 69(1): 182–236.
- [6] Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, et al. Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. *Hepatol Res*. 2020; 50(1): 15–46.
- [7] Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. *Hepatology*. 2018; 68(2): 723–50.
- [8] Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. *Hepatology*. 2011; 53(3): 1020–2.
- [9] International Consensus Group for Hepatocellular neoplasia. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. *Hepatology*. 2009; 49(2): 658–64.
- [10] Midorikawa Y, Takayama T, Shimada K, Nakayama H, Higaki T, Moriguchi M, et al. Marginal survival benefit in the treatment of early hepatocellular carcinoma. *J Hepatol*. 2013; 58(2): 306–11.
- [11] Kumada T, Toyoda H, Tada T, Sone Y, Fujimori M, Ogawa S, et al. Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. *AJR*. 2011; 197(1): 58–63.
- [12] Regimbeau JM, Kianmanesh R, Farges O, Dondero F, Sauvanet A, Belghiti J. Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma. *Surgery*. 2002; 131(3): 311–7.
- [13] Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. *Semin Liver Dis*. 2010; 30(1): 52–60.
- [14] Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, Ebinuma H, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. *Cancer*. 2016; 122(13): 2041–9.
- [15] Lasley FD, Mannina EM, Johnson CS, Perkins SM, Althouse S, Maluccio M, et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. *Pract Radiat Oncol*. 2015; 5(5): e443-e9.
- [16] Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. *Cancer*. 2012; 118(21): 5424–31.
- [17] Feng M, Suresh K, Schipper MJ, Bazzi L, Ben-Josef E, Matuszak MM, et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial. *JAMA Oncol*. 2018; 4(1): 40–7.
- [18] Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. *J Clin Oncol*. 2016; 34(5): 452–9.
- [19] Rajyaguru DJ, Borgert AJ, Smith AL, Thomes RM, Conway PD, Halfdanarson TR, et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the national cancer database. *J Clin Oncol*. 2018; 36(6): 600–8.
- [20] Hara K, Takeda A, Tsurugai Y, Saigusa Y, Sanuki N, Eriguchi T, et al. Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis. *Hepatology*. 2019; 69(6): 2533–45.
- [21] Kim N, Kim HJ, Won JY, Kim DY, Han KH, Jung I, et al. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. *Radiother Oncol*. 2019; 131: 81–7.
- [22] Kim N, Cheng J, Jung I, Liang J, Shih YL, Huang WY, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. *J Hepatol*. 2020; 73(1): 121–9.
- [23] Su TS, Liang P, Liang J, Lu HZ, Jiang HY, Cheng T, et al. Long-term survival analysis of stereotactic ablative radiotherapy versus liver resection for small hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2017; 98(3): 639–46.
- [24] Nakano R, Ohira M, Kobayashi T, Ide K, Tahara H, Kuroda S, et al. Hepatectomy versus stereotactic body radiotherapy for primary early hepatocellular carcinoma: a propensity-matched analysis in a single institution. *Surgery*. 2018; 164(2): 219–26.
- [25] Izumi N, Hasegawa K, Nishioka N, editors. A multicenter

- randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial). ASCO 2019 annual meeting; 2019.
- [26] Kim YS, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. *J Hepatol*. 2013; 58(1): 89–97.
- [27] Feng K, Yan J, Li X, Xia F, Ma K, Wang S, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. *J Hepatol*. 2012; 57(4): 794–802.
- [28] Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. *Ann Surg*. 2010; 252(6): 903–12.
- [29] Kim JW, Kim DY, Han KH, Seong J. Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma. *Dig Liver Dis*. 2019; 51(3): 445–51.
- [30] Kimura T, Takeda A, Ishikura S, Ariyoshi K, Yamaguchi T, Imagumbai T, et al., editors. Multicenter prospective study of stereotactic body radiotherapy for untreated solitary primary hepatocellular carcinoma: the STRSPH Study. The American Society for Radiation Oncology 61st Annual Meeting; 2019.
- [31] Jang WI, Bae SH, Kim MS, Han CJ, Park SC, Kim SB, et al. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: safety and efficacy. *Cancer*. 2020; 126(2): 363–72.
- [32] Durand-Labrunie J, Baumann AS, Ayav A, Laurent V, Boleslawski E, Cattan S, et al. Curative irradiation treatment of hepatocellular carcinoma: a multicenter phase 2 trial. *Int J Radiat Oncol Biol Phys*. 2020; 107(1): 116–25.
- [33] Takeda A, Sanuki N, Eriguchi T, Kobayashi T, Iwabuchi S, Matsunaga K, et al. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. *J Gastroenterol Hepatol*. 2014; 29(2): 372–9.
- [34] European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol*. 2012; 56(4): 908–43.
- [35] <https://clinicaltrials.gov/ct2/show/NCT03898921?cond=NCT03898921&draw=2&rank=1> [Internet].
- [36] NCT04202523. <https://clinicaltrials.gov/ct2/show/NCT04202523?cond=NCT04202523&draw=2&rank=1>
- [37] NCT03338647. <https://clinicaltrials.gov/ct2/show/NCT03338647?cond=NCT03338647&draw=2&rank=1>
- [38] NCT02470533. <https://clinicaltrials.gov/ct2/show/NCT02470533?cond=NCT02470533&draw=2&rank=1>
- [39] NCT02762266. <https://clinicaltrials.gov/ct2/show/NCT02762266?cond=NCT02762266&draw=2&rank=1>
- [40] NCT01730937. <https://clinicaltrials.gov/ct2/show/NCT01730937?cond=NCT01730937&draw=1&rank=1>
- [41] Park HC, Seong J, Han KH, Chon CY, Moon YM, Suh CO. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2002; 54(1): 150–5.
- [42] Jang WI, Kim MS, Bae SH, Cho CK, Yoo HJ, Seo YS, et al. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. *Radiat Oncol*. 2013; 8: 250.
- [43] Lausch A, Sinclair K, Lock M, Fisher B, Jensen N, Gaede S, et al. Determination and comparison of radiotherapy dose responses for hepatocellular carcinoma and metastatic colorectal liver tumours. *Br J Radiol*. 2013; 86(1027): 20130147.
- [44] Ohri N, Tome WA, Mendez Romero A, Miften M, Ten Haken RK, Dawson LA, et al. Local control after stereotactic body radiation therapy for liver tumors. *Int J Rad Oncol Biol Phys*. 2018; <https://doi.org/10.1016/j.ijrobp.2017.12.288>.
- [45] Bang A, Dawson LA. Radiotherapy for HCC: ready for prime time? *JHEP Rep*. 2019; 1(2): 131–7.
- [46] Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. *Radiother Oncol*. 2019; 131: 135–44.
- [47] Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. *J Clin Oncol*. 2013; 31(13): 1631–9.
- [48] Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C, et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). *J Cancer Res Clin Oncol*. 2015; 141(7): 1301–9.
- [49] Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, Eriguchi T, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. *Acta oncologica (Stockholm, Sweden)*. 2014; 53(3): 399–404.
- [50] Bae SH, Kim MS, Jang WI, Cho CK, Yoo HJ, Kim KB, et al. Low hepatic toxicity in primary and metastatic liver cancers after stereotactic ablative radiotherapy using 3 fractions. *J Korean Med Sci*. 2015; 30(8): 1055–61.
- [51] Okuwaki Y, Nakazawa T, Shibuya A, Ono K, Hidaka H, Watanabe M, et al. Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns. *J Gastroenterol*. 2008; 43(1): 71–8.
- [52] Park JH, Yoon SM, Lim YS, Kim SY, Shim JH, Kim KM, et al. Two-week schedule of hypofractionated radiotherapy as a local salvage treatment for small hepatocellular carcinoma. *J Gastroenterol Hepatol*. 2013; 28(10): 1638–42.
- [53] Park J, Jung J, Kim D, Jung IH, Park JH, Kim JH, et al. Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma. *BMC Cancer*. 2018; 18(1): 1040.

肝动脉化学治疗栓塞联合外照射 放射治疗

13

Transarterial Chemoembolization Plus External Beam Radiotherapy

- [1] Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. *Radiology*. 1993; 188(1): 79–83.
- [2] Golfieri R, Cappelli A, Cucchetti A, Piscaglia F, Carpenzano M, Peri E, et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. *Hepatology*. 2011; 53(5): 1580–9.
- [3] Iwazawa J, Ohue S, Hashimoto N, Muramoto O, Mitani T. Survival after C-arm CT-assisted chemoembolization of unresectable hepatocellular carcinoma. *Eur J Radiol*. 2012; 81(12): 3985–92.
- [4] Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. *Hepatology*. 2003; 37(2): 429–42.
- [5] Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. *Hepatology*. 2016; 64(1): 106–16.
- [6] Kudo M, Han G, Finn RS, Poon RT, Blanc JF, Yan L, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. *Hepatology*. 2014; 60(5): 1697–707.
- [7] Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. *J Hepatol*. 2012; 56(6): 1330–5.
- [8] Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, doubleblind, phase 3 trial. *Lancet Gastroenterol Hepatol*. 2017; 2(8): 565–75.
- [9] Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology*. 2011; 53(3): 1020–2.
- [10] Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. *Liver Int*. 2015; 35(9): 2155–66.
- [11] Raoul JL, Gilibert M, Piana G. How to define transarterial chemoembolization failure or refractoriness: a European perspective. *Liver Cancer*. 2014; 3(2): 119–24.
- [12] Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. *Dig Dis*. 2011; 29(3): 339–64.
- [13] Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, et al. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). *Liver Int*. 2013; 33(3): 327–37.
- [14] Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Müller C, et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. *Hepatology*. 2013; 57(6): 2261–73.
- [15] Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. *Acta Radiol*. 2008; 49(5): 523–9.
- [16] Yoon SM, Ryou BY, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. *JAMA Oncol*. 2018; 4(5): 661–9.
- [17] Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis. *JAMA Oncol*. 2015; 1(6): 756–65.
- [18] Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. *Cancer*. 2006; 106(8): 1653–63.
- [19] Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. *Nat Rev Cancer*. 2007; 7(11): 834–46.
- [20] Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. *Int J Radiat Oncol Biol Phys*. 1979; 5(1): 85–91.
- [21] Seong J, Kim SH, Suh CO. Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma. *J Gastroenterol Hepatol*. 2001; 16(8): 883–9.
- [22] Chen WJ, Yuan SF, Zhu LJ, Sun XN, Zheng W. Three-dimensional conformal radiotherapy in combination with transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma. *Journal of BUON*. 2014; 19(3): 692–7.
- [23] Choi C, Koom WS, Kim TH, Yoon SM, Kim JH, Lee HS, et al. A prospective phase 2 multicenter study for the efficacy of radiation therapy following incomplete transarterial chemoembolization in unresectable hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2014; 90(5): 1051–60.
- [24] Guo WJ, Yu EX, Liu LM, Li J, Chen Z, Lin JH, et al. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. *World J Gastroenterol*. 2003; 9(8): 1697–701.

- [25] Li B, Yu J, Wang L, Li C, Zhou T, Zhai L, et al. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma. *Am J Clin Oncol*. 2003; 26(4): e92-9.
- [26] Oh D, Lim DH, Park HC, Paik SW, Koh KC, Lee JH, et al. Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization: a prospective evaluation of efficacy and toxicity. *Am J Clin Oncol*. 2010; 33(4): 370-5.
- [27] Koo JE, Kim JH, Lim YS, Park SJ, Won HJ, Sung KB, et al. Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. *Int J Radiat Oncol Biol Phys*. 2010; 78(1): 180-7.
- [28] Cheng JC, Chuang VP, Cheng SH, Huang AT, Lin YM, Cheng TI, et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2000; 47(2): 435-42.
- [29] Zeng ZC, Tang ZY, Fan J, Zhou J, Qin LX, Ye SL, et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. *Cancer J*. 2004; 10(5): 307-16.
- [30] Shim SJ, Seong J, Han KH, Chon CY, Suh CO, Lee JT. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. *Liver Int*. 2005; 25(6): 1189-96.
- [31] Byun HK, Kim HJ, Im YR, Kim DY, Han KH, Seong J. Dose escalation in radiotherapy for incomplete transarterial chemoembolization of hepatocellular carcinoma. *Strahlenther Onkol*. 2020; 196(2): 132-41.
- [32] Meng MB, Cui YL, Lu Y, She B, Chen Y, Guan YS, et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. *Radiother Oncol*. 2009; 92(2): 184-94.
- [33] Fujii T, Takayasu K, Muramatsu Y, Moriyama N, Wakao F, Kosuge T, et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. *Jpn J Clin Oncol*. 1993; 23(2): 105-9.
- [34] Albacete RA, Matthews MJ, Saini N. Portal vein thromboses in malignant hepatoma. *Ann Intern Med*. 1967; 67(2): 337-48.
- [35] Price J, Chan M, Hamilton-Wood C, Chronos NA, Mok SD, Metreweli C. Sonographic diagnosis of portal vein invasion in patients with hepatocellular carcinoma: comparison with arterial portography. *Clin Radiol*. 1990; 41(1): 9-12.
- [36] Tazawa J, Maeda M, Sakai Y, Yamane M, Ohbayashi H, Kakinuma S, et al. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. *J Gastroenterol Hepatol*. 2001; 16(6): 660-5.
- [37] Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. *Radiology*. 1983; 148(2): 397-401.
- [38] Lim HS, Jeong YY, Kang HK, Kim JK, Park JG. Imaging features of hepatocellular carcinoma after transcatheter arterial chemoembolization and radiofrequency ablation. *AJR Am J Roentgenol*. 2006; 187(4): W341-9.
- [39] Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. *Cancer*. 2002; 94(6): 1747-52.
- [40] Park HC, Seong J, Han KH, Chon CY, Moon YM, Suh CO. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2002; 54(1): 150-5.
- [41] Toya R, Murakami R, Baba Y, Nishimura R, Morishita S, Ikeda O, et al. Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. *Radiother Oncol*. 2007; 84(3): 266-71.

局部晚期肝细胞癌根治性放射治疗

14

Definitive Radiotherapy for Locally Advanced Hepatocellular Carcinoma

- [1] Korean Liver Cancer Association, National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center. Korea practice guidelines for the management of hepatocellular carcinoma. *Gut Liver*. 2019; 13(3): 227–99.
- [2] Forner A, Reig M, Bruix J. Hepatocellular carcinoma. *Lancet*. 2018; 391(10127): 1301–14.
- [3] Park HC, Seong J, Tanaka M, Zeng ZC, Lim HY, Guan S, et al. Multidisciplinary management of nonresectable hepatocellular carcinoma. *Oncology*. 2011; 81(Suppl 1): 134–40.
- [4] Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. *J Hepatol*. 2017; 67(5): 999–1008.
- [5] Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. *Hepatology*. 1999; 29(1): 62–7.
- [6] Katagiri S, Yamamoto M. Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus. *Surg Today*. 2014; 44(2): 219–26.
- [7] Knox JJ, Cleary SP, Dawson LA. Localized and systemic approaches to treating hepatocellular carcinoma. *J Clin Oncol*. 2015; 33(16): 1835–44.
- [8] Yoon SM, Lim YS, Won HJ, Kim JH, Kim KM, Lee HC, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. *Int J Radiat Oncol Biol Phys*. 2012; 82(5): 2004–11.
- [9] Koo JE, Kim JH, Lim YS, Park SJ, Won HJ, Sung KB, et al. Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. *Int J Radiat Oncol Biol Phys*. 2010; 78(1): 180–7.
- [10] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. *J Hepatol*. 2018; 69(1): 182–236.
- [11] Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. *Hepatology*. 2018; 68(2): 723–50.
- [12] Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol*. 2009; 10(1): 25–34.
- [13] Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*. 2008; 359(4): 378–90.
- [14] Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet*. 2018; 391(10126): 1163–73.
- [15] Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med*. 2020; 382(20): 1894–905.
- [16] Bang A, Dawson LA. Radiotherapy for HCC: ready for prime time? *JHEP Rep*. 2019; 1(2): 131–7.
- [17] Yu JI, Park HC, Lim DH, Park W, Yoo BC, Paik SW, et al. Prognostic index for portal vein tumor thrombosis in patients with hepatocellular carcinoma treated with radiation therapy. *J Korean Med Sci*. 2011; 26(8): 1014–22.
- [18] Zeng ZC, Fan J, Tang ZY, Zhou J, Wang JH, Wang BL, et al. Prognostic factors for patients with hepatocellular carcinoma with macroscopic portal vein or inferior vena cava tumor thrombi receiving external-beam radiation therapy. *Cancer Sci*. 2008; 99(12): 2510–7.
- [19] Han KH, Seong J, Kim JK, Ahn SH, Lee DY, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. *Cancer*. 2008; 113(5): 995–1003.
- [20] Toya R, Murakami R, Baba Y, Nishimura R, Morishita S, Ikeda O, et al. Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. *Radiother Oncol*. 2007; 84(3): 266–71.
- [21] Lin CS, Jen YM, Chiu SY, Hwang JM, Chao HL, Lin HY, et al. Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. *Jpn J Clin Oncol*. 2006; 36(4): 212–7.
- [22] Zeng ZC, Fan J, Tang ZY, Zhou J, Qin LX, Wang JH, et al. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. *Int J Radiat Oncol Biol Phys*. 2005; 61(2): 432–43.
- [23] Kim DY, Park W, Lim DH, Lee JH, Yoo BC, Paik SW, et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. *Cancer*. 2005; 103(11): 2419–26.
- [24] Yu JI, Park JW, Park HC, Yoon SM, Lim DH, Lee JH, et al. Clinical impact of combined transarterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: An external validation study. *Radiother Oncol*. 2016; 118(2): 408–15.
- [25] Kim KM, Kim JH, Park IS, Ko GY, Yoon HK, Sung KB, et al.

- Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. *J Gastroenterol Hepatol.* 2009; 24(5): 806–14.
- [26] Sinn DH, Choi GS, Park HC, Kim JM, Kim H, Song KD, et al. Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. *PLoS One.* 2019; 14(1): e0210730.
- [27] Lee DW, Yim HJ, Seo YS, Na SK, Kim SY, Suh SJ, et al. Prognostic assessment using a new substaging system for Barcelona clinic liver cancer stage C hepatocellular carcinoma: a nationwide study. *Liver Int.* 2019; 39(6): 1109–19.
- [28] Kim YJ, Jung J, Joo JH, Kim SY, Kim JH, Lim YS, et al. Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: necessity to subclassify Barcelona Clinic Liver Cancer stage C. *Radiother Oncol.* 2019; 141: 95–100.
- [29] Chen SC, Lian SL, Chang WY. The effect of external radiotherapy in treatment of portal vein invasion in hepatocellular carcinoma. *Cancer Chemother Pharmacol.* 1994; 33(Suppl): S124–7.
- [30] Yamada K, Soejima T, Sugimoto K, Mayahara H, Izaki K, Sasaki R, et al. Pilot study of local radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. *Jpn J Clin Oncol.* 2001; 31(4): 147–52.
- [31] Igaki H, Nakagawa K, Shiraishi K, Shiina S, Kokudo N, Terahara A, et al. Three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava invasion. *Jpn J Clin Oncol.* 2008; 38(6): 438–44.
- [32] Nakazawa T, Adachi S, Kitano M, Isobe Y, Kokubu S, Hidaka H, et al. Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels. *Oncology.* 2007; 73(1–2): 90–7.
- [33] Huang YJ, Hsu HC, Wang CY, Wang CJ, Chen HC, Huang EY, et al. The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2009; 73(4): 1155–63.
- [34] Lee SU, Park JW, Kim TH, Kim YJ, Woo SM, Koh YH, et al. Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. *Strahlenther Onkol.* 2014; 190(9): 806–14.
- [35] Xi M, Zhang L, Zhao L, Li QQ, Guo SP, Feng ZZ, et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. *PLoS One.* 2013; 8(5): e63864.
- [36] Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, et al. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. *Strahlenther Onkol.* 2009; 185(12): 782–8.
- [37] Hata M, Tokuyue K, Sugahara S, Kagei K, Igaki H, Hashimoto T, et al. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. *Cancer.* 2005; 104(4): 794–801.
- [38] Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. *JAMA Oncol.* 2018; 4(5): 661–9.
- [39] Han K, Kim JH, Yoon HM, Kim EJ, Gwon DI, Ko GY, et al. Transcatheter arterial chemoembolization for infiltrative hepatocellular carcinoma: clinical safety and efficacy and factors influencing patient survival. *Korean J Radiol.* 2014; 15(4): 464–71.
- [40] Reynolds AR, Furlan A, Fetzer DT, Sasatomi E, Borhani AA, Heller MT, et al. Infiltrative hepatocellular carcinoma: what radiologists need to know. *Radiographics.* 2015; 35(2): 371–86.
- [41] Ishikura S, Ogino T, Furuse J, Satake M, Baba S, Kawashima M, et al. Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. *Am J Clin Oncol.* 2002; 25(2): 189–93.
- [42] Tazawa J, Maeda M, Sakai Y, Yamane M, Ohbayashi H, Kakinuma S, et al. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. *J Gastroenterol Hepatol.* 2001; 16(6): 660–5.
- [43] Yamada K, Izaki K, Sugimoto K, Mayahara H, Morita Y, Yoden E, et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2003; 57(1): 113–9.
- [44] Yu JI, Park HC, Lim DH, Kim CJ, Oh D, Yoo BC, et al. Scheduled interval trans-catheter arterial chemoembolization followed by radiation therapy in patients with unresectable hepatocellular carcinoma. *J Korean Med Sci.* 2012; 27(7): 736–43.
- [45] Kim BK, Kim DY, Byun HK, Choi HJ, Beom SH, Lee HW, et al. Efficacy and safety of liver-directed concurrent chemoradiotherapy and sequential sorafenib for advanced hepatocellular carcinoma: a prospective phase 2 trial. *Int J Radiat Oncol Biol Phys.* 2020; 107(1): 106–15.
- [46] Im JH, Yoon SM, Park HC, Kim JH, Yu JI, Kim TH, et al. Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. *Liver Int.* 2017; 37(1): 90–100.
- [47] Wei X, Jiang Y, Zhang X, Feng S, Zhou B, Ye X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. *J Clin Oncol.* 2019; 37(24): 2141–51.
- [48] Lu DH, Fei ZL, Zhou JP, Hu ZT, Hao WS. A comparison between three-dimensional conformal radiotherapy combined with interventional treatment and interventional treatment alone for hepatocellular carcinoma with portal vein tumour thrombosis. *J Med Imaging Radiat Oncol.* 2015; 59(1): 109–14.
- [49] Chu HH, Kim JH, Shim JH, Yoon SM, Kim PH, Alrashidi I. Chemoembolization plus radiotherapy versus chemoembolization plus sorafenib for the treatment of hepatocellular carcinoma invading the portal vein: a propensity score matching analysis. *Cancers (Basel).* 2020; 12(5): 1116.
- [50] Onishi H, Nouse K, Nakamura S, Katsui K, Wada N, Morimoto Y, et al. Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion. *Hepatol Int.* 2015; 9(1): 105–12.
- [51] Fujino H, Kimura T, Aikata H, Miyaki D, Kawaoka T, Kan H, et al. Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. *Hepatol*

- Res. 2015; 45(6): 607–17.
- [52] Lee D, Lee HC, An J, Shim JH, Kim KM, Lim YS, et al. Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion. *Clin Mol Hepatol*. 2018; 24(2): 144–50.
- [53] Cho JY, Paik YH, Park HC, Yu JI, Sohn W, Gwak GY, et al. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma. *Liver Int*. 2014; 34(5): 795–801.
- [54] Kim GA, Shim JH, Yoon SM, Jung J, Kim JH, Ryu MH, et al. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. *J Vasc Interv Radiol*. 2015; 26(3): 320–9.e6.
- [55] Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. *Int J Radiat Oncol Biol Phys*. 1995; 31(5): 1237–48.
- [56] Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. *Int J Radiat Oncol Biol Phys*. 2010; 76(3 Suppl): S94–100.
- [57] Yu JI, Cho JY, Park HC, Lim DH, Gwak GY, Paik SW. Child-Pugh score maintenance in cirrhotic hepatocellular carcinoma patients after radiotherapy: aspects of gastroduodenal complications. *Tumori*. 2014; 100(6): 645–51.
- [58] Chon YE, Seong J, Kim BK, Cha J, Kim SU, Park JY, et al. Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors. *Int J Radiat Oncol Biol Phys*. 2011; 81(5): 1343–51.
- [59] Dong Y, Liu TH, Yau T, Hsu C. Novel systemic therapy for hepatocellular carcinoma. *Hepatol Int*. 2020; 14(5): 638–51.
- [60] Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. *J Hepatol*. 2020; 72(2): 307–19.

根治性切除前的放射治疗

Neoadjuvant Radiotherapy Converting to Curative Resection

15

- [1] Lim KC, Chow PK, Allen JC, Siddiqui FJ, Chan ES, Tan SB. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. *Br J Surg*. 2012; 99(12): 1622–9.
- [2] European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol*. 2018; 69(1): 182–236.
- [3] Korean Liver Cancer Association, National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center. Korea practice guidelines for the management of hepatocellular carcinoma. *Gut Liver*. 2019; 13(3): 227–99.
- [4] Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Iacono C. How much remnant is enough in liver resection? *Dig Surg*. 2012; 29(1): 6–17.
- [5] Poon RT, Cheung TT, Kwok PC, Lee AS, Li TW, Loke KL, et al. Hong Kong consensus recommendations on the management of hepatocellular carcinoma. *Liver Cancer*. 2015; 4(1): 51–69.
- [6] Nakayama H, Takayama T. Role of surgical resection for hepatocellular carcinoma based on Japanese clinical guidelines for hepatocellular carcinoma. *World J Hepatol*. 2015; 7(2): 261–9.
- [7] Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. *J Hepatol*. 2016; 65(5): 938–43.
- [8] Wei X, Jiang Y, Zhang X, Feng S, Zhou B, Ye X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. *J Clin Oncol*. 2019; 37(24): 2141–51.
- [9] Yu JI, Park HC, Lim DH, Kim CJ, Oh D, Yoo BC, et al. Scheduled interval trans-catheter arterial chemoembolization followed by radiation therapy in patients with unresectable hepatocellular carcinoma. *J Korean Med Sci*. 2012; 27(7): 736–43.
- [10] Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. *Cancer*. 2012; 118(21): 5424–31.
- [11] Lee HS, Choi GH, Choi JS, Kim KS, Han KH, Seong J, et al. Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy. *Ann Surg Oncol*. 2014; 21(11): 3646–53.
- [12] Rim CH, Park S, Woo JY, Seong J. Compensatory hypertrophy of the liver after external beam radiotherapy for primary liver cancer. *Strahlenther Onkol*. 2018; 194(11): 1017–29.
- [13] Lau WY, Lai EC. Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability. *Ann Surg Oncol*. 2007; 14(12): 3301–9.
- [14] Sitzmann JV, Abrams R. Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. *Ann Surg*. 1993; 217(2): 149–54.
- [15] Lau WY, Ho SK, Yu SC, Lai EC, Liew CT, Leung TW. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. *Ann Surg*. 2004; 240(2): 299–305.
- [16] Akateh C, Black SM, Conteh L, Miller ED, Noonan A, Elliott E, et al. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. *World J Gastroenterol*. 2019; 25(28): 3704–21.
- [17] Han KH, Seong J, Kim JK, Ahn SH, Lee DY, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. *Cancer*. 2008; 113(5): 995–1003.
- [18] Chong JU, Choi GH, Han DH, Kim KS, Seong J, Han KH, et al. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus. *Ann Surg Oncol*. 2018; 25(11): 3308–15.
- [19] Lee WH, Byun HK, Choi JS, Choi GH, Han DH, Joo DJ, et al. Liver-directed combined radiotherapy as a bridge to curative surgery in locally advanced hepatocellular carcinoma beyond the milan criteria. *Radiother Oncol*. 2020; 152: 1–7.

- [1] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. *J Hepatol.* 2018; 69(1): 182–236.
- [2] Majno P, Lencioni R, Mornex F, Girard N, Poon RT, Cherqui D. Is the treatment of hepatocellular carcinoma on the waiting list necessary? *Liver Transpl.* 2011; 17(Suppl 2): S98–108.
- [3] Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. *Lancet Oncol.* 2012; 13(1): e11–22.
- [4] Munoz-Schuffenegger P, Ng S, Dawson LA. Radiation-induced liver toxicity. *Semin Radiat Oncol.* 2017; 27(4): 350–7.
- [5] Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. *J Clin Oncol.* 2013; 31(13): 1631–9.
- [6] Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. *Cancer.* 2012; 118(21): 5424–31.
- [7] Ohri N, Tome WA, Mendez Romero A, Miften M, Ten Haken RK, Dawson LA, et al. Local control after stereotactic body radiation therapy for liver tumors. *Int J Radiat Oncol Biol Phys.* 2018; <https://doi.org/10.1016/j.ijrobp.2017.12.288>.
- [8] Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. *Gastroenterology.* 2010; 138(1): 52–64.
- [9] Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. *Gastroenterology.* 2016; 151(6): 1155–63.e2.
- [10] Cescon M, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. *J Hepatol.* 2013; 58(3): 609–18.
- [11] Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. *Hepatology.* 2015; 61(6): 1968–77.
- [12] Andreou A, Bahra M, Schmelzle M, Ollinger R, Sucher R, Sauer IM, et al. Predictive factors for extrahepatic recurrence of hepatocellular carcinoma following liver transplantation. *Clin Transpl.* 2016; 30(7): 819–27.
- [13] Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet.* 2002; 359(9319): 1734–9.
- [14] Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology.* 2002; 35(5): 1164–71.
- [15] Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. *Ann Surg.* 1997; 226(6): 688–701. discussion 701–3
- [16] Nicolini A, Martinetti L, Crespi S, Maggioni M, Sangiovanni A. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. *J Vasc Interv Radiol.* 2010; 21(3): 327–32.
- [17] Allard MA, Sebah M, Ruiz A, Guettier C, Paule B, Vibert E, et al. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation? *J Hepatol.* 2015; 63(1): 83–92.
- [18] Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. *Ann Surg.* 2004; 240(5): 900–9.
- [19] Rodriguez-Sanjuan JC, Gonzalez F, Juanco C, Herrera LA, Lopez-Bautista M, Gonzalez-Noriega M, et al. Radiological and pathological assessment of hepatocellular carcinoma response to radiofrequency. A study on removed liver after transplantation. *World J Surg.* 2008; 32(7): 1489–94.
- [20] DuBay DA, Sandroussi C, Kachura JR, Ho CS, Beecroft JR, Vollmer CM, et al. Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. *HPB (Oxford).* 2011; 13(1): 24–32.
- [21] O'Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, Goldstein RM. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. *Liver Transpl.* 2012; 18(8): 949–54.
- [22] Mannina EM, Cardenas HR, Lasley FD, Goodman B, Zook J, Althouse S, et al. Role of stereotactic body radiation therapy before orthotopic liver transplantation: retrospective evaluation of pathologic response and outcomes. *Int J Radiat Oncol Biol Phys.* 2017; 97(5): 931–8.
- [23] Guarneri A, Franco P, Romagnoli R, Trino E, Mirabella S, Molinaro L, et al. Stereotactic ablative radiation therapy prior to liver transplantation in hepatocellular carcinoma. *Radiol Med.*

- 2016; 121(11): 873–81.
- [24] Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. *J Hepatol*. 2017; 67(1): 92–9.
- [25] Bush DA, Smith JC, Slater JD, Volk ML, Reeves ME, Cheng J, et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. *Int J Radiat Oncol Biol Phys*. 2016; 95(1): 477–82.
- [26] Mohamed M, Katz AW, Tejani MA, Sharma AK, Kashyap R, Noel MS, et al. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. *Adv Radiat Oncol*. 2016; 1(1): 35–42.
- [27] Velec M, Haddad CR, Craig T, Wang L, Lindsay P, Brierley J, et al. Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2017; 97(5): 939–46.
- [28] Pursley J, El Naqa I, Sanford NN, Noe B, Wo JY, Eyler CE, et al. Dosimetric analysis and normal tissue complication probability modeling of Child-Pugh score and Albumin-Bilirubin grade increase after hepatic irradiation. *Int J Radiat Oncol Biol Phys*. 2020; 107(5): 986–95.
- [29] Hasan S, Abel S, Uemura T, Verma V, Koay EJ, Herman J, et al. Liver transplant mortality and morbidity following preoperative radiotherapy for hepatocellular carcinoma. *HPB (Oxford)*. 2019; 22(5): 770–8.
- [30] Mastrocostas K, Jang HJ, Fischer S, Dawson LA, Munoz-Schuffenegger P, Sapisochin G, et al. Imaging post-stereotactic body radiation therapy responses for hepatocellular carcinoma: typical imaging patterns and pitfalls. *Abdom Radiol (NY)*. 2019; 44(5): 1795–807.
- [31] Mendiratta-Lala M, Gu E, Owen D, Cuneo KC, Bazzi L, Lawrence TS, et al. Imaging findings within the first 12 months of hepatocellular carcinoma treated with stereotactic body radiation therapy. *Int J Radiat Oncol Biol Phys*. 2018; 102(4): 1063–9.
- [32] Voroney JP, Brock KK, Eccles C, Haider M, Dawson LA. Prospective comparison of computed tomography and magnetic resonance imaging for liver cancer delineation using deformable image registration. *Int J Radiat Oncol Biol Phys*. 2006; 66(3): 780–91.
- [33] Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. *Int J Radiat Oncol Biol Phys*. 2010; 76(3 Suppl): S94–100.
- [34] Brandner ED, Chetty IJ, Giaddui TG, Xiao Y, Huq MS. Motion management strategies and technical issues associated with stereotactic body radiotherapy of thoracic and upper abdominal tumors: a review from NRG oncology. *Med Phys*. 2017; 44(6): 2595–612.
- [35] Hawkins MA, Brock KK, Eccles C, Moseley D, Jaffray D, Dawson LA. Assessment of residual error in liver position using kV cone-beam computed tomography for liver cancer high-precision radiation therapy. *Int J Radiat Oncol Biol Phys*. 2006; 66(2): 610–9.
- [36] Witt JS, Rosenberg SA, Bassetti MF. MRI-guided adaptive radiotherapy for liver tumours: visualising the future. *Lancet Oncol*. 2020; 21(2): e74–82.
- [37] Feng M, Suresh K, Schipper MJ, Bazzi L, Ben-Josef E, Matuszak MM, et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial. *JAMA Oncol*. 2018; 4(1): 40–7.
- [38] Sanford NN, Pursley J, Noe B, Yeap BY, Goyal L, Clark JW, et al. Protons versus photons for unresectable hepatocellular carcinoma: liver decompensation and overall survival. *Int J Radiat Oncol Biol Phys*. 2019; 105(1): 64–72.

- [1] Pirisi M, Avellini C, Fabris C, et al. Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study. *J Cancer Res Clin Oncol*. 1998; 124: 397–400.
- [2] Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic feature, treatment outcome, and survival. *Cancer*. 1996; 77: 2217–22.
- [3] Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western Center. *Ann Surg*. 1999; 229: 790–800.
- [4] Rabe C, Pilz T, Klostermann C, et al. Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. *World J Gastroenterol*. 2001; 7: 208–15.
- [5] Ando E, Yamashita F, Tanaka M, Tanikawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. *Cancer*. 1997; 79: 1890–6.
- [6] The Cancer of the Liver Italian Program Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. *Hepatology*. 1998; 28: 751–5.
- [7] Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, openlabel, multicenter controlled study. *J Clin Oncol*. 2019; 37(24): 2141–51.
- [8] Abou-Alfa GK, Shi Q, Knox JJ, et al. Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: phase 3 CALGB 80802 randomized clinical trial. *JAMA Oncol*. 2019; 5(11): 1582–8.
- [9] He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. *JAMA Oncol*. 2019; 5(7): 953–60.
- [10] Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, Lee HC, Lim YS. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. *JAMA Oncol*. 2018; 4(5): 661–9.
- [11] Kodama K, Kawaoka T, Aikata H, et al. Comparison of outcome of hepatic arterial infusion chemotherapy combined with radiotherapy and sorafenib for advanced hepatocellular carcinoma patients with major portal vein tumor thrombosis. *Oncology*. 2018; 94(4): 215–22.
- [12] Hou JZ, Zeng ZC, Wang BL, Yang P, Zhang JY, Mo HF. High dose radiotherapy with image-guided hypo-IMRT for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombi is more feasible and efficacious than conventional 3D-CRT. *Jpn J Clin Oncol*. 2016; 46(4): 357–62.
- [13] Wang K, Guo WX, Chen MS, et al. Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: a large-scale, multicenter, propensity matching score analysis. *Medicine (Baltimore)*. 2016; 95(11): e3015.
- [14] Kim GA, Shim JH, Yoon SM, et al. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. *J Vasc Interv Radiol*. 2015; 26(3): 320–9.e6.
- [15] Onishi H, Nouse K, Nakamura S, et al. Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion. *Hepatol Int*. 2015; 9(1): 105–12.
- [16] Lu DH, Fei ZL, Zhou JP, et al. A comparison between three-dimensional conformal radiotherapy combined with interventional treatment and interventional treatment alone for hepatocellular carcinoma with portal vein tumour thrombosis. *J Med Imaging Radiat Oncol*. 2015; 59(1): 109–14.
- [17] Nakazawa T, Hidaka H, Shibuya A, et al. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. *BMC Gastroenterol*. 2014; 14: 84.
- [18] Tang QH, Li AJ, Yang GM, et al. Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study. *World J Surg*. 2013; 37(6): 1362–70.
- [19] Chuma M, Taguchi H, Yamamoto Y, et al. Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. *J Gastroenterol Hepatol*. 2011; 26(7): 1123–32.
- [20] Chung YH, Song IHH, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon- α for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. *Cancer*. 2000; 88: 1986–91.
- [21] Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. *Cancer*. 2002; 95: 588–95.
- [22] Yen FS, Wu JC, Kuo BI, et al. Transcatheter arterial embolization for hepatocellular carcinoma with portal vein thrombosis. *J Gastroenterol Hepatol*. 1995; 10: 237–40.
- [23] Minagawa M, Makuuchi M, Takayama TK, et al. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. *Ann Surg*. 2001;

- 233: 379–84.
- [24] Cheng SH, Lin YM, Chuang VP, et al. A pilot study of three dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. *J Gastroenterol Hepatol.* 1999; 14: 1025–33.
- [25] Ishikura S, Ogino T, Furuse J, et al. Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. *Am J Clin Oncol.* 2002; 25: 189–93.
- [26] Zeng ZC, Fan J, Zhou J, et al. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. *Int J Radiation Oncology Boil Phys.* 2005; 61: 432–43.
- [27] Nakazawa T, Adachi S, Kitano M, et al. Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels. *Oncology.* 2007; 73: 90–7.
- [28] Koo JE, Kim JH, Lim YS, et al. Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. *Int J Radiat Oncol Biol Phys.* 2010; 78: 180–7.
- [29] Chen LW, Chien RN, Fang KM, et al. Elucidating therapeutic effects on patients with hepatocellular carcinoma and main portal vein thrombosis. *Hepato-Gastroenterology.* 2010; 57(98): 228–31.
- [30] Kim DY, Park W, Lim DH, et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. *Cancer.* 2005; 103: 2419–26.
- [31] Nakagawa K, Yamashita H, Shiraishi K, et al. Radiation therapy for portal venous invasion by hepatocellular carcinoma. *World J Gastroenterol.* 2005; 11: 7237–41.
- [32] Lin CS, Jen YM, Chiu SY, et al. Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. *Jpn J Clin Oncol.* 2006; 36: 212–7.
- [33] Toya R, Murakami R, Baba Y, et al. Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. *Radiother Oncol.* 2007; 84: 266–71.
- [34] Yoon SM, Lim YS, Won HJ, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. *Int J Radiat Oncol Biol Phys.* 2012; 82: 2004–11.
- [35] Hou JZ, Zeng ZC, Zhang JY, et al. Influence of tumor thrombus location on the outcome of external-beam radiation therapy in advanced hepatocellular carcinoma with macrovascular invasion. *Int J Radiat Oncol Biol Phys.* 2012; 84: 362–8.
- [36] Rim CH, Yang DS, Park YJ, et al. Effectiveness of high-dose three-dimensional conformal radiotherapy in hepatocellular carcinoma with portal vein thrombosis. *Jpn J Clin Oncol.* 2012; 42: 721–9.
- [37] Zhang XB, Wang JH, Yan ZP, et al. Hepatocellular carcinoma with main portal vein tumor thrombus. Treatment with 3-D conformal radiotherapy after portal vein stenting and transarterial chemoembolization. *Cancer.* 2009; 115: 1245–52.
- [38] Han KH, Seong J, Kim JK, et al. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. *Cancer.* 2008; 113: 995–1003.
- [39] Katamura Y, Aikata H, Takaki S, et al. Intraarterial 5-Fu/interferon combination therapy for advanced hepatocellular carcinoma with or without 3-dimensional conformal radiotherapy for portal vein tumor thrombosis. *J Gastroenterol.* 2009; 44: 492–502.
- [40] Kim BK, Kim DY, Byun HK, et al. Efficacy and safety of liver-directed concurrent chemoradiotherapy and sequential sorafenib for advanced hepatocellular carcinoma: a prospective phase 2 trial. *Int J Radiat Oncol Biol Phys.* 2020; 107(1): 106–15.
- [41] Kamiyama T, Nakanishi K, Yokoo H, et al. Efficacy of preoperative radiotherapy to portal vein tumor thrombus in the main trunk or first branch in patients with hepatocellular carcinoma. *Int J Clin Oncol.* 2007; 12: 363–8.
- [42] Kim J, Lee I, Kim J, et al. Clinical features of hepatocellular carcinoma patients undergoing resection after concurrent chemoradiation therapy. *Int J Radiat Oncol Biol Phys.* 2012; 84: S336–7.
- [43] Shirabe K, Shimada M, Tsujita E, et al. Thrombectomy before hepatic resection for hepatocellular carcinoma with a tumor thrombus extending to the inferior vena cava. *Int Surg.* 2001; 86: 141–3.
- [44] Yogita S, Tashiro S, Harada M, et al. Hepatocellular carcinoma with extension into the right atrium: report of a successful liver resection by hepatic vascular exclusion using cardiopulmonary bypass. *J Med Investig.* 2000; 47: 155–60.
- [45] Wu CC, Hseih S, Ho WM, et al. Surgical treatment for recurrent hepatocellular carcinoma with tumor thrombi in right atrium: using cardiopulmonary bypass and deep hypothermic circulatory arrest. *J Surg Oncol.* 2000; 74: 227–31.
- [46] Rim CH, Jeong BK, Kim TH, Hee Kim J, Kang HC, Seong J. Effectiveness and feasibility of external beam radiotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium involvement: a multicenter trial in Korea (KROG 17-10). *Int J Radiat Biol.* 2020; 96(6): 759–66.
- [47] Murakami E, Aikata H, Miyaki D, et al. Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon- α for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava. *Hepatol Res.* 2012; 42: 442–53.
- [48] Zeng ZC, Fan J, Tang ZY, et al. Prognostic factors for hepatocellular carcinoma with macroscopic portal vein or inferior vena cava tumor thrombi receiving radiotherapy. *Cancer Sci.* 2008; 99: 2510–7.
- [49] Kim JY, Yoo EJ, Jang JW, Kwon JH, Kim KJ, Kay CS. Hypofractionated radiotherapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. *Radiat Oncol.* 2013; 8: 15.
- [50] Sun HC, Zhuang PY, Qin LX, et al. Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy. *J Surg Oncol.* 2007; 96: 37–45.
- [51] Kobayashi S, Takahashi S, Kato Y, et al. Surgical treatment of lymph node metastases from hepatocellular carcinoma. *J Hepatobiliary Pancreat Sci.* 2011; 18: 559–66.
- [52] Watanabe J, Nakashima O, Kojiro M. Clinicopathologic study on lymph node metastasis of hepatocellular carcinoma: a retrospective study of 660 consecutive autopsy cases. *Jpn J Clin Oncol.* 1994; 24: 37–41.
- [53] Yuki K, Hirohashi S, Sakamoto M, et al. Growth and spread of

- hepatocellular carcinoma: a review of 240 consecutive autopsy cases. *Cancer*. 1990; 66: 2174-9.
- [54] Zeng ZC, Tang ZY, et al. Consideration of the role of radiotherapy for lymph node metastases in patients with HCC-A retrospective analysis for prognostic factors from 125 patients. *Int J Radiation Oncology Boil Phys*. 2005; 63: 1067-76.
- [55] Uenishi T, Hirohashi K, Shuto T, et al. The clinical significance of lymph node metastases in patients undergoing surgery for hepatocellular carcinoma. *Surg Today*. 2000; 30: 892-5.
- [56] Prat F, Chapat O, Ducot B, et al. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. *Gastrointest Endosc*. 1998; 47: 1-7.
- [57] Cheng AL, Guan Z, Chen Z, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. *Eur J Cancer*. 2012; 48(10): 1452-65.
- [58] Chen SC, Lian SL, Chuang WL, et al. Radiotherapy in the treatment of hepatocellular carcinoma and its metastases. *Cancer Chemother Pharmacol*. 1992; 31(suppl): 103-5.
- [59] Omuraya M, Beppu T, Ishiko T, et al. Lymph node excision with laparotomy and chemo-radiation therapy for a hepatocellular carcinoma patient with multiple lymph node metastases. *Gan To Kagaku Tyoho*. 2001; 28: 1699-703.
- [60] Park YJ, Lim DH, Paik SW, et al. Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma. *J Gastroenterol*. 2006; 41: 1099-106.
- [61] Yamashita H, Nakagawa K, Shiraishi K, et al. Radiotherapy for lymph node metastases in patients with hepatocellular carcinoma: retrospective study. *J Gastroenterol Hepatol*. 2007; 22: 523-7.
- [62] Toya R, Murakami R, Yasunaga T, et al. Radiation therapy for lymph node metastases from hepatocellular carcinoma. *Hepato-Gastroenterology*. 2009; 56: 476-80.
- [63] Kim K, Chie EK, Kim W, et al. Absence of symptom and intact liver function are positive prognosticators for patients undergoing radiotherapy for lymph node metastasis from hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2010; 78: 729-34.
- [64] Chen YX, Zeng ZC, Fan J, et al. Defining prognostic factors of survival after external beam radiotherapy treatment of hepatocellular carcinoma with lymph node metastases. *Clin Transl Oncol*. 2013; 15(9): 732-40.
- [65] Zhang HG, Chen YX, Hu Y, et al. Image-guided intensity-modulated radiotherapy improves short-term survival for abdominal lymph node metastases from hepatocellular carcinoma. *Ann Palliat Med*. 2019; 8(5): 717-27.
- [66] Marsh JW, Dvorchik I, Bonham CA, et al. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? *Cancer*. 2000; 88: 538-43.
- [67] Uchino K, Tateishi R, Shiina S, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. *Cancer*. 2011; 117: 4475-83.
- [68] Ho CL, Chen S, Cheng TK, Leung YL. PET/CT characteristics of isolated bone metastases in hepatocellular carcinoma. *Radiology*. 2011; 258: 515-23.
- [69] He J, Zeng ZC, Tang ZY, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external-beam radiotherapy. *Cancer*. 2009; 115: 2710-20.
- [70] Cho HS, Oh JH, Han I, Kim HS. Survival of patients with skeletal metastases from hepatocellular carcinoma after surgical management. *J Bone Joint Surg Br*. 2009; 91: 1505-12.
- [71] Kashima M, Yamakado K, Takaki H, et al. Radiofrequency ablation for the treatment of bone metastases from hepatocellular carcinoma. *AJR Am J Roentgenol*. 2010; 194: 536-41.
- [72] Koike Y, Takizawa K, Ogawa Y, et al. Transcatheter arterial chemoembolization (TACE) or embolization (TAE) for symptomatic bone metastases as a palliative treatment. *Cardiovasc Intervent Radiol*. 2011; 34(4): 793-801.
- [73] Uemura A, Fujimoto H, Yasuda S, et al. Transcatheter arterial embolization for bone metastases from hepatocellular carcinoma. *Eur Radiol*. 2001; 11: 1457-62.
- [74] Katamura Y, Aikata H, Hashimoto Y, et al. Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma. *Hepatol Res*. 2010; 40: 1195-203.
- [75] Montella L, Addeo R, Palmieri G, et al. Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series. *Cancer Chemother Pharmacol*. 2010; 65: 1137-43.
- [76] Suzawa N, Yamakado K, Takaki H, et al. Complete regression of multiple painful bone metastases from hepatocellular carcinoma after administration of strontium-89 chloride. *Ann Nucl Med*. 2010; 24: 617-20.
- [77] Kaizu T, Karasawa K, Tanaka Y, et al. Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective study of 57 patients. *Am J Gastroenterol*. 1998; 93: 2167-71.
- [78] Seong J, Koom WS, Park HC. Radiotherapy for painful bone metastases from hepatocellular carcinoma. *Liver Int*. 2005; 25: 261-5.
- [79] Nakamura N, Igaki H, Yamashita H, et al. A retrospective study of radiotherapy for spinal bone metastases from hepatocellular carcinoma (HCC). *Jpn J Clin Oncol*. 2007; 37: 38-43.
- [80] He J, Zeng ZC, Fan J, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma after liver transplantation. *BMC Cancer*. 2011; 11: 492.
- [81] Kneuert PJ, Cosgrove DP, Cameron AM, et al. Multidisciplinary management of recurrent hepatocellular carcinoma following liver transplantation. *J Gastrointest Surg*. 2012; 16: 874-81.
- [82] Tung WC, Huang YJ, Leung SW, et al. Incidence of needle tract seeding and responses of soft tissue metastasis by hepatocellular carcinoma postradiotherapy. *Liver Int*. 2007; 27: 192-200.
- [83] Szpakowski JL, Drasin TE, Lyon LL. Rate of seeding with biopsies and ablations of hepatocellular carcinoma: a retrospective cohort study. *Hepatol Commun*. 2017; 1(9): 841-51.
- [84] He J, Shi S, Ye L, Ma G, Pan X, Huang Y, Zeng Z. A randomized trial of conventional fraction versus hypofraction radiotherapy for bone metastases from hepatocellular carcinoma. *J Cancer*. 2019; 10(17): 4031-7.
- [85] Kim SU, Kim DY, Park JY, et al. Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. *J Cancer Res Clin Oncol*. 2008; 134: 1377-84.
- [86] Katyal S, Oliver JH III, Peterson MS, Ferris JV, Carr BS, Baron RL. Extrahepatic metastases of hepatocellular carcinoma. *Radiology*. 2000; 216: 698-703.
- [87] Nakashima T, Okuda K, Kojiro M, Jimi A, Yamaguchi R, Sakamoto K, et al. Pathology of hepatocellular carcinoma in

- Japan. 232 consecutive cases autopsied in ten years. *Cancer*. 1983; 51: 863–77.
- [88] Momoi H, Shimahara Y, Terajima H, et al. Management of adrenal metastasis from hepatocellular carcinoma. *Surg Today*. 2002; 32: 1035–41.
- [89] Park JS, Yoon DS, Kim KS, et al. What is the best treatment modality for adrenal metastasis from hepatocellular carcinoma? *J Surg Oncol*. 2007; 96: 32–6.
- [90] Taniai N, Egami K, Wada M, Tajiri T, Onda M. Adrenal metastasis from hepatocellular carcinoma: report of 3 cases. *Hepato-Gastroenterology*. 1999; 46: 2523–8.
- [91] Shibata T, Maetani Y, Ametani F, et al. Percutaneous ethanol injection for treatment of adrenal metastasis from hepatocellular carcinoma. *Am J Roentgenol*. 2000; 174: 333–5.
- [92] Yamakado K, Anai H, Takaki H, et al. Adrenal metastasis from hepatocellular carcinoma: radiofrequency ablation combined with adrenal arterial chemoembolization in six patients. *Am J Roentgenol*. 2009; 192: 300–5.
- [93] Zeng ZC, Tang ZY, Fan J, et al. Radiation therapy for adrenal gland metastases from hepatocellular carcinoma. *Jpn J Clin Oncol*. 2005; 35: 61–7.
- [94] Zhou LY, Zeng ZC, Fan J, et al. Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors. *BMC Cancer*. 2014; 14: 878.
- [95] Chen B, Hu Y, Liu J, Cao AN, Ye LX, Zeng ZC. Respiratory motion of adrenal gland metastases: analyses using four-dimensional computed tomography images. *Phys Med*. 2017; 38: 54–8.
- [96] Yuan BY, Hu Y, Zhang L, Chen YH, Dong YY, Zeng ZC. Radiotherapy for adrenal gland metastases from hepatocellular carcinoma. *Clin Transl Oncol*. 2017; 19(9): 1154–60.
- [97] Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. *Ann Surg*. 1990; 211: 277–87.
- [98] Kakumu S. Trends in liver cancer researched by the Liver Cancer Study Group of Japan. *Hepatol Res*. 2002; 24: S21–7.
- [99] Ikai I, Itai Y, Okita K, et al. Report of the 15th follow-up survey of primary liver cancer. *Hepatol Res*. 2004; 28: 21–9.
- [100] Yoon KT, Kim JK, Kim DY, et al. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. *Oncology*. 2007; 72: 104–10.
- [101] Natsuizaka M, Omura T, Akaike T, et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. *J Gastroenterol Hepatol*. 2005; 20: 1781–7.
- [102] Taketomi A, Toshima T, Kitagawa D, et al. Predictors of extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. *Ann Surg Oncol*. 2010; 17: 2740–6.
- [103] Yang T, Lu JH, Lin C, et al. Concomitant lung metastasis in patients with advanced hepatocellular carcinoma. *World J Gastroenterol*. 2012; 18: 2533–9.
- [104] Zhang SM, Zeng ZC, Tang ZY, et al. Prognostic analysis of pulmonary metastases from hepatocellular carcinoma. *Hepatol Int*. 2008; 2: 237–43.
- [105] Zheng SS, Chen J, Wang WL, et al. Recurrence and metastasis of hepatocellular carcinoma after liver transplantation: single center experiences. *Zhonghua Wai Ke Za Zhi*. 2008; 46: 1609–13.
- [106] Zhang M, Dai C, Zhu H, et al. Cyclophilin A promotes human hepatocellular carcinoma cell metastasis via regulation of MMP3 and MMP9. *Mol Cell Biochem*. 2011; 357: 387–95.
- [107] Duan F, Wang MQ, Liu FY, et al. Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis. *Asia Pac J Clin Oncol*. 2012; 8: 156–63.
- [108] Hu HT, Yao QJ, Meng YL, Li HL, Zhang H, Luo JP, Guo CY, Geng X. Arsenic trioxide intravenous infusion combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with pulmonary metastasis: long-term outcome analysis. *J Gastroenterol Hepatol*. 2017; 32(2): 295–300.
- [109] Katamura Y, Aikata H, Kimura Y, et al. Successful treatment of pulmonary metastases associated with advanced hepatocellular carcinoma by systemic 5-fluorouracil combined with interferon-alpha in a hemodialysis patient. *Hepatol Res*. 2009; 39: 415–20.
- [110] Tomokuni A, Marubashi S, Nagano H, et al. A case of complete response to S-1 therapy for multiple pulmonary recurrences of hepatocellular carcinoma after hepatic resection. *Gan To Kagaku Ryoho*. 2009; 36: 2383–5.
- [111] Koyama J, Honjo S, Morizono R, et al. Hepatocellular carcinoma with multiple lung metastasis resulting in long-term disease-free survival by transcatheter arterial infusion chemotherapy of SMANCS. *Gan To Kagaku Ryoho*. 2011; 38: 461–4.
- [112] Vogl TJ, Naguib NN, Gruber-Rouh T, et al. Microwave ablation therapy: clinical utility in treatment of pulmonary metastases. *Radiology*. 2011; 261: 643–51.
- [113] Hiraki T, Gobara H, Mimura H, et al. Long-term survival after radiofrequency ablation for pulmonary metastasis from hepatocellular carcinoma: report of two cases. *J Vasc Interv Radiol*. 2009; 20: 1106–7.
- [114] Jiang W, Zeng ZC, Zhang JY, et al. Palliative radiation therapy for pulmonary metastases from hepatocellular carcinoma. *Clin Exp Metastasis*. 2012; 29: 197–205.
- [115] Sun TW, He J, Zhang SM, Sun J, Zeng MS, Zeng ZC. Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma. *Oncotarget*. 2016; 7(30): 48586–99.
- [116] Jang JW, Kay CS, You CR, et al. Simultaneous multitarget irradiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases. *Int J Radiat Oncol Biol Phys*. 2009; 74: 412–8.
- [117] Kim JY, Kay CS, Kim YS, et al. Helical tomotherapy for simultaneous multitarget radiotherapy for pulmonary metastasis. *Int J Radiat Oncol Biol Phys*. 2009; 75: 703–10.
- [118] Okuma K, Yamashita H, Niibe Y, et al. Abscopal effect of radiation on lung metastases of hepatocellular carcinoma: a case report. *J Med Case Rep*. 2011; 5: 111.
- [119] Hodge JW, Sharp HJ, Gameiro SR. Cancer Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. *Biother Radiopharm*. 2012; 27: 12–22.
- [120] Lin G, Xiao H, Zeng Z, Xu Z, He J, Sun T, Liu J, Guo G, Ji W, Hu Y. Constraints for symptomatic radiation pneumonitis of helical tomotherapy hypofractionated simultaneous multitarget radiotherapy for pulmonary metastasis from hepatocellular

- carcinoma. *Radiother Oncol.* 2017; 123(2): 246–50.
- [121] Kim M, Na DL, Park SH, et al. Nervous system involvement by metastatic hepatocellular carcinoma. *J Neuro-Oncol.* 1998; 36: 85–90.
- [122] Chang L, Chen YL, Kao MC. Intracranial metastasis of hepatocellular carcinoma: review of 45 cases. *Surg Neurol.* 2004; 62: 172–7.
- [123] Chen SF, Tsai NW, Lui CC, et al. Hepatocellular carcinoma presenting as nervous system involvement. *Eur J Neurol.* 2007; 14: 408–12.
- [124] Choi HJ, Cho BC, Sohn JH, et al. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. *J Neuro-Oncol.* 2009; 91: 307–13.
- [125] Shao YY, Lu LC, Cheng AL, Hsu CH. Increasing incidence of brain metastasis in patients with advanced hepatocellular carcinoma in the era of antiangiogenic targeted therapy. *Oncologist.* 2011; 16: 82–6.
- [126] Jiang XB, Ke C, Zhang GH, et al. Brain metastases from hepatocellular carcinoma: clinical features and prognostic factors. *BMC Cancer.* 2012; 12: 49.
- [127] Qiu SJ, Zeng ZC, Chen J, et al. Clinical features and prognosis of patients with brain metastasis from hepatocellular carcinoma. *Chin J Cancer Prev Treat.* 2013; 20: 1924–7.
- [128] Han MS, Moon KS, Lee KH, et al. Brain metastasis from hepatocellular carcinoma: the role of surgery as a prognostic factor. *BMC Cancer.* 2013; 13: 567.
- [129] Nam HC, Sung PS, Song DS, et al. Control of intracranial disease is associated with improved survival in patients with brain metastasis from hepatocellular carcinoma. *Int J Clin Oncol.* 2019; 24: 666–76.
- [130] Hsieh MJ, Lu CH, Tsai NW, et al. Prediction, clinical characteristics and prognosis of intracerebral hemorrhage in hepatocellular carcinoma patients with intracerebral metastasis. *J Clin Neurosci.* 2009; 16: 394–8.
- [131] Hsiao SY, Chen SF, Chang CC, et al. Central nervous system involvement in hepatocellular carcinoma: clinical characteristics and comparison of intracranial and spinal metastatic groups. *J Clin Neurosci.* 2011; 18: 364–8.
- [132] Kwak MS, Lee JH, Yoon JH, et al. Risk factors, clinical features, and prognosis of the hepatocellular carcinoma with peritoneal metastasis. *Dig Dis Sci.* 2012; 57: 813–9.
- [133] Yeh CN, Chen MF. Resection of peritoneal implantation of hepatocellular carcinoma after hepatic resection: risk factors and prognostic analysis. *World J Surg.* 2004; 28: 382–6.
- [134] Yeh CN, Chen MF, Jeng LB. Resection of peritoneal implantation from hepatocellular carcinoma. *Ann Surg Oncol.* 2002; 9: 863–8.
- [135] Ryu JK, Lee SB, Kim KH, Yoh KT. Surgical treatment in a patient with multiple implanted intraperitoneal metastases after resection of ruptured large hepatocellular carcinoma. *Hepato-Gastroenterology.* 2004; 51: 239–42.
- [136] Moon DB, Hwang S, Wang HJ, et al. Surgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus: a korean multicenter study. *World J Surg.* 2013; 37: 443–51.
- [137] Liu QY, Lai DM, Liu C, et al. A special recurrent pattern in small hepatocellular carcinoma after treatment: bile duct tumor thrombus formation. *World J Gastroenterol.* 2011; 17: 4817–24.
- [138] Wang YD, Xue HZ, Jiang QF, et al. Surgical operation and re-operation for hepatocellular carcinoma with bile duct thrombosis. *Chin Med J.* 2010; 123: 2163–70.
- [139] Yu XH, Xu LB, Liu C. Clinicopathological characteristics of 20 cases of hepatocellular carcinoma with bile duct tumor thrombi. *Dig Dis Sci.* 2011; 56: 252–9.
- [140] Buskirk SJ, Gunderson LL, Schild SF. Analysis of patterns of failure following curative irradiation of extrahepatic bile duct carcinoma. *Ann Surg.* 1992; 215: 125–31.
- [141] Jiang T, Zeng ZC, Yang P, Hu Y. Exploration of superior modality: safety and efficacy of hypofractionated image-guided intensity modulated radiation therapy in patients with unresectable but confined intrahepatic hepatocellular carcinoma. *Can J Gastroenterol Hepatol.* 2017; 2017: 6267981.
- [142] Zhang HG, Yang P, Jiang T, Zhang JY, Jin XJ, Hu Y, Sun J, Du SS, Zeng ZC. Lymphopenia is associated with gross target volumes and fractions in hepatocellular carcinoma patients treated with external beam radiation therapy and also indicates worse overall survival. *Can J Gastroenterol Hepatol.* 2019; 2019: 9691067.
- [143] Zeng ZC, Tang ZY, et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. *Cancer J.* 2004; 10: 307–16.
- [144] Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis. *JAMA Oncol.* 2015; 1(6): 756–65.
- [145] Kitano K, Murayama T, Sakamoto M, et al. Outcome and survival analysis of pulmonary metastasectomy for hepatocellular carcinoma. *Eur J Cardiothorac Surg.* 2012; 41: 376–82.

肝细胞癌的多学科团队诊疗

Multidisciplinary Team Approaches for the Management of Hepatocellular Carcinoma

18

- [1] Nault JC, Cheng AL, Sangro B, Llovet JM. Milestones in the pathogenesis and management of primary liver cancer. *J Hepatol.* 2020; 72(2): 209–14.
- [2] Kudo M, Han KH, Ye SL, Zhou J, Huang YH, et al. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements. *Liver Cancer.* 2020; 9(3): 245–60.
- [3] Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med.* 2008; 359: 378–90.
- [4] Kudo M, Finn RS, Qin S, Ikeda M, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet.* 2018; 391: 1163–73.
- [5] Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2017; 389: 56–66.
- [6] Zhu AX, Kang YK, Yen CJ, Finn RS, et al. Ramucicromab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2019; 20: 282–96.
- [7] Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. *N Engl J Med.* 2018; 379: 54–63.
- [8] El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet.* 2017; 389: 2492–502.
- [9] Zhu AX, Finn RS, Edeline J, Cattani S, Ogasawara S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. *Lancet Oncol.* 2018; 19: 940–52.
- [10] Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. *J Clin Oncol.* 2020; 38(3): 193–202.
- [11] Cheng A-L, Hsu C, Chan SL, Choo S-P, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. *J Hepatol.* 2020; 72: 307–19.
- [12] Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL. IMbrave150 investigators. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med.* 2020; 382(20): 1894–905.
- [13] Kim DY, Kim HJ, Han KH, Han SY, Heo J, Woo HY, Um SH, Kim YH, Kweon YO, Lim HY, Yoon JH, Lee WS, Lee BS, Lee HC, Ryoo BY, Yoon SK. Real-life experience of sorafenib treatment for hepatocellular carcinoma in Korea: from GIDEON data. *Cancer Res Treat.* 2016; 48(4): 1243–52.
- [14] Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro VJ. Liver cancer: approaching a personalized care. *J Hepatol.* 2015; 62(1 Suppl): S144–56.
- [15] Greten TF, Mauda-Havakuk M, Heinrich B, Korangy F, Wood BJ. Combined locoregional-immunotherapy for liver cancer. *J Hepatol.* 2019; 70(5): 999–1007.
- [16] Greten TF, Lai CW, Li G, Staveley-O’Carroll KF. Targeted and immune-based therapies for hepatocellular carcinoma. *Gastroenterology.* 2019; 156: 510–24.
- [17] Kim BK, Kim DY, Byun HK, Choi HJ, Beom SH, Lee HW, Kim SU, Park JY, Ahn SH, Seong J, Han KH. Efficacy and safety of liver-directed concurrent chemoradiotherapy and sequential sorafenib for advanced hepatocellular carcinoma: a prospective phase 2 trial. *Int J Radiat Oncol Biol Phys.* 2020; 107(1): 106–15.
- [18] Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. *Hepatology.* 2018; 67: 358–80.
- [19] Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int.* 2017; 11: 317–70.
- [20] Kim BK, Kim DY, Han KH, Seong JS. Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: a nationwide random sample study. *PLoS One* 2019; 17; 14(10).
- [21] Agarwal PD, Phillips P, Hillman L, et al. Multidisciplinary management of hepatocellular carcinoma improves access to therapy and patient survival. *J Clin Gastroenterol.* 2017; 51(9): 845–9.
- [22] Serper M, Taddei TH, Mehta R, et al. Association of provider specialty and multi-disciplinary care with hepatocellular carcinoma treatment and mortality. *Gastroenterology.* 2017; 152: 1954–64.
- [23] Yopp AC, Mansour JC, Beg MS, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated

- with improved clinical outcome. *Ann Surg Oncol*. 2014; 21: 1287–95.
- [24] Guy J, Kelley RK, Roberts J, et al. Multidisciplinary management of hepatocellular carcinoma. *Clin Gastroenterol Hepatol*. 2012; 10(4): 354–62.
- [25] Chang TT, Sawhney R, Monto A, et al. Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. *HPB (Oxford)*. 2008; 10(6): 405–11.
- [26] Han HJ, Kim MS, Cha J, Choi JS, Han KH, Seong J. Multimodality treatment with radiotherapy for huge hepatocellular carcinoma. *Oncology*. 2014; 87(Suppl 1): 82–9.
- [27] Byun HK, Kim HJ, Im YR, Kim DY, Han KH, Seong J. Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma. *Radiother Oncol*. 2019; 133: 1–8.
- [28] Yoon HI, Song KJ, Lee IJ, Kim DY, Han KH, Seong J. Clinical benefit of hepatic arterial infusion concurrent chemoradiotherapy in locally advanced hepatocellular carcinoma: a propensity score matching analysis. *Cancer Res Treat*. 2016; 48(1): 190–7.
- [29] Lee WH, Byun HK, Choi JS, Choi GH, Han DH, Joo DJ, Kim DY, Han KH, Seong J. Liver-directed combined radiotherapy as a bridge to curative surgery in locally advanced hepatocellular carcinoma beyond the Milan criteria. *Radiother Oncol*. 2020; 152: 1–7.
- [30] Chong JU, Choi GH, Han DH, Kim KS, Seong J, Han KH, Choi JS. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus. *Ann Surg Oncol*. 2018; 25(11): 3308–15.
- [31] Han DH, Joo DJ, Kim MS, Choi GH, Choi JS, Park YN, Seong J, Han KH, Kim SI. Living donor liver transplantation for advanced hepatocellular carcinoma with portal vein tumor thrombosis after concurrent chemoradiation therapy. *Yonsei Med J*. 2016; 57(5): 1276–81.
- [32] Lee HS, Choi GH, Choi JS, Kim KS, Han KH, Seong J, Ahn SH, Kim DY, Park JY, Kim SU, Kim BK. Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy. *Ann Surg Oncol*. 2014; 21(11): 3646–53.
- [33] Choi Y, Kim JW, Cha H, Han KH, Seong J. Overall response of both intrahepatic tumor and portal vein tumor thrombosis is a good prognostic factor for hepatocellular carcinoma patients receiving concurrent chemoradiotherapy. *J Radiat Res*. 2014; 55(1): 113–20.
- [34] Han KH, Seong J, Kim JK, Ahn SH, Lee DY, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. *Cancer*. 2008; 113(5): 995–1003.

- [1] Haddad MM, Merrell KW, Hallemeier CL, Johnson GB, Mounajjed T, Olivier KR, et al. Stereotactic body radiation therapy of liver tumors: post-treatment appearances and evaluation of treatment response: a pictorial review. *Abdom Radiol (NY)*. 2016; 41(10): 2061–77.
- [2] Fu X, Sluka JP, Clendenon SG, Dunn KW, Wang Z, Klaunig JE, et al. Modeling of xenobiotic transport and metabolism in virtual hepatic lobule models. *PLoS One*. 2018; 13(9): e0198060.
- [3] Takamatsu S, Kozaka K, Kobayashi S, Yoneda N, Yoshida K, Inoue D, et al. Pathology and images of radiation-induced hepatitis: a review article. *Jpn J Radiol*. 2018; 36(4): 241–56.
- [4] Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensinger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. *Int J Radiat Oncol Biol Phys*. 1995; 31(5): 1237–48.
- [5] Maturen KE, Feng MU, Wasnik AP, Azar SF, Appelman HD, Francis IR, et al. Imaging effects of radiation therapy in the abdomen and pelvis: evaluating “innocent bystander” tissues. *Radiographics*. 2013; 33(2): 599–619.
- [6] Olsen CC, Welsh J, Kavanagh BD, Franklin W, McCarter M, Cardenes HR, et al. Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. *Int J Radiat Oncol Biol Phys*. 2009; 73(5): 1414–24.
- [7] Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst*. 2000; 92(3): 205–16.
- [8] Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009; 45(2): 228–47.
- [9] Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. *European Association for the Study of the Liver. J Hepatol*. 2001; 35(3): 421–30.
- [10] Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. *Semin Liver Dis*. 2010; 30(1): 52–60.
- [11] De Santis M, Alborino S, Tartoni PL, Torricelli P, Casolo A, Romagnoli R. Effects of lipiodol retention on MRI signal intensity from hepatocellular carcinoma and surrounding liver treated by chemoembolization. *Eur Radiol*. 1997; 7(1): 10–6.
- [12] Tsien C, Cao Y, Chenevert T. Clinical applications for diffusion magnetic resonance imaging in radiotherapy. *Semin Radiat Oncol*. 2014; 24(3): 218–26.
- [13] Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. *J Clin Oncol*. 2007; 25(26): 4104–9.
- [14] Yu JI, Park HC, Lim DH, Choi Y, Jung SH, Paik SW, et al. The role of diffusion-weighted magnetic resonance imaging in the treatment response evaluation of hepatocellular carcinoma patients treated with radiation therapy. *Int J Radiat Oncol Biol Phys*. 2014; 89(4): 814–21.
- [15] Park HJ, Kim SH, Jang KM, Lim S, Kang TW, Park HC, et al. Added value of diffusion-weighted MRI for evaluating viable tumor of hepatocellular carcinomas treated with radiotherapy in patients with chronic liver disease. *AJR Am J Roentgenol*. 2014; 202(1): 92–101.
- [16] Lo CH, Huang WY, Hsiang CW, Lee MS, Lin CS, Yang JF, et al. Prognostic significance of apparent diffusion coefficient in hepatocellular carcinoma patients treated with stereotactic ablative radiotherapy. *Sci Rep*. 2019; 9(1): 14157.
- [17] Eccles CL, Haider EA, Haider MA, Fung S, Lockwood G, Dawson LA. Change in diffusion weighted MRI during liver cancer radiotherapy: preliminary observations. *Acta Oncol*. 2009; 48(7): 1034–43.
- [18] Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. *Radiology*. 2014; 273(1): 30–50.
- [19] Sanuki N, Takeda A, Oku Y, Eriguchi T, Nishimura S, Aoki Y, et al. Threshold doses for focal liver reaction after stereotactic ablative body radiation therapy for small hepatocellular carcinoma depend on liver function: evaluation on magnetic resonance imaging with Gd-EOB-DTPA. *Int J Radiat Oncol Biol Phys*. 2014; 88(2): 306–11.
- [20] Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. *N Engl J Med*. 2006; 354(5): 496–507.
- [21] Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. *Am J Gastroenterol*. 1999; 94(11): 3314–9.
- [22] Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. *J Hepatol*. 2000; 32(5): 792–7.
- [23] Chung YH, Yu CF, Chiu SC, Chiu H, Hsu ST, Wu CR, et al. Diffusion-weighted MRI and (18)F-FDG PET correlation with immunity in early radiotherapy response in BNL hepatocellular carcinoma mouse model: timeline validation. *Eur J Nucl Med Mol Imaging*. 2019; 46(8): 1733–44.

- [24] Talbot JN, Fartoux L, Balogova S, Nataf V, Kerrou K, Gutman F, et al. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. *J Nucl Med*. 2010; 51(11): 1699–706.
- [25] Wallace MC, Sek K, Francis RJ, Samuelson S, Ferguson J, Tibballs J, et al. Baseline and post-treatment 18F-fluorocholine PET/CT predicts outcomes in hepatocellular carcinoma following locoregional therapy. *Dig Dis Sci*. 2020; 65(2): 647–57.
- [26] Price TR, Perkins SM, Sandrasegaran K, Henderson MA, Maluccio MA, Zook JE, et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. *Cancer*. 2012; 118(12): 3191–8.
- [27] Mendiratta-Lala M, Masch W, Shankar PR, Hartman HE, Davenport MS, Schipper MJ, et al. Magnetic resonance imaging evaluation of hepatocellular carcinoma treated with stereotactic body radiation therapy: long term imaging follow-up. *Int J Radiat Oncol Biol Phys*. 2019; 103(1): 169–79.
- [28] Mannina EM, Cardenes HR, Lasley FD, Goodman B, Zook J, Althouse S, et al. Role of stereotactic body radiation therapy before orthotopic liver transplantation: retrospective evaluation of pathologic response and outcomes. *Int J Radiat Oncol Biol Phys*. 2017; 97(5): 931–8.
- [29] Mastrocostas K, Jang HJ, Fischer S, Dawson LA, Munoz-Schuffenegger P, Sapisochin G, et al. Imaging post-stereotactic body radiation therapy responses for hepatocellular carcinoma: typical imaging patterns and pitfalls. *Abdom Radiol (NY)*. 2019; 44(5): 1795–807.
- [30] Fajardo LF. The pathology of ionizing radiation as defined by morphologic patterns. *Acta Oncol*. 2005; 44(1): 13–22.
- [31] Oldrini G, Huertas A, Renard-Oldrini S, Taste-George H, Vogin G, Laurent V, et al. Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma. *PLoS One*. 2017; 12(4): e0176118.
- [32] Park MJ, Kim SY, Yoon SM, Kim JH, Park SH, Lee SS, et al. Stereotactic body radiotherapy-induced arterial hypervascularity of non-tumorous hepatic parenchyma in patients with hepatocellular carcinoma: potential pitfalls in tumor response evaluation on multiphase computed tomography. *PLoS One*. 2014; 9(2): e90327.
- [33] Edeline J, Boucher E, Rolland Y, Vauleon E, Pracht M, Perrin C, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. *Cancer*. 2012; 118(1): 147–56.
- [34] Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. *J Hepatol*. 2011; 55(6): 1309–16.
- [35] Sanuki-Fujimoto N, Takeda A, Ohashi T, Kunieda E, Iwabuchi S, Takatsuka K, et al. CT evaluations of focal liver reactions following stereotactic body radiotherapy for small hepatocellular carcinoma with cirrhosis: relationship between imaging appearance and baseline liver function. *Br J Radiol*. 2010; 83(996): 1063–71.
- [36] Mendiratta-Lala M, Gu E, Owen D, Cuneo KC, Bazzi L, Lawrence TS, et al. Imaging findings within the first 12 months of hepatocellular carcinoma treated with stereotactic body radiation therapy. *Int J Radiat Oncol Biol Phys*. 2018; 102(4): 1063–9.

- [1] Goh BK. Measured versus estimated total liver volume to preoperatively assess the adequacy of future liver remnant: which method should we use? *Ann Surg.* 2015; 262(2): e72.
- [2] Tanaka K, Shimada H, Matsuo K, Ueda M, Endo I, Togo S. Remnant liver regeneration after two-stage hepatectomy for multiple bilobar colorectal metastases. *Eur J Surg Oncol (EJSO).* 2007; 33(3): 329–35.
- [3] Hemming AW, Reed AI, Howard RJ, Fujita S, Hochwald SN, Caridi JG, et al. Preoperative portal vein embolization for extended hepatectomy. *Ann Surg.* 2003; 237(5): 686.
- [4] Rous P, Larimore LD. Relation of the portal blood to liver maintenance: a demonstration of liver atrophy conditional on compensation. *J Exp Med.* 1920; 31(5): 609–32.
- [5] Honjo I, Kozaka S. Extensive resection of the liver in two stages. *Revue internationale d'hepatologie.* 1965; 15: 309–19.
- [6] Kinoshita H, Sakai K, Hirohashi K, Igawa S, Yamasaki O, Kubo S. Preoperative portal vein embolization for hepatocellular carcinoma. *World J Surg.* 1986; 10(5): 803–8.
- [7] Azoulay D, Castaing D, Krissat J, Smail A, Hargreaves GM, Lemoine A, et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. *Ann Surg.* 2000; 232(5): 665.
- [8] de Baere T, Roche A, Elias D, Lasser P, Lagrange C, Bousson V. Preoperative portal vein embolization for extension of hepatectomy indications. *Hepatology.* 1996; 24(6): 1386–91.
- [9] Kawasaki S, Makuuchi M, Kakazu T, Miyagawa S, Takayama T, Kosuge T, et al. Resection for multiple metastatic liver tumors after portal embolization. *Surgery.* 1994; 115(6): 674–7.
- [10] Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. *Ann Surg.* 2012; 255(3): 405–14.
- [11] Goto Y, Nagino M, Nimura Y. Doppler estimation of portal blood flow after percutaneous transhepatic portal vein embolization. *Ann Surg.* 1998; 228(2): 209.
- [12] Yuceturk H, Yagmurdu M, Gur G, Demirbilek M, Bilezikci B, Turan M, et al. Role of heparin on TNF- α and IL-6 levels in liver regeneration after partial hepatic resection. *Eur Surg Res.* 2007; 39(4): 216–21.
- [13] Kim RD, Kim JS, Watanabe G, Mohuczy D, Behrns KE, editors. *Liver regeneration and the atrophy-hypertrophy complex. Seminars in interventional radiology;* 2008: © Thieme Medical Publishers.
- [14] Ribero D, Abdalla E, Madoff D, Donadon M, Loyer EM, Vauthey JN. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. *Br J Surg Incorp Eur J Surg Swiss Surg.* 2007; 94(11): 1386–94.
- [15] Cazejust J, Bessoud B, Le Bail M, Menu Y. Preoperative portal vein embolization with a combination of trisacryl microspheres, gelfoam and coils. *Diagn Interv Imaging.* 2015; 96(1): 57–64.
- [16] Giraudo G, Greget M, Oussoultzoglou E, Rosso E, Bachellier P, Jaeck D. Preoperative contralateral portal vein embolization before major hepatic resection is a safe and efficient procedure: a large single institution experience. *Surgery.* 2008; 143(4): 476–82.
- [17] de Baere T, Teriitehau C, Deschamps F, Catherine L, Rao P, Hakime A, et al. Predictive factors for hypertrophy of the future remnant liver after selective portal vein embolization. *Ann Surg Oncol.* 2010; 17(8): 2081–9.
- [18] Lee KC, Kinoshita H, Hirohashi K, Kubo S, Iwasa R. Extension of surgical indications for hepatocellular carcinoma by portal vein embolization. *World J Surg.* 1993; 17(1): 109–15.
- [19] Mizuno S-i, Nimura Y, Suzuki H, Yoshida S. Portal vein branch occlusion induces cell proliferation of cholestatic rat liver. *J Surg Res.* 1996; 60(1): 249–57.
- [20] Imamura H, Shimada R, Kubota M, Matsuyama Y, Nakayama A, Miyagawa S, et al. Preoperative portal vein embolization: an audit of 84 patients. *Hepatology.* 1999; 29(4): 1099–105.
- [21] Nagino M, Ando M, Kamiya J, Uesaka K, Sano T, Nimura Y. Liver regeneration after major hepatectomy for biliary cancer. *Br J Surg.* 2001; 88(8): 1084–91.
- [22] Kishi Y, Madoff DC, Abdalla EK, Palavecino M, Ribero D, Chun YS, et al. Is embolization of segment 4 portal veins before extended right hepatectomy justified? *Surgery.* 2008; 144(5): 744–51.
- [23] Massimino KP, Kolbeck KJ, Enestvedt CK, Orloff S, Billingsley KG. Safety and efficacy of preoperative right portal vein embolization in patients at risk for postoperative liver failure following major right hepatectomy. *HPB.* 2012; 14(1): 14–9.
- [24] Van Lienden K, Hoekstra L, Bennink R, van Gulik T. Intrahepatic left to right portoportal venous collateral vascular formation in patients undergoing right portal vein ligation. *Cardiovasc Intervent Radiol.* 2013; 36(6): 1572–9.
- [25] Zeile M, Bakal A, Volkmer JE, Stavrou GA, Dautel P, Hoeltje J, et al. Identification of cofactors influencing hypertrophy of the future liver remnant after portal vein embolization—the effect of collaterals on embolized liver volume. *Br J Radiol.* 2016; 89(1068): 20160306.
- [26] May BJ, Madoff DC, editors. *Portal vein embolization: rationale, technique, and current application. Seminars in*

- interventional radiology; 2012: Thieme Medical Publishers.
- [27] Abdalla EK, Denys A, Chevalier P, Nemr RA, Vauthey J-N. Total and segmental liver volume variations: implications for liver surgery. *Surgery*. 2004; 135(4): 404–10.
- [28] Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. *Gastroenterology*. 2010; 138(1): 52–64.
- [29] Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. *Hepatology*. 2008; 47(1): 71–81.
- [30] Rim CH, Kim CY, Yang DS, Yoon WS. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis and systematic review. *Radiother Oncol*. 2018; 129(1): 112–22.
- [31] Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. *Gastroenterology*. 2016; 151(6): 1155–63.e2.
- [32] Khor AY-K, Toh Y, Allen JC, Ng DC-E, Kao Y-H, Zhu G, et al. Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma. *Hepatol Int*. 2014; 8(3): 395–404.
- [33] Garlipp B, de Baere T, Damm R, Irmscher R, van Buskirk M, Stübs P, et al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. *Hepatology*. 2014; 59(5): 1864–73.
- [34] Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, et al. Radiation lobectomy: Time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. *J Hepatol*. 2013; 59(5): 1029–36.
- [35] Fernandez-Ros N, Silva N, Bilbao JI, Inarrairaegui M, Benito A, D'Avola D, et al. Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension. *HPB*. 2014; 16(3): 243–9.
- [36] Theysohn J, Ertle J, Müller S, Schlaak J, Nensa F, Sipilae S, et al. Hepatic volume changes after lobar selective internal radiation therapy (SIRT) of hepatocellular carcinoma. *Clin Radiol*. 2014; 69(2): 172–8.
- [37] Teo JY, Allen JC Jr, Ng DC, Choo SP, Tai DW, Chang JP, et al. A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. *HPB (Oxford)*. 2016; 18(1): 7–12.
- [38] Di Stefano DR, de Baere T, Denys A, Hakime A, Gorin G, Gillet M, et al. Preoperative percutaneous portal vein embolization: evaluation of adverse events in 188 patients. *Radiology*. 2005; 234(2): 625–30.
- [39] Rim CH, Park S, Woo JY, Seong J. Compensatory hypertrophy of the liver after external beam radiotherapy for primary liver cancer. *Strahlenther Onkol*. 2018; 194(11): 1017–29.
- [40] Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol*. 2018; 69(1): 182–236.
- [41] Rim CH, Kim CY, Yang DS, Yoon WS. External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and/or right atrium: a meta-analysis and systemic review. *Radiother Oncol*. 2018; 129(1): 123–9.
- [42] Imada H, Kato H, Yasuda S, Yamada S, Yanagi T, Hara R, et al. Compensatory enlargement of the liver after treatment of hepatocellular carcinoma with carbon ion radiotherapy—relation to prognosis and liver function. *Radiother Oncol*. 2010; 96(2): 236–42.
- [43] Karasu Z, Tekin F, Ersoz G, Gunsar F, Batur Y, Ilter T, et al. Liver fibrosis is associated with decreased peripheral platelet count in patients with chronic hepatitis B and C. *Dig Dis Sci*. 2007; 52(6): 1535–9.
- [44] Kim YI, Park HC, Do Hoon Lim HJP, Kang SW, Park SY, Kim JS, et al. Changes of the liver volume and the Child-Pugh score after high dose hypofractionated radiotherapy in patients with small hepatocellular carcinoma. *Radiat Oncol J*. 2012; 30(4): 189.

放射治疗后的肝功能障碍及处理

Hepatic Dysfunction Following Radiotherapy and Management

21

- [1] Jung BG, Kim YD, Kim SG, et al. Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: a multicenter study. *PLoS One*. 2018; 13: e0201316.
- [2] Lawrence TS, Robertson JM, Anscher MS, et al. Hepatic toxicity resulting from cancer treatment. *Int J Radiat Oncol Biol Phys*. 1995; 31: 1237–48.
- [3] Choi SH, Seong J. Strategic application of radiotherapy for hepatocellular carcinoma. *Clin Mol Hepatol*. 2018; 24: 114–34.
- [4] Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. *Best Pract Res Clin Gastroenterol*. 2011; 25: 195–206.
- [5] Kim J, Jung Y. Radiation-induced liver disease: current understanding and future perspectives. *Exp Mol Med*. 2017; 49: e359.
- [6] Dawson LA, Normolle D, Balter JM. Analysis of radiation-induced liver disease using the Lyman NTCP model. *Int J Radiat Oncol Biol Phys*. 2002; 53: 810–21.
- [7] Pan CC, Kavanagh BD, Dawson LA. Radiation-associated liver injury. *Int J Radiat Oncol Biol Phys*. 2010; 76: 256–63.
- [8] Guha C, Kavanagh BD. Hepatic radiation toxicity: avoidance and amelioration. *Semin Radiat Oncol*. 2011; 21: 256–63.
- [9] Munoz-Schuffenegger P, Ng S, Dawson LA. Radiation-induced liver toxicity. *Semin Radiat Oncol*. 2017; 27: 350–7.
- [10] Fortune B, Cardenas A. Ascites, refractory ascites and hyponatremia in cirrhosis. *Gastroenterol Rep*. 2017; 5: 104–12.
- [11] Runyon BA. Care of patients with ascites. *New Engl J Med*. 1994; 330: 337–42.
- [12] Runyon BA. Ascites and spontaneous bacterial peritonitis. In: Feldman M, Friedman LS, Brandt LJ, editors. *Sleisenger and Fordtran's gastrointestinal and liver disease*. 9th ed. Philadelphia: Saunders Elsevier; 2010. p. 1517–41.
- [13] Eisenmenger WJ, Ahrens EH, Blondheim SH, et al. The effect of rigid sodium restriction in patients with cirrhosis of the liver and ascites. *J Lab Clin Med*. 1949; 34: 1029–38.
- [14] Sungaila I, Bartle WR, Walker SE, et al. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. *Gastroenterology*. 1992; 102: 1680–5.
- [15] Arroyo V. Pathophysiology, diagnosis and treatment of ascites in cirrhosis. *Ann Hepatol*. 2002; 1: 72–9.
- [16] Sola E, Gines P. Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. *J Hepatol*. 2020; 53: 1135–45.
- [17] Serste T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. *Hepatology*. 2010; 52: 1017–22.
- [18] Boyer TD, Zia P, Reynolds TB. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. *Gastroenterology*. 1979; 77: 215–22.
- [19] Peltekian KM, Wong F, Liu PP, et al. Cardiovascular, renal and neurohumoral responses to single large-volume paracentesis in cirrhotic patients with diuretic-resistant ascites. *Am J Gastroenterol*. 1997; 92: 394–9.
- [20] Tito L, Gines P, Arroyo V, et al. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. *Gastroenterology*. 1990; 98: 146–51.
- [21] Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. *Hepatology*. 2013; 57: 1651–3.
- [22] Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. *Hepatology*. 1996; 23: 164–76.
- [23] Moreau R, Deleuge P, Pessione F, et al. Clinical characteristics and outcomes of patients with cirrhosis and refractory ascites. *Liver Int*. 2004; 24: 457–64.
- [24] Hoefs JC, Canawati HN, Sapico FL, et al. Spontaneous peritoneal peritonitis. *Hepatology*. 1982; 2: 399–407.
- [25] Felisart J, Rimola A, Arroyo V, et al. Randomized comparative study of efficacy and nephrotoxicity of ampicillin plus tobramycin versus cefotaxim in cirrhotics with severe infection. *Hepatology*. 1985; 5: 457–62.
- [26] Navasa M, Follo A, Llovet JM, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. *Gastroenterology*. 1996; 111: 1011–7.
- [27] Soriano G, Teixedo M, Guarner C, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. *Gastroenterology*. 1991; 100: 477–81.
- [28] Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. *Hepatology*. 1990; 12: 716–4.
- [29] Chaudhury P, Barkin A, Barkun J. ACS surgery: principles and practice. 2010. Available from: <http://www.slideshare.net/medbookonline/acs0503-jaundice-2006>.
- [30] Moses RA, Grodzki WJ, Starcher BC, et al. Elastin content of the scleral spur, trabecular mesh, and sclera. *Invest Ophthalmol Vis Sci*. 1978; 17: 817–8.
- [31] Blasco A, Forns X, Carrion JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. *Hepatology*. 2006; 43: 492–9.
- [32] Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. *N*

- Engl J Med. 2005; 353: 2254–61.
- [33] Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. *Gastroenterology*. 2007; 133: 481–8.
- [34] Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients. Prognostic value of preoperative portal pressure. *Gastroenterology*. 1996; 111: 1018–22.
- [35] Lebrec D, De Fleury P, Rueff B, et al. Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. *Gastroenterology*. 1980; 79: 1139–44.
- [36] Garcia-Tsao G, Groszmann RJ, Fisher RL, et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. *Hepatology*. 1985; 5: 419–24.
- [37] Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments. *J Hepatol*. 2015; 62(1 Suppl): S121–30.
- [38] Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. *J Hepatol*. 2007; 46: 927–34.
- [39] Turco L, Garcia-Tsao G. Portal hypertension: pathogenesis and diagnosis. *Clin Liver Dis*. 2019; 23: 573–87.
- [40] D'Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. *Aliment Pharmacol Ther*. 2014; 39: 1180–93.
- [41] de Franchis R, Baveno V. Faculty. Expanding consensus in portal hypertension. Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. *J Hepatol*. 2015; 63: 743–52.
- [42] Villanueva C, Colombo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. *N Engl J Med*. 2013; 368: 11–21.
- [43] Bernard B, Grange JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. *Hepatology*. 1999; 29: 1655–61.
- [44] Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding—an updated Cochrane review. *Aliment Pharmacol Ther*. 2011; 34: 509–18.
- [45] Fernandez J, Ruiz dA, Gomez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. *Gastroenterology*. 2006; 131: 1049–56.
- [46] Seo YS, Park SY, Kim MY, et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. *Hepatology*. 2014; 60: 954–63.
- [47] Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. *Hepatology*. 2007; 46: 922–38.
- [48] Gines P, Guevara M, Arroyo V, et al. Hepatorenal syndrome. *Lancet*. 2003; 362: 1819–27.
- [49] Busk TM, Bendtsen F, Moller S. Hepatorenal syndrome in cirrhosis: diagnostic, pathophysiological, and therapeutic aspects. *Expert Rev Gastroenterol Hepatol*. 2016; 10: 1153–61.
- [50] Gines P, Schrier RW. Renal failure in cirrhosis. *N Engl J Med*. 2009; 361: 1279–90.
- [51] Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. *Hepatology*. 2006; 43: 385–94.
- [52] Gines P, Guevara M. Therapy with vasoconstrictor drugs in cirrhosis: the time has arrived. *Hepatology*. 2007; 46: 1685–7.
- [53] Wong F, Pappas SC, Boyer TD, et al. Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory syndrome. *Clin Gastroenterol Hepatol*. 2017; 15: 266–73.
- [54] Russell JA, Walley KR. Vasopressin and its immune effects in septic shock. *J Innate Imm*. 2010; 2: 446–60.
- [55] Nazar A, Pereira GH, Guevara M, et al. Predictors of response to therapy to terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. *Hepatology*. 2010; 51: 219–26.
- [56] Guevara M, Gines P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. *Hepatology*. 1998; 28: 416–22.
- [57] Gines P, Uriz J, Calahorra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. *Gastroenterology*. 2002; 123: 1839–47.
- [58] Zhang Z, Maddukuri G, Jaipaul N, et al. Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin. *J Crit Care*. 2015; 30: 969–74.
- [59] Lenhart A, Hussain S, Salgia R. Chances of renal recovery of liver transplantation after hospitalization for alcoholic liver disease requiring dialysis. *Dig Dis Sci*. 2018; 63: 2800–9.
- [60] Fraley DS, Burr RT, Bernadini J, et al. Impact of acute renal failure on mortality in end-stage liver disease with or without transplantation. *Kidney Int*. 1998; 54: 518–24.
- [61] Allegretti AS, Parada XV, Eneanya ND, et al. Prognosis of patients with cirrhosis and AKI who initiate RRT. *Clin J Am Soc Nephrol*. 2018; 13: 16–25.
- [62] Gonwa TA, Morris CA, Goldstein RM, et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome – experience in 300 patients. *Transplantation*. 1991; 51: 428–30.
- [63] Israni AK, Xiong H, Liu J, et al. Predicting end-stage renal disease after liver transplant. *Am J Transplant*. 2013; 13: 1782–92.
- [64] Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. *J Hepatol*. 1999; 30: 890–5.
- [65] Riggio O, Ridola L, Pasquale C, et al. Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. *Clin Gastroenterol Hepatol*. 2011; 9: 181–3.
- [66] Bajaj JS, Schubert CM, Heuman DM, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. *Gastroenterology*. 2020; 138: 2332–40.
- [67] Bajaj JS. Current and future diagnosis of hepatic encephalopathy. *Metab Brain Dis*. 2020; 25: 107–10.
- [68] Kappus MR, Bajaj JS. Covert hepatic encephalopathy: not as minimal as you might think. *Clin Gastroenterol Hepatol*. 2012; 10: 1208–19.
- [69] Montagnese S, De Pitta C, De Rui M, et al. Sleep-wake abnormalities in patients with cirrhosis. *Hepatology*. 2014; 59: 705–12.
- [70] Weissenborn K. Diagnosis of encephalopathy. *Digestion*. 1998;

- 59(Supple 2): 22–4.
- [71] Patidar KR, Bajaj JS. Covert and overt hepatic encephalopathy: diagnosis and management. *Clin Gastroenterol Hepatol*. 2015; 13: 2048–61.
- [72] Wijdicks EE, Rabinstein AA, Bamlet WR, et al. FOUR score and Glasgow Coma Scale in predicting outcome of comatose patients: a pooled analysis. *Neurology*. 2011; 77: 84–5.
- [73] Lockwood AH. Blood ammonia levels and hepatic encephalopathy. *Metab Brain Dis*. 2004; 19: 345–9.
- [74] Vilstrup H, Amodio P, Bajaj JS. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. *Hepatology*. 2014; 60: 715–35.
- [75] Gronbaek H, Johnson SP, Jepsen P, et al. Liver cirrhosis, other liver diseases, and risk of hospitalization for intracerebral haemorrhage: a Danish population-based case-control study. *BMC Gastroenterol*. 2008; 8: 16.
- [76] Strauss E, Tramote R, Silva EP, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. *Hepato-Gastroenterology*. 1992: 542–5.
- [77] Nielsen K, Clemmesen JO, Vassiliadis E, et al. Liver collagen in cirrhosis correlates with portal hypertension and liver dysfunction. *APMIS*. 2014; 122: 1213–22.
- [78] Gerber T, Schomerus H. Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management. *Drugs*. 2000; 60: 1353–70.
- [79] Bajaj JS, Sanyal AJ, Bell D, et al. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. *Aliment Pharmacol Ther*. 2020; 31: 1012–7.
- [80] Patidar KR, Bajaj JS. Antibiotics for the treatment of hepatic encephalopathy. *Metab Brain Dis*. 2013; 28: 307–12.
- [81] Sundaram V, Shaikh OS. Hepatic encephalopathy: pathophysiology and emerging therapies. *Med Clin North Am* 2009; 93: 819–836, vii.
- [82] Sharma BC, Sharma P, Agrawal A, et al. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. *Gastroenterology*. 2009; 137: 885–91.
- [83] Sharma P, Agrawal A, Sharma BC, et al. Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. *J Gastroenterol Hepatol*. 2011; 26: 996–1003.

肝癌放射治疗诱导淋巴细胞减少症

22

Lymphopenia Following Radiotherapy for Hepatocellular Carcinoma

- [1] Button LN, DeWolf WC, Newburger PE, Jacobson MS, Kevy SV. The effects of irradiation on blood components. *Transfusion*. 1981; 21(4): 419–26.
- [2] Nakamura N, Kusunoki Y, Akiyama M. Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. *Radiat Res*. 1990; 123(2): 224–7.
- [3] Belka C, Ottinger H, Kreuzfelder E, Weinmann M, Lindemann M, Lepple-Wienhues A, et al. Impact of localized radiotherapy on blood immune cells counts and function in humans. *Radiother Oncol*. 1999; 50(2): 199–204.
- [4] Arina A, Beckett M, Fernandez C, Zheng W, Pitroda S, Chmura SJ, et al. Tumor-reprogrammed resident T cells resist radiation to control tumors. *Nat Commun*. 2019; 10(1): 3959.
- [5] Grossman SA, Ellsworth S, Campian J, Wild AT, Herman JM, Laheru D, et al. Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. *J Natl Compr Cancer Netw*. 2015; 13(10): 1225–31.
- [6] Deng W, Xu C, Liu A, van Rossum PSN, Deng W, Liao Z, et al. The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy. *Radiother Oncol*. 2019; 133: 9–15.
- [7] Byun HK, Kim N, Yoon HI, Kang SG, Kim SH, Cho J, et al. Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era. *Radiat Oncol (London, England)*. 2019; 14(1): 51.
- [8] Park S, Byun HK, Seong J. Irradiation-related lymphopenia for bone metastasis from hepatocellular carcinoma. *Liver Cancer*. 2019; 8(6): 468–79.
- [9] Cho Y, Park S, Byun HK, Lee CG, Cho J, Hong MH, et al. Impact of treatment-related lymphopenia on immunotherapy for advanced non-small cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2019; 105(5): 1065–73.
- [10] Byun HK, Kim N, Park S, Seong J. Acute severe lymphopenia by radiotherapy is associated with reduced overall survival in hepatocellular carcinoma. *Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft [et al]*. 2019; 195(11): 1007–17.
- [11] Liu H, Wang H, Wu J, Wang Y, Zhao L, Li G, et al. Lymphocyte nadir predicts tumor response and survival in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: Immunologic relevance. *Radiother Oncol*. 2019; 131: 52–9.
- [12] Chadha AS, Liu G, Chen HC, Das P, Minsky BD, Mahmood U, et al. Does unintentional splenic radiation predict outcomes after pancreatic cancer radiation therapy? *Int J Radiat Oncol Biol Phys*. 2017; 97(2): 323–32.
- [13] Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. *Cancer Investig*. 2013; 31(2): 140–4.
- [14] Rudra S, Hui C, Rao YJ, Samson P, Lin AJ, Chang X, et al. Effect of radiation treatment volume reduction on lymphopenia in patients receiving chemoradiotherapy for glioblastoma. *Int J Radiat Oncol Biol Phys*. 2018; 101(1): 217–25.
- [15] Wild AT, Herman JM, Dholakia AS, Moningi S, Lu Y, Rosati LM, et al. Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer. *Int J Radiat Oncol Biol Phys*. 2016; 94(3): 571–9.
- [16] Liu J, Zhao Q, Deng W, Lu J, Xu X, Wang R, et al. Radiation-related lymphopenia is associated with spleen irradiation dose during radiotherapy in patients with hepatocellular carcinoma. *Radiat Oncol (London, England)*. 2017; 12(1): 90.
- [17] Shiraishi Y, Fang P, Xu C, Song J, Krishnan S, Koay EJ, et al. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: a propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. *Radiother Oncol*. 2018; 128(1): 154–60.
- [18] Lin AJ, Campian JL, Hui C, Rudra S, Rao YJ, Thotala D, et al. Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. *J Neuro-Oncol*. 2018; 136(2): 403–11.
- [19] Badiyan SN, Robinson CG, Bradley JD. Radiation toxicity in lung cancer patients: the heart of the problem? *Int J Radiat Oncol Biol Phys*. 2019; 104(3): 590–2.
- [20] Fang P, Shiraishi Y, Verma V, Jiang W, Song J, Hobbs BP, et al. Lymphocyte-sparing effect of proton therapy in patients with esophageal cancer treated with definitive chemoradiation. *Int J Particle Therapy*. 2018; 4(3): 23–32.
- [21] Fang P, Jiang W, Davuluri R, Xu C, Krishnan S, Mohan R, et al. High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer. *Radiother Oncol*. 2018; 128(3): 584–90.
- [22] Lee BM, Byun HK, Seong J. Significance of lymphocyte recovery from treatment-related lymphopenia in locally advanced pancreatic cancer. *Radiother Oncol*. 2020; 151: 82–7.
- [23] Sun GY, Wang SL, Song YW, Jin J, Wang WH, Liu YP, et al. Radiation-induced lymphopenia predicts poorer prognosis in patients with breast cancer: a post hoc analysis of a randomized controlled trial of postmastectomy hypofractionated radiation therapy. *Int J Radiat Oncol Biol Phys*. 2020; 108(1): 277–85.
- [24] Formenti SC, Demaria S. Systemic effects of local radiotherapy.

- Lancet Oncol. 2009; 10(7): 718–26.
- [25] Dean RM, Fry T, Mackall C, Steinberg SM, Hakim F, Fowler D, et al. Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. *J Clin Oncol.* 2008; 26(35): 5735–41.
- [26] Ellsworth S, Balmanoukian A, Kos F, Nirschl CJ, Nirschl TR, Grossman SA, et al. Sustained CD4(+) T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide. *Onco Targets Ther.* 2014; 3(1): e27357.
- [27] Lambin P, Lieverse RIY, Eckert F, Marcus D, Oberije C, van der Wiel AMA, et al. Lymphocytesparing radiotherapy: the rationale for protecting lymphocyte-rich organs when combining radiotherapy with immunotherapy. *Semin Radiat Oncol.* 2020; 30(2): 187–93.
- [28] Campian JL, Ye X, Gladstone DE, Ambady P, Nirschl TR, Borrello I, et al. Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas. *J Neuro-Oncol.* 2015; 124(2): 307–16.
- [29] Nguyen V, Mendelsohn A, Larrick JW. Interleukin-7 and immunosenescence. *J Immunol Res.* 2017; 2017: 4807853.
- [30] Corfe SA, Paige CJ. The many roles of IL-7 in B cell development; mediator of survival, proliferation and differentiation. *Semin Immunol.* 2012; 24(3): 198–208.
- [31] Ponchel F, Cuthbert RJ, Goeb V. IL-7 and lymphopenia. *Clin Chim Acta Int J Clin Chem.* 2011; 412(1–2): 7–16.
- [32] Levy Y, Sereti I, Tambussi G, Routy JP, Lelievre JD, Delfraissy JF, et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. *Clin Infect Dis.* 2012; 55(2): 291–300.
- [33] Rosenberg SA, Sportes C, Ahmazadeh M, Fry TJ, Ngo LT, Schwarz SL, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. *J Immunother (Hagerstown, Md: 1997).* 2006; 29(3): 313–9.
- [34] Study of the Effect IL 7/NT-17 on CD4 Counts in Patients With High Grade Gliomas 2016. Available from: <https://clinicaltrials.gov/ct2/show/NCT02659800>.

放射治疗在免疫肿瘤学时代的前景展望

23

Perspectives of Radiotherapy in Immunology Era

- [1] Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. *Cell*. 2017; 169(7): 1327–41.e23.
- [2] Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS, et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. *Hepatology*. 2005; 41(4): 722–30.
- [3] Yeung OW, Lo CM, Ling CC, Qi X, Geng W, Li CX, et al. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. *J Hepatol*. 2015; 62(3): 607–16.
- [4] Zhang HH, Mei MH, Fei R, Liu F, Wang JH, Liao WJ, et al. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses. *J Viral Hepat*. 2010; 17(Suppl 1): 34–43.
- [5] Ding X, He M, Chan AWH, Song QX, Sze SC, Chen H, et al. Genomic and epigenomic features of primary and recurrent hepatocellular carcinomas. *Gastroenterology*. 2019; 157(6): 1630–45.e6.
- [6] Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. *Hepatology*. 1999; 29(1): 62–7.
- [7] Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*. 2008; 359(4): 378–90.
- [8] Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol*. 2009; 10(1): 25–34.
- [9] Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet (London, England)*. 2017; 389(10064): 56–66.
- [10] Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. *N Engl J Med*. 2018; 379(1): 54–63.
- [11] Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet (London, England)*. 2018; 391(10126): 1163–73.
- [12] Sangro B, Gomez-Martin C, de la Mata M, Iñárraiaegui M, Garralda E, Barrera P, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. *J Hepatol*. 2013; 59(1): 81–8.
- [13] El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet (London, England)*. 2017; 389(10088): 2492–502.
- [14] Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology*. 2018; 68(2): 723–50.
- [15] EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. *J Hepatol*. 2018; 69(1): 182–236.
- [16] Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. *J Immunother*. 2005; 28(5): 496–504.
- [17] El Ansary M, Mogawer S, Elhamid SA, Alwakil S, Aboelkasem F, Sabaawy HE, et al. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC. *J Cancer Res Clin Oncol*. 2013; 139(1): 39–48.
- [18] Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. *Clin Cancer Res*. 2012; 18(13): 3686–96.
- [19] Buonaguro L. Developments in cancer vaccines for hepatocellular carcinoma. *Cancer Immunol Immunother*. 2016; 65(1): 93–9.
- [20] Sharma M, Krammer F, García-Sastre A, Tripathi S. Moving from empirical to rational vaccine design in the ‘omics’ era. *Vaccines (Basel)*. 2019; 7(3).
- [21] Zhu AX, Finn RS, Edeline J, Cattani S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. *Lancet Oncol*. 2018; 19(7): 940–52.
- [22] Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med*. 2020; 382(20): 1894–905.
- [23] Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. *J Clin Oncol Off J Am Soc Clin Oncol*. 2020; 38(26): 2960–70.
- [24] Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1

- drugs: systematic review and meta-analysis. *BMJ*. 2018; 360: k793.
- [25] Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. *J Immunother Cancer*. 2019; 7(1): 306.
- [26] Stone HB, Peters LJ, Milas L. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. *J Natl Cancer Inst*. 1979; 63(5): 1229–35.
- [27] Cameron RB, Spiess PJ, Rosenberg SA. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action. *J Exp Med*. 1990; 171(1): 249–63.
- [28] Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. *J Immunol (Baltimore, Md: 1950)*. 2008; 181(5): 3099–107.
- [29] Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. *J Immunol (Baltimore, Md: 1950)*. 2008; 180(5): 3132–9.
- [30] Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. *Annu Rev Immunol*. 2013; 31: 51–72.
- [31] Hallahan D, Kuchibhotla J, Wyble C. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. *Cancer Res*. 1996; 56(22): 5150–5.
- [32] Boustani J, Grapin M, Laurent PA, Apetoh L, Mirjolet C. The 6th R of radiobiology: reactivation of anti-tumor immune response. *Cancers (Basel)*. 2019; 11(6).
- [33] Chew V, Lee YH, Pan L, Nasir NJM, Lim CJ, Chua C, et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. *Gut*. 2019; 68(2): 335–46.
- [34] Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. *Onco Targets Ther*. 2014; 3: e28780.
- [35] Xu J, Escamilla J, Mok S, David J, Priceman S, West B, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. *Cancer Res*. 2013; 73(9): 2782–94.
- [36] Tsai CS, Chen FH, Wang CC, Huang HL, Jung SM, Wu CJ, et al. Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. *Int J Radiat Oncol Biol Phys*. 2007; 68(2): 499–507.
- [37] Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. *Nature*. 2015; 520(7547): 373–7.
- [38] Hader M, Frey B, Fietkau R, Hecht M, Gaipl US. Immune biological rationales for the design of combined radio- and immunotherapies. *Cancer Immunol Immunother*. 2020; 69(2): 293–306.
- [39] Cai X, Chiu YH, Chen ZJ. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. *Mol Cell*. 2014; 54(2): 289–96.
- [40] Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. *Nat Commun*. 2017; 8: 15618.
- [41] Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. *J Immunol (Baltimore, Md: 1950)*. 2005; 174(12): 7516–23.
- [42] Seegenschmiedt MH, Micke O, Muecke R. Radiotherapy for non-malignant disorders: state of the art and update of the evidence-based practice guidelines. *Br J Radiol*. 2015; 88(1051): 20150080.
- [43] Teresa Pinto A, Laranjeiro Pinto M, Patricia Cardoso A, Monteiro C, Teixeira Pinto M, Filipe Maia A, et al. Ionizing radiation modulates human macrophages towards a pro-inflammatory phenotype preserving their pro-invasive and pro-angiogenic capacities. *Sci Rep*. 2016; 6: 18765.
- [44] Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. *Blood*. 2009; 114(3): 589–95.
- [45] Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. *Nat Commun*. 2017; 8(1): 15618.
- [46] Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. *N Engl J Med*. 2017; 377(20): 1919–29.
- [47] Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Three-year overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC. *J Thorac Oncol*. 2020; 15(2): 288–93.
- [48] Gong X, Li X, Jiang T, Xie H, Zhu Z, Zhou F, et al. Combined radiotherapy and anti-PD-L1 antibody synergistically enhances antitumor effect in non-small cell lung cancer. *J Thorac Oncol*. 2017; 12(7): 1085–97.
- [49] Ohri N, Jackson A, Mendez Romero A, Miften M, Ten Haken RK, Dawson LA, et al. Local control following stereotactic body radiotherapy for liver tumors: a preliminary report of the AAPM Working Group for SBRT. *Int J Radiat Oncol Biol Phys*. 2014; 90(1): S52.
- [50] Huang WY, Jen YM, Lee MS, Chang LP, Chen CM, Ko KH, et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2012; 84(2): 355–61.
- [51] Kim KJ, Kim JH, Lee SJ, Lee EJ, Shin EC, Seong J. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. *Oncotarget*. 2017; 8(25): 41242–55.
- [52] Coulouarn C, Factor VM, Conner EA, Thorgerirsson SS. Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer. *Carcinogenesis*. 2011; 32(10): 1434–40.
- [53] Kim DH, Cho E, Cho SB, Choi SK, Kim S, Yu J, et al. Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): a case report and literature review. *Medicine*. 2018; 97(42): e12866.
- [54] Fang L, Gong J, Wang Y, Liu R, Li Z, Wang Z, et al. MICA/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma. *J Exp Clin Cancer Res*. 2014; 33(1): 76.
- [55] López-Soto A, Huergo-Zapico L, Acebes-Huerta A, Villa-

- Alvarez M, Gonzalez S. NKG2D signaling in cancer immunosurveillance. *Int J Cancer*. 2015; 136(8): 1741–50.
- [56] Shen J, Wang LF, Zou ZY, Kong WW, Yan J, Meng FY, et al. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. *World J Gastroenterol*. 2017; 23(29): 5395–404.
- [57] Palata O, Hradilova Podzimekova N, Nedvedova E, Umpracht A, Sadilkova L, Palova Jelinkova L, et al. Radiotherapy in combination with cytokine treatment. *Front Oncol*. 2019; 9: 367.
- [58] Wu CJ, Tsai YT, Lee IJ, Wu PY, Lu LS, Tsao WS, et al. Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of tumor microenvironment. *Onco Targets Ther*. 2018; 7(9): e1477459.
- [59] Pugh JL, Sukhina AS, Seed TM, Manley NR, Sempowski GD, van den Brink MR, et al. Histone deacetylation critically determines T cell subset radiosensitivity. *J Immunol (Baltimore, Md: 1950)*. 2014; 193(3): 1451–8.
- [60] Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, Egea J, et al. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. *Cancer Immunol Immunother*. 2019; 68(3): 379–93.
- [61] Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. *Cancer Res*. 2005; 65(14): 6321–9.
- [62] Pedroza-Gonzalez A, Zhou G, Singh SP, Boor PP, Pan Q, Grunhagen D, et al. GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells *ex vivo*. *Onco Targets Ther*. 2015; 4(12): e1051297.
- [63] van Beek AA, Zhou G, Doukas M, Boor PPC, Noordam L, Mancham S, et al. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma. *Int J Cancer*. 2019; 145(4): 1111–24.
- [64] He Y, Cao J, Zhao C, Li X, Zhou C, Hirsch FR. TIM-3, a promising target for cancer immunotherapy. *Onco Targets Ther*. 2018; 11: 7005–9.
- [65] Friedlaender A, Addeo A, Banna G. New emerging targets in cancer immunotherapy: the role of TIM3. *ESMO Open*. 2019; 4(Suppl 3): e000497.
- [66] Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. *J Exp Med*. 2010; 207(10): 2187–94.
- [67] Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. *Nature*. 2015; 517(7534): 386–90.
- [68] Kurtulus S, Sakuishi K, Ngiow SF, Joller N, Tan DJ, Teng MW, et al. TIGIT predominantly regulates the immune response via regulatory T cells. *J Clin Invest*. 2015; 125(11): 4053–62.
- [69] Ndhlovu LC, Lopez-Vergès S, Barbour JD, Jones RB, Jha AR, Long BR, et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. *Blood*. 2012; 119(16): 3734–43.
- [70] Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, Cooley SA, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. *Blood*. 2012; 119(13): 3064–72.
- [71] Golden-Mason L, McMahan RH, Strong M, Reisdorph R, Mahaffey S, Palmer BE, et al. Galectin-9 functionally impairs natural killer cells in humans and mice. *J Virol*. 2013; 87(9): 4835–45.
- [72] Khan M, Arooj S, Wang H. NK cell-based immune checkpoint inhibition. *Front Immunol*. 2020; 11: 167.
- [73] Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. *Cancer Res*. 2014; 74(19): 5458–68.
- [74] Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. *N Engl J Med*. 2012; 366(10): 925–31.
- [75] Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. *Lancet Oncol*. 2017; 18(7): 895–903.
- [76] Choi C, Yoo GS, Cho WK, Park HC. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. *World J Gastroenterol*. 2019; 25(20): 2416–29.
- [77] Wehrenberg-Klee E, Goyal L, Dugan M, Zhu AX, Ganguli S. Y-90 radioembolization combined with a PD-1 inhibitor for advanced hepatocellular carcinoma. *Cardiovasc Intervent Radiol*. 2018; 41(11): 1799–802.
- [78] Yu JI, Lee SJ, Lee J, Lim HY, Paik SW, Yoo GS, et al. Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma. *Cancer Med*. 2019; 8(16): 6986–94.
- [79] Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. *Nat Med*. 2015; 21(11): 1318–25.